<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1802256912
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1988
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MARVELON TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DESOGESTREL,ETHINYLESTRADIOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150,30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        14.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ORGANON" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ORGANON
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ORGANON
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03AA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:11.1pt">Marvelon is a combined oral contraceptive pill (&lsquo;the Pill&rsquo;). <strong>You take it to prevent pregnancy.</strong></p><p><strong>&nbsp;</strong></p><p style="margin-left:11.1pt; margin-right:12.3pt">This low-dose contraceptive contains two types of female sex hormones, oestrogen and progestogen. These hormones prevent an egg being released from your ovaries so you can&rsquo;t get pregnant. Marvelon also makes the fluid (mucus) in your cervix thicker which makes it more difficult for sperm to enter the womb.</p><p>&nbsp;</p><p style="margin-left:11.1pt; margin-right:12.3pt">Marvelon is a 21-day pill &ndash; you take one each day for 21 days, followed by 7 days when you take no pills.</p><p>&nbsp;</p><p>The benefits of taking the Pill include:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->it is one of the most reliable reversible methods of contraception if used correctly</p><p style="margin-left:46.6pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->it doesn&rsquo;t interrupt sex</p><p style="margin-left:46.6pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->it usually makes your periods regular, lighter and less painful</p><p style="margin-left:46.6pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->it may help with pre-menstrual symptoms.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:12.75pt">Marvelon will not protect you against sexually transmitted infections, such as Chlamydia or HIV. Only condoms can help to do this.</p><p>&nbsp;</p><p>Marvelon needs to be taken as directed to prevent pregnancy.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:11.0pt; margin-right:201.35pt; text-indent:0in"><!--[if !supportLists]--><strong>1.&nbsp; </strong><!--[endif]--><strong>General notes</strong></p><p style="margin-left:11.0pt; margin-right:14.25pt">Before you start using Marvelon you should read the information on blood clots in section 2. It is particularly important to read the symptoms of a blood clot - see section 2 &ldquo;Blood clots&rdquo;.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:18.9pt; text-align:justify">It&rsquo;s important that you understand the benefits and risks of taking the Pill before you start taking it, or when deciding whether to carry on taking it. Although the Pill is suitable for most healthy women, it isn&rsquo;t suitable for everyone.</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:11.0pt">&rarr;<strong>Tell your doctor </strong>if you have any of the illnesses or risk factors mentioned in this leaflet.</p><p>&nbsp;</p><p>Before you start taking the Pill</p><p style="margin-left:46.6pt; margin-right:37.8pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Your doctor will ask about you and your family&rsquo;s medical problems and check your blood pressure. You may also need other checks, such as a breast examination.</p><p>&nbsp;</p><p>While you&rsquo;re on the Pill</p><p style="margin-right:32.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->You will need <strong>regular check-ups </strong>with your doctor or family planning nurse, usually when you need another prescription of the Pill.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->You should go for <strong>regular cervical smear </strong>tests.</p><p style="margin-right:25.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Check your breasts </strong>and nipples every month for changes &ndash; tell your doctor if you can see or feel anything odd, such as lumps or dimpling of the skin.</p><p style="margin-right:15.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>If you need a blood test </strong>tell your doctor that you are taking the Pill, because the Pill can affect the results of some tests.</p><p style="margin-right:18.65pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If <strong>you&rsquo;re going to have an operation, </strong>make sure your doctor knows about it. You may need to stop taking the Pill about 4&ndash;6 weeks before the operation. This is to reduce the risk of a blood clot (see section 2.1). Your doctor will tell you when you can start taking the Pill again.</p><p>&nbsp;</p><p><!--[if !supportLists]-->2.1&nbsp; <!--[endif]-->Do not use Marvelon</p><p style="margin-left:11.0pt; margin-right:12.3pt">You should not use Marvelon if you have any of the conditions listed below. If you do have any of the conditions listed below, you must tell your doctor. Your doctor will discuss with you what other form of birth control would be more appropriate. See also section 2.2 &lsquo;Warnings and precautions&rsquo;.</p><p style="margin-left:46.6pt; margin-right:39.2pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have (or have ever had) a blood clot in a blood vessel of your legs (deep vein thrombosis, DVT), your lungs (pulmonary embolus, PE) or other organs;</p><p>&nbsp;</p><p style="margin-left:46.6pt; margin-right:26.4pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you know you have a disorder affecting your blood clotting &ndash; for instance, protein C deficiency, protein S deficiency, antithrombin-III deficiency, Factor V Leiden or antiphospholipid antibodies;</p><p style="margin-left:46.6pt; margin-right:30.1pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you need an operation or if you are off your feet for a long time (see section &lsquo;Blood clots&rsquo;);</p><p style="margin-left:46.6pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have ever had a heart attack or stroke;</p><p style="margin-left:46.6pt; margin-right:20.55pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have (or have ever had) angina pectoris (a condition that causes severe chest pain and may be a first sign of a heart attack) or transient ischaemic attack [TIA -temporary stroke symptoms]);</p><p style="margin-left:46.6pt; margin-right:38.4pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have any of the following diseases that may increase your risk of a clot in the arteries:</p><p style="margin-left:60.65pt; text-indent:-14.25pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe diabetes with blood vessel damage,</p><p style="margin-left:60.65pt; text-indent:-14.25pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->very high blood pressure,</p><p style="margin-left:60.65pt; text-indent:-14.25pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->a very high level of fat in the blood (cholesterol or triglycerides),</p><p style="margin-left:60.65pt; text-indent:-14.25pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->a condition known as hyperhomocysteinaemia;</p><p style="margin-left:46.6pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have (or have ever had) a type of migraine called &lsquo;migraine with aura&rsquo;;</p><p style="margin-left:46.6pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have or have recently had a <strong>severe liver disease</strong>;</p><p style="margin-left:46.6pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have ever had a <strong>liver tumour</strong>;</p><p style="margin-right:15.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have or have had a <strong>pancreatitis </strong>(an inflammation of the pancreas) associated with high levels of fatty substances in your blood;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->known or suspected <strong>pregnancy</strong>;</p><p style="margin-left:46.6pt; margin-right:39.55pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have cancer affected by sex hormones &ndash; such as some <strong>cancers of the breast, womb lining or ovary</strong>;</p><p style="margin-left:46.6pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have <strong>vaginal bleeding </strong>that has not been explained by your doctor;</p><p style="margin-left:46.6pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are <strong>allergic </strong>(<em>hypersensitive</em>) to any of the ingredients in Marvelon.</p><p style="margin-left:46.6pt; margin-right:53.8pt; text-indent:-17.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have hepatitis C and are taking medicinal products containing ombitasvir/ paritaprevir/ ritonavir and dasabuvir (see also section 2.3 &ldquo;Other medicines and Marvelon&rdquo;).</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:18.25pt">&rarr;<strong>If you suffer from any of these, </strong>or get them for the first time while taking Marvelon, contact your doctor as soon as possible. Do not take Marvelon.</p><p>&nbsp;</p><p><!--[if !supportLists]-->2.2&nbsp; <!--[endif]-->Warnings and precautions</p><p style="margin-left:11.0pt; margin-right:0in"><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
  type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
  margin-left:84.6pt;margin-top:22.95pt;width:442.8pt;height:88.2pt;z-index:-251657216;
  visibility:visible;mso-wrap-style:square;mso-width-percent:0;
  mso-height-percent:0;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
  mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
  mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-left:5.15pt;line-height:12.35pt;
     mso-line-height-rule:exactly'><u>Seek urgent medical attention</u><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:41.8pt;margin-bottom:
     0in;margin-left:36.8pt;margin-bottom:.0001pt;text-indent:-.25in;
     line-height:115%;tab-stops:36.8pt'><span style='font-family:"Arial",sans-serif;
     mso-bidi-font-family:"Times New Roman"'>–<span style='mso-tab-count:1'>    </span></span>if
     you notice possible signs of a blood clot that may mean you are suffering
     from a blood clot in the leg (i.e. deep vein thrombosis), a blood clot in
     the lung (i.e. pulmonary<span style='letter-spacing:-.2pt'> </span>embolism),<span
     style='letter-spacing:-.15pt'> </span>a<span style='letter-spacing:-.2pt'>
     </span>heart<span style='letter-spacing:-.2pt'> </span>attack<span
     style='letter-spacing:-.15pt'> </span>or<span style='letter-spacing:-.2pt'>
     </span>a<span style='letter-spacing:-.15pt'> </span>stroke<span
     style='letter-spacing:-.2pt'> </span>(see<span style='letter-spacing:-.15pt'>
     </span>‘Blood<span style='letter-spacing:-.2pt'> </span>clots’<span
     style='letter-spacing:-.15pt'> </span>section<span style='letter-spacing:
     -.2pt'> </span>below).<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.05pt;margin-right:66.2pt;
     margin-bottom:0in;margin-left:5.15pt;margin-bottom:.0001pt'>For a
     description of the symptoms of these serious side effects please go to
     “How to recognise a blood clot”.<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--><!--[if !vml]--></p><table cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="595" height="121" alt="Text Box: Seek urgent medical attention
–	if you notice possible signs of a blood clot that may mean you are suffering from a blood clot in the leg (i.e. deep vein thrombosis), a blood clot in the lung (i.e. pulmonary embolism), a heart attack or a stroke (see ‘Blood clots’ section below).
For a description of the symptoms of these serious side effects please go to “How to recognise a blood clot”.
" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[endif]--><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p><br />When should you contact your doctor?</p><p>&nbsp;</p><p>&nbsp;</p><p>Tell your doctor if any of the following conditions apply to you.</p><p style="margin-left:11.0pt; margin-right:30.05pt">If the condition develops, or gets worse while you are using Marvelon, you should also tell your doctor.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have ever had problems with your <strong>heart, circulation or blood clotting</strong>.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have <strong>diabetes</strong>.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have ever had <strong>kidney or liver problems</strong>.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have ever had <strong>severe depression</strong>.</p><p>&nbsp;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have ever had <strong>migraines</strong>.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have had <strong>problems while pregnant or while using the pill, </strong>like:</p><p style="margin-left:53.2pt; margin-right:0in; text-indent:-6.2pt"><!--[if !supportLists]-->-&nbsp; <!--[endif]-->itching of the whole body (<em>pruritus</em>),</p><p style="margin-left:53.2pt; text-indent:-6.2pt"><!--[if !supportLists]-->-&nbsp; <!--[endif]-->jaundice which was not caused by infection,</p><p style="margin-left:53.35pt; margin-right:0in; text-indent:-6.35pt"><!--[if !supportLists]-->-&nbsp; <!--[endif]-->gall stones,</p><p style="margin-left:53.2pt; text-indent:-6.2pt"><!--[if !supportLists]-->-&nbsp; <!--[endif]-->systemic lupus erythematosus (SLE),</p><p style="margin-left:53.2pt; margin-right:0in; text-indent:-6.2pt"><!--[if !supportLists]-->-&nbsp; <!--[endif]-->a blister-like rash, called <em>herpes gestationis,</em></p><p style="margin-left:53.2pt; text-indent:-6.2pt"><!--[if !supportLists]-->-&nbsp; <!--[endif]-->a hearing problem called <em>otosclerosis,</em></p><p style="margin-left:53.2pt; text-indent:-6.2pt"><!--[if !supportLists]-->-&nbsp; <!--[endif]-->other rare conditions called <em>porphyria </em>and <em>hereditary angioedema.</em></p><p style="margin-right:31.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have <strong>brown patches on your face or body </strong>(<em>chloasma</em>) &ndash; if so avoid too much exposure to the sun or ultraviolet light.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have Crohn&rsquo;s disease or ulcerative colitis (chronic inflammatory bowel disease).</p><p style="margin-right:12.95pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have systemic lupus erythematosus (SLE - a disease affecting your natural defence system).</p><p style="margin-right:27.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have haemolytic uraemic syndrome (HUS - a disorder of blood clotting causing failure of the kidneys).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have sickle cell anaemia (an inherited disease of the red blood cells).</p><p style="margin-right:11.7pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have elevated levels of fat in the blood (hypertriglyceridaemia) or a positive family history for this condition. Hypertriglyceridaemia has been associated with an increased risk of developing pancreatitis (inflammation of the pancreas).</p><p style="margin-right:16.4pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you need an operation, or you are off your feet for a long time (see in section 2 &lsquo;Blood clots&rsquo;).</p><p style="margin-right:15.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have just given birth you are at an increased risk of blood clots. You should ask your doctor how soon after delivery you can start taking Marvelon (see section 2.2.1 The Pill and Thrombosis).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have an inflammation in the veins under the skin (superficial thrombophlebitis).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have varicose veins.</p><p>&nbsp;</p><p><!--[if !supportLists]-->2.2.1.&nbsp; <!--[endif]-->The Pill and Thrombosis Blood Clots</p><p style="margin-left:11.0pt; margin-right:15.55pt">Using a combined hormonal contraceptive such as Marvelon, increases your risk of developing a blood clot compared with not using one. In rare cases a blood clot can block blood vessels and cause serious problems.</p><p>&nbsp;</p><p style="margin-left:11.0pt">Blood clots can develop</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->in veins (referred to as a &lsquo;venous thrombosis&rsquo;, &lsquo;venous thromboembolism&rsquo; or VTE)</p><p style="margin-right:37.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->in the arteries (referred to as an &lsquo;arterial thrombosis&rsquo;, &lsquo;arterial thromboembolism&rsquo; or ATE).</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:18.25pt">Recovery from blood clots is not always complete. Rarely, there may be serious lasting effects or, very rarely, they may be fatal.</p><p>&nbsp;</p><p>It is important to remember that the overall risk of a harmful blood clot due to Marvelon is small.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:0in"><strong>How to recognise a blood clot</strong></p><p style="margin-left:11.0pt; margin-right:0in">Seek urgent medical attention if you notice any of the following signs or symptoms.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="background-color:#cccccc; border-color:black; height:25.25pt; width:300.25pt"><p style="margin-left:9.95pt; margin-right:0in; text-indent:0in">Are you experiencing any of these signs?</p></td><td style="background-color:#cccccc; border-color:black; height:25.25pt; width:142.55pt"><p style="margin-left:5.35pt; text-indent:0in">What are you possibly</p><p style="margin-left:5.35pt; text-indent:0in">suffering from?</p></td></tr><tr><td style="border-color:black; height:104.95pt; vertical-align:top; width:300.25pt"><p style="margin-right:47.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->swelling of one leg or along a vein in the leg or foot especially when accompanied by:</p><p style="margin-left:59.35pt; margin-right:12.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->pain or tenderness in the leg which may be felt only when standing or walking,</p><p style="margin-left:59.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->increased warmth in the affected leg,</p><p style="margin-left:59.35pt; margin-right:18.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->change in colour of the skin on the leg e.g. turning pale, red or blue.</p></td><td style="height:104.95pt; vertical-align:top; width:142.55pt"><p style="margin-left:5.35pt; text-indent:0in">Deep vein thrombosis</p></td></tr><tr><td style="border-color:black; height:182.35pt; vertical-align:top; width:300.25pt"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden unexplained breathlessness or rapid breathing,</p><p style="margin-left:23.35pt; margin-right:21.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden cough without an obvious cause, which may bring up blood,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sharp chest pain which may increase with deep breathing,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe light headedness or dizziness,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->rapid or irregular heartbeat,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe pain in your stomach.</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:5.35pt; margin-right:11.1pt; text-indent:0in">If you are unsure, talk to a doctor as some of these symptoms such as coughing or being short of breath may be mistaken for a milder condition such as a respiratory tract infection (e.g. a &lsquo;common cold&rsquo;).</p></td><td style="height:182.35pt; vertical-align:top; width:142.55pt"><p style="margin-left:5.35pt; text-indent:0in">Pulmonary embolism</p></td></tr><tr><td style="border-color:black; height:70.5pt; vertical-align:top; width:300.25pt"><p style="margin-left:5.35pt; text-indent:0in">Symptoms most commonly occur in one eye:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->immediate loss of vision or</p><p style="margin-left:23.35pt; margin-right:30.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->painless blurring of vision which can progress to loss of vision.</p></td><td style="height:70.5pt; vertical-align:top; width:142.55pt"><p style="margin-left:5.35pt; margin-right:30.55pt; text-indent:0in">Retinal vein thrombosis (blood clot in the eye)</p></td></tr><tr><td style="border-color:black; height:149.1pt; vertical-align:top; width:300.25pt"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->chest pain, discomfort, pressure, heaviness;</p><p style="margin-left:23.35pt; margin-right:10.55pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sensation of squeezing or fullness in the chest, arm or below the breastbone;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->fullness, indigestion or choking feeling;</p><p style="margin-left:23.35pt; margin-right:27.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->upper body discomfort radiating to the back, jaw, throat, arm and stomach;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sweating, nausea, vomiting or dizziness;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->extreme weakness, anxiety, or shortness of breath;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->rapid or irregular heartbeats.</p></td><td style="height:149.1pt; vertical-align:top; width:142.55pt"><p style="margin-left:5.35pt; text-indent:0in">Heart attack</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:184.25pt; vertical-align:top; width:300.25pt"><p style="margin-right:38.9pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden weakness or numbness of the face, arm or leg, especially on one side of the body;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden confusion, trouble speaking or understanding;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden trouble seeing in one or both eyes;</p><p style="margin-left:23.35pt; margin-right:44.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden trouble walking, dizziness, loss of balance or coordination;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden, severe or prolonged headache with no known cause;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->loss of consciousness or fainting with or without seizure.</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:5.35pt; margin-right:16.6pt; text-indent:0in">Sometimes the symptoms of stroke can be brief with an almost immediate and full recovery, but you should still seek urgent medical attention as you may be at risk of another stroke.</p></td><td style="border-color:black; height:184.25pt; vertical-align:top; width:142.55pt"><p style="margin-left:5.35pt; text-indent:0in">Stroke</p></td></tr><tr><td style="border-color:black; height:38.0pt; vertical-align:top; width:300.25pt"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->swelling and slight blue discolouration of an extremity;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe pain in your stomach (acute abdomen)</p></td><td style="height:38.0pt; vertical-align:top; width:142.55pt"><p style="margin-left:5.35pt; margin-right:18.65pt; text-indent:0in">Blood clots blocking other blood vessels</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:0in"><strong><u>Blood clots in a vein</u></strong></p><p style="margin-left:11.0pt; margin-right:0in"><strong>What can happen if a blood clot forms in a vein?</strong></p><p style="margin-left:29.0pt; margin-right:28.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The use of combined hormonal contraceptives has been connected with an increase in the risk of blood clots in the vein (venous thrombosis). However, these side effects are rare. Most frequently, they occur in the first year of use of a combined hormonal contraceptive.</p><p style="margin-left:29.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If a blood clot forms in a vein in the leg or foot it can cause a deep vein thrombosis (DVT).</p><p style="margin-left:29.0pt; margin-right:62.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If a blood clot travels from the leg and lodges in the lung it can cause a pulmonary embolism.</p><p style="margin-left:29.0pt; margin-right:60.95pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Very rarely a clot may form in a vein in another organ such as the eye (retinal vein thrombosis).</p><p>&nbsp;</p><p>When is the risk of developing a blood clot in a vein highest?</p><p style="margin-left:11.0pt; margin-right:16.45pt">The risk of developing a blood clot in a vein is highest during the first year of taking a combined hormonal contraceptive for the first time. The risk may also be higher if you restart taking a combined hormonal contraceptive (the same product or a different product) after a break of 4 weeks or more.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:14.3pt">After the first year, the risk gets smaller but is always slightly higher than if you were not using a combined hormonal contraceptive.</p><p>&nbsp;</p><p style="margin-left:11.0pt">When you stop Marvelon your risk of a blood clot returns to normal within a few weeks.</p><p>&nbsp;</p><p>What is the risk of developing a blood clot?</p><p style="margin-left:11.0pt; margin-right:20.15pt">The risk depends on your natural risk of VTE and the type of combined hormonal contraceptive you are taking.</p><p style="margin-left:11.0pt; margin-right:0in">The overall risk of a blood clot in the leg or lung (DVT or PE) with Marvelon is small.</p><p style="margin-left:29.0pt; margin-right:23.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Out of 10,000 women who are not using any combined hormonal contraceptive and are not pregnant, about 2 will develop a blood clot in a year.</p><p style="margin-left:29.0pt; margin-right:19.1pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Out of 10,000 women who are using a combined hormonal contraceptive that contains levonorgestrel, norethisterone, or norgestimate about 5-7 will develop a blood clot in a year.</p><p>&nbsp;</p><p style="margin-left:29.0pt; margin-right:21.5pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Out of 10,000 women who are using a combined hormonal contraceptive that contains desogestrel such as Marvelon between about 9 and 12 women will develop a blood clot in a year.</p><p style="margin-left:29.0pt; margin-right:35.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The risk of having a blood clot will vary according to your personal medical history (see &ldquo;Factors that increase your risk of a blood clot&rdquo; below).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="height:25.3pt; vertical-align:top; width:276.95pt"><p style="margin-left:0in; text-indent:0in">&nbsp;</p></td><td style="border-color:black; height:25.3pt; vertical-align:top; width:165.85pt"><p style="margin-left:5.4pt; margin-right:6.8pt; text-indent:0in"><strong>Risk of developing a blood clot in a year</strong></p></td></tr><tr><td style="border-color:black; height:35.85pt; vertical-align:top; width:276.95pt"><p style="margin-left:9.95pt; margin-right:48.25pt; text-indent:0in">Women who are <strong>not using </strong>a combined hormonal pill/patch/ring and are not pregnant</p></td><td style="height:35.85pt; vertical-align:top; width:165.85pt"><p style="margin-left:5.4pt; text-indent:0in">About 2 out of 10,000 women</p></td></tr><tr><td style="border-color:black; height:48.05pt; vertical-align:top; width:276.95pt"><p style="margin-left:9.95pt; margin-right:26.0pt; text-indent:0in">Women using a combined hormonal contraceptive pill containing <strong>levonorgestrel, norethisterone or norgestimate</strong></p></td><td style="height:48.05pt; vertical-align:top; width:165.85pt"><p style="margin-left:5.4pt; text-indent:0in">About 5-7 out of 10,000 women</p></td></tr><tr><td style="border-color:black; height:23.95pt; vertical-align:top; width:276.95pt"><p style="margin-left:9.95pt; text-indent:0in">Women using Marvelon</p></td><td style="height:23.95pt; vertical-align:top; width:165.85pt"><p style="margin-left:5.4pt; text-indent:0in">About 9-12 out of 10,000 women</p></td></tr></tbody></table><p>&nbsp;</p><p>Factors that increase your risk of a blood clot in a vein</p><p><strong>&nbsp;</strong></p><p style="margin-left:11.0pt; margin-right:21.0pt">The risk of a blood clot with Marvelon is small but some conditions will increase the risk. Your risk is higher:</p><p style="margin-left:28.85pt; margin-right:0in; text-indent:-17.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are very overweight (body mass index or BMI over 30kg/m<sup>2</sup>);</p><p style="margin-left:28.85pt; margin-right:26.1pt; text-indent:-17.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if one of your immediate family has had a blood clot in the leg, lung or other organ at a young age (e.g. below the age of about 50). In this case you could have a hereditary blood clotting disorder;</p><p style="margin-left:28.85pt; margin-right:16.5pt; text-indent:-17.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you need to have an operation, or if you are off your feet for a long time because of an injury or illness, or you have your leg in a cast. The use of Marvelon may need to be stopped several weeks before surgery or while you are less mobile. If you need to stop Marvelon ask your doctor when you can start using it again.</p><p style="margin-left:28.85pt; margin-right:0in; text-indent:-17.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->as you get older (particularly above about 35 years);</p><p style="margin-left:28.85pt; margin-right:0in; text-indent:-17.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you gave birth less than a few weeks ago.</p><p>&nbsp;</p><p style="margin-left:11.0pt">The risk of developing a blood clot increases the more conditions you have.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:16.05pt">Air travel (&gt; 4 hours) may temporarily increase your risk of a blood clot, particularly if you have some of the other factors listed.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:20.1pt">It is important to tell your doctor if any of these conditions apply to you, even if you are unsure. Your doctor may decide that Marvelon needs to be stopped.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:18.9pt">If any of the above conditions change while you are using Marvelon, for example a close family member experiences a thrombosis for no known reason; or you gain a lot of weight, tell your doctor.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:0in"><strong><u>Blood clots in an artery</u></strong></p><p style="margin-left:11.0pt; margin-right:0in"><strong>What can happen if a blood clot forms in an artery?</strong></p><p style="margin-left:11.0pt; margin-right:42.75pt">Like a blood clot in a vein, a clot in an artery can cause serious problems. For example, it can cause a heart attack or a stroke.</p><p>&nbsp;</p><p>Factors that increase your risk of a blood clot in an artery</p><p style="margin-left:11.0pt; margin-right:21.95pt">It is important to note that the risk of a heart attack or stroke from using Marvelon is very small but can increase:</p><p style="margin-left:28.85pt; margin-right:0in; text-indent:-17.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->with increasing age (beyond about 35 years);</p><p style="margin-left:29.0pt; margin-right:15.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>if you smoke. </strong>When using a combined hormonal contraceptive like Marvelon you are advised to stop smoking. If you are unable to stop smoking and are older than 35 your doctor may advise you to use a different type of contraceptive;</p><p style="margin-left:29.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are overweight;</p><p style="margin-left:29.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have high blood pressure;</p><p style="margin-left:29.0pt; margin-right:27.55pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if a member of your immediate family has had a heart attack or stroke at a young age (less than about 50). In this case you could also have a higher risk of having a heart attack or stroke;</p><p style="margin-left:29.0pt; margin-right:65.5pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you, or someone in your immediate family, have a high level of fat in the blood (cholesterol or triglycerides);</p><p style="margin-left:29.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you get migraines, especially migraines with aura;</p><p style="margin-left:29.0pt; margin-right:16.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have a problem with your heart (valve disorder, disturbance of the rhythm called atrial fibrillation);</p><p style="margin-left:29.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have diabetes.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:15.9pt">If you have more than one of these conditions or if any of them are particularly severe the risk of developing a blood clot may be increased even more.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:27.15pt">If any of the above conditions change while you are using Marvelon, for example you start smoking, a close family member experiences a thrombosis for no known reason; or you gain a lot of weight, tell your doctor.</p><p>&nbsp;</p><p><!--[if !supportLists]-->2.2.2&nbsp; <!--[endif]-->The Pill and cancer</p><p style="margin-left:11.0pt; margin-right:17.7pt">The Pill reduces your risk of cancer of the ovary and womb if used in the long term. However, it also seems to slightly increase your risk of <strong>cancer of the cervix </strong>&ndash; although this may be due to having sex without a condom rather than the Pill itself. All women should have regular <strong>smear tests.</strong></p><p><strong>&nbsp;</strong></p><p style="margin-left:11.0pt; margin-right:22.65pt">If you have <strong>breast cancer, </strong>or have had it in the past, you should not take the Pill. The Pill slightly increases your risk of breast cancer. This risk goes up the longer you&rsquo;re on the Pill, but returns to normal within about 10 years of stopping it. Because breast cancer is rare in women under the age of 40 the extra number of cases of breast cancer in current and recent users of the Pill is small.</p><p>&nbsp;</p><p style="margin-left:11.0pt">For example:</p><p style="margin-right:26.45pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Of 10,000 women who have <strong>never taken the Pill, </strong>about 16 will have breast cancer by the time they are 35 years.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Of 10,000 women who <strong>take the Pill for 5 years in their early twenties, </strong>about <strong>17-18</strong></p><p style="margin-left:47.0pt">will have breast cancer by the time they are 35 years.</p><p>&nbsp;</p><p style="margin-left:47.0pt; margin-right:20.95pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Of 10,000 women who have <strong>never taken the Pill, </strong>about <strong>100 </strong>will have breast cancer by the time they are 45 years old.</p><p style="margin-right:24.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Of 10,000 women who <strong>take the Pill for 5 years in their early thirties, </strong>about <strong>110 </strong>will have breast cancer by the time they are 45 years old.</p><p>&nbsp;</p><p>Your risk of breast cancer is higher:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have a close relative (mother, sister or grandmother) who has had breast cancer;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are seriously overweight.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:11.15pt">&rarr;<strong>See a doctor as soon as possible if you notice any changes in your breasts, </strong>such as dimpling of the skin, changes in the nipple or any lumps you can see or feel.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:10.35pt">Taking the Pill has also been linked to liver diseases, such as jaundice and non-cancer liver tumours, but this is rare. Very rarely, the Pill has also been linked with some forms of liver cancer in women who have taken it for a long time.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:20.0pt">&rarr;<strong>See a doctor as soon as possible if you get severe pain in your stomach, or yellow skin or eyes </strong>(jaundice). You may need to stop taking Marvelon.</p><p>&nbsp;</p><p><!--[if !supportLists]-->2.2.3&nbsp; <!--[endif]-->Psychiatric disorders</p><p style="margin-left:11.0pt; margin-right:14.25pt">Some women using hormonal contraceptives including Marvelon have reported <strong>depression or depressed mood</strong>. Depression can be serious and may sometimes lead to suicidal thoughts. If you experience mood changes and depressive symptoms contact your doctor for further medical advice as soon as possible.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if !supportLists]-->2.3&nbsp; <!--[endif]-->Other medicines and Marvelon</p><p style="margin-left:11.0pt; margin-right:11.05pt">Tell your doctor, pharmacist or family planning nurse if you are using, have recently used or might use any other medicines or herbal products, even those not prescribed. Also tell any other doctor or dentist who prescribes another medicine (or your pharmacist) that you use Marvelon. This is because Marvelon can also affect how well other medicines work, causing either an increase in effect (e.g., ciclosporin) or a decrease in effect (e.g., lamotrigine). Remind your doctor if you are taking these in case your treatment needs to be adjusted.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:50.7pt">Also check the leaflets that come with all your medicines to see if they can be taken with hormonal contraceptives.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:24.65pt"><strong>Some medicines may stop Marvelon from working properly</strong>. These include medicines used for the treatment of:</p><p style="margin-left:46.4pt; margin-right:54.85pt; text-indent:-14.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>epilepsy </strong>(primidone, phenytoins, phenobarbital, carbamazepine, oxcarbazepine, topiramate, felbamate, modafinil);</p><p style="margin-left:46.4pt; text-indent:-14.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>tuberculosis </strong>(rifampicin);</p><p style="margin-left:46.4pt; text-indent:-14.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>HIV infection </strong>(ritonavir, nelfinavir, nevirapine, efavirenz);</p><p style="margin-left:46.4pt; text-indent:-14.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Hepatitis C virus infection </strong>(e.g., boceprevir, telaprevir);</p><p style="margin-left:46.4pt; text-indent:-14.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>other infectious disease </strong>(e.g., griseofulvin);</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->high blood pressure in the blood vessels of the lungs (bosentan);</p><p style="margin-left:46.4pt; text-indent:-14.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>depressive moods </strong>(the herbal remedy <strong>St. John&rsquo;s wort</strong>).</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:0in">If you are taking medicines or herbal products that might make Marvelon less effective, a barrier contraceptive method should also be used. Since the effect of another medicine on Marvelon may last up to 28 days after stopping the medicine, it is necessary to use the additional barrier contraceptive method for that long.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:33.9pt">Do not use Marvelon if you have Hepatitis C and are taking medicinal products containing ombitasvir/ paritaprevir/ ritonavir and dasabuvir as this may cause increases in liver function blood test results (increase in ALT liver enzyme).</p><p style="margin-left:11.0pt; margin-right:17.1pt">Your doctor will prescribe another type of contraceptive prior to start of the treatment with these medicinal products.</p><p style="margin-left:11.0pt; margin-right:69.95pt">Marvelon can be restarted approximately 2 weeks after completion of this treatment. See section 2.1 &ldquo;Do not use Marvelon&rdquo;.</p><p>&nbsp;</p><p><!--[if !supportLists]-->2.4&nbsp; <!--[endif]-->Marvelon with food and drink</p><p style="margin-left:11.0pt; margin-right:0in">There are no special instructions about food and drink while on Marvelon.</p><p>&nbsp;</p><p><!--[if !supportLists]-->2.5&nbsp; <!--[endif]-->Pregnancy and breast-feeding</p><p style="margin-left:11.0pt; margin-right:12.5pt">Do not use Marvelon if you are pregnant. If you think you might be pregnant, do a pregnancy test to confirm that you are before you stop taking Marvelon.</p><p>&nbsp;</p><p style="margin-left:11.0pt">Marvelon is not recommended for use during breast-feeding. Ask your doctor or family planning nurse about alternative contraception. Breast-feeding may not stop you getting pregnant.</p><p>&nbsp;</p><p><!--[if !supportLists]-->2.6&nbsp; <!--[endif]-->Driving and using machines</p><p style="margin-left:11.0pt; margin-right:0in">Marvelon has no known effect on the ability to drive or use machines.</p><p>&nbsp;</p><p><!--[if !supportLists]-->2.7&nbsp; <!--[endif]-->Marvelon contains lactose</p><p style="margin-left:11.0pt; margin-right:25.95pt">If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before using Marvelon.</p><p>&nbsp;</p><p><!--[if !supportLists]-->2.8&nbsp; <!--[endif]-->Use in adolescents</p><p style="margin-left:11.0pt; margin-right:0in">No clinical data on efficacy and safety are available in adolescents below 18 years.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:11.0pt; margin-right:28.4pt">To prevent pregnancy, always take this medicine exactly as described in this leaflet or as your doctor, family planning nurse or pharmacist has told you. Check with your doctor, family planning nurse or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Take Marvelon every day for 21 days</p><p style="margin-left:11.0pt">Marvelon comes in strips of 21 pills, each marked with a day of the week.</p><p style="margin-left:46.4pt; text-indent:-14.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Take your pill at the same time every day.</p><p style="margin-left:46.4pt; text-indent:-14.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Start by taking a pill marked with the correct day of the week.</p><p style="margin-left:46.4pt; margin-right:.4in; text-indent:-14.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Follow the direction of the arrows on the strip. Take one pill each day, until you have finished all 21 pills.</p><p style="margin-left:46.4pt; text-indent:-14.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Swallow each pill whole, with water if necessary. Do not chew the pill.</p><p>&nbsp;</p><p>Then have seven pill-free days</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:18.9pt">After you have taken all 21 pills in the strip, you have seven days when you take no pills. So if you take the last pill of one pack on a Friday, you will take the first pill of your next pack on the Saturday of the following week.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:10.3pt">Within a few days of taking the last pill from the strip, you should have a withdrawal bleed like a period. This bleed may not have finished when it is time to start your next strip of pills. You don&rsquo;t need to use extra contraception during these seven pill-free days &ndash; as long as you have taken your pills correctly and start the next strip of pills on time.</p><p>&nbsp;</p><p>Then start your next strip</p><p style="margin-left:11.0pt; margin-right:42.75pt">Start taking your next strip of Marvelon after the seven pill-free days &ndash; even if you are still bleeding. Always start the new strip on time.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:18.9pt">As long as you take Marvelon correctly, you will always start each new strip on the same day of the week.</p><p>&nbsp;</p><p><!--[if !supportLists]-->3.2&nbsp; <!--[endif]-->Starting Marvelon</p><p style="margin-left:11.0pt; margin-right:0in"><strong>As a new user or starting the Pill again after a break</strong></p><p style="margin-left:11.0pt; margin-right:20.4pt"><strong>Either </strong>take your first Marvelon pill on the first day of your next period. By starting in this way, you will have contraceptive protection with your first pill.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:.15in; text-align:justify"><strong>Or </strong>if your period has already begun start taking Marvelon on day 5 (counting the first day of your period as day 1) whether or not your bleeding has stopped. You must also use extra contraception, such as condoms, until you have taken the first seven pills correctly.</p><p>&nbsp;</p><p>Changing to Marvelon from another contraceptive Pill</p><p style="margin-left:46.4pt; margin-right:11.7pt; text-align:justify; text-indent:-14.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>If you are currently on a 21-day Pill: </strong>start taking Marvelon the next day after the end of the previous strip. You will have contraceptive protection with your first pill but you will not have a bleed until after you finish your first strip of Marvelon.</p><p style="margin-left:46.4pt; margin-right:11.0pt; text-indent:-14.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>If you are currently on a 28-day Pill: </strong>start taking Marvelon the day after your last active pill. You will have contraceptive protection with your first pill. You will not have a bleed until after you finish your first strip of Marvelon.</p><p style="margin-left:46.4pt; margin-right:13.25pt; text-indent:-14.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Or if you are taking a progestogen-only Pill </strong>(mini-Pill or POP): start Marvelon on the first day of bleeding, even if you have already taken the POP for that day. You will have contraceptive cover straight away. If you don&rsquo;t usually have any bleeding while you are taking a progestogen-only Pill, you can stop taking it any day and start Marvelon the next day. You will need to use extra contraception, such as a condom, for seven days.</p><p>&nbsp;</p><p>Changing to Marvelon from a progestogen-only injection, implant of progestogen releasing intrauterine device (IUD)</p><p style="margin-left:11.0pt; margin-right:10.85pt; text-align:justify">Start taking Marvelon when your next injection is due or on the day that your implant or IUD is removed. Make sure you also use an additional contraceptive method, such as a condom, for the first 7 days that you are taking Marvelon.</p><p>&nbsp;</p><p>Starting Marvelon after a miscarriage or abortion</p><p style="margin-left:11.0pt; margin-right:24.1pt">If you have had a miscarriage or an abortion, your doctor may tell you to start taking Marvelon straight away. This means that you will have contraceptive protection with your first pill.</p><p>&nbsp;</p><p>Contraception after having a baby</p><p style="margin-left:11.0pt">If you have just had a baby, ask your doctor for advice about contraception.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:0in">If you are not breast-feeding:</p><p style="margin-left:46.4pt; text-indent:-14.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->you can start taking Marvelon three weeks after the birth or,</p><p style="margin-left:46.4pt; margin-right:16.4pt; text-indent:-14.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->you can start taking Marvelon more than three weeks after the birth but you need to use extra contraception, such as a condom until you have taken the first seven pills correctly.</p><p style="margin-left:46.4pt; margin-right:21.5pt; text-indent:-14.05pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have had sex since the birth there is a chance that you could be pregnant, you should therefore use another form of contraception, such as a condom. In this case, take your first Marvelon pill on the first day of your next period.</p><p>&nbsp;</p><p><!--[if !supportLists]-->3.3&nbsp; <!--[endif]-->A missed pill</p><p style="margin-left:11.0pt; margin-right:0in">If you miss a pill, follow these instructions:</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="image3.png" o:spid="_x0000_s1026" type="#_x0000_t75"
  style='position:absolute;margin-left:113.55pt;margin-top:12.45pt;width:388.3pt;
  height:337.9pt;z-index:251655168;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--><!--[if !vml]--></p><table align="left" cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="518" height="451" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></td></tr></tbody></table><p><!--[endif]--><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:19.85pt; text-align:justify"><strong>If you have missed any of the pills in a strip, and you do not bleed </strong>in the first pill-free break, you may be pregnant. <strong>Contact your doctor or family planning clinic, or do a pregnancy test yourself.</strong></p><p><strong>&nbsp;</strong></p><p style="margin-left:11.0pt; margin-right:11.25pt">If you start a new strip of pills late, or make your &ldquo;week off&rdquo; longer than seven days, you may not be protected from pregnancy. If you had sex in the last seven days, ask your doctor, family planning nurse or pharmacist for advice. You may need to consider emergency contraception.</p><p style="margin-left:11.0pt">You should also use extra contraception, such as a condom, for seven days.</p><p>&nbsp;</p><p><!--[if !supportLists]-->3.4&nbsp; <!--[endif]-->A lost pill</p><p style="margin-left:11.0pt; margin-right:0in">If you lose a pill,</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:24.7pt"><strong>Either </strong>take the last pill of the strip in place of the lost pill. Then take all the other pills on their proper days. Your cycle will be one day shorter than normal, but your contraceptive protection won&rsquo;t be affected. After your seven pill-free days you will have a new starting day, one day earlier than before.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:11.6pt"><strong>Or </strong>if you do not want to change the starting day of your cycle, take a pill from a spare strip. Then take all the other pills from your current strip as usual. You can then keep the opened spare strip in case you lose any more pills.</p><p>&nbsp;</p><p><!--[if !supportLists]-->3.5&nbsp; <!--[endif]-->If you are sick or have diarrhoea</p><p style="margin-left:11.0pt; margin-right:47.3pt">If you are sick (<em>vomit</em>) or have very bad diarrhoea your body may not get its usual dose of hormones from that pill.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:11.75pt">If you vomit within <strong>3 to 4 hours </strong>after taking your pill, this is like missing a pill. You must follow the advice for missed pills &ndash; see section 3.3, <em>A missed pill.</em></p><p><em>&nbsp;</em></p><p style="margin-left:11.0pt; margin-right:52.2pt">If you have severe diarrhoea for <strong>more than 12 hours after taking Marvelon </strong>follow the instructions for if you are more than 12 hours late &ndash; see section 3.3, <em>A missed pill.</em></p><p><em>&nbsp;</em></p><p>&rarr;Talk to your doctor if your stomach upset carries on or gets worse. He or she may recommend another form of contraception.</p><p><strong>&nbsp;</strong></p><p style="margin-left:27.5pt; text-indent:-16.5pt"><!--[if !supportLists]--><strong>3.6&nbsp; </strong><!--[endif]--><strong>Missed a period &ndash; could you be pregnant?</strong></p><p style="margin-left:11.0pt; margin-right:18.1pt; text-align:justify">Occasionally, you may miss a withdrawal bleed. This could mean that you are pregnant, but that is very unlikely if you have taken your pills correctly. Start your next strip at the normal time. If you think that you might have put yourself at risk of pregnancy (for example, by missing pills or taking other medicines), or if you miss a second bleed, you should do a pregnancy test. You can buy these from the chemist or get a free test at your family planning clinic or doctors surgery. If you are pregnant, stop taking Marvelon and see your doctor.</p><p>&nbsp;</p><p><!--[if !supportLists]-->3.7&nbsp; <!--[endif]-->Taking more than one pill should not cause harm</p><p style="margin-left:11.0pt; margin-right:13.65pt">It is unlikely that taking more than one pill will do you any harm, but you may feel sick, vomit or have some vaginal bleeding. Talk to your doctor if you have any of these symptoms.</p><p>&nbsp;</p><p><!--[if !supportLists]-->3.8&nbsp; <!--[endif]-->You can delay a period</p><p style="margin-left:11.0pt; margin-right:11.25pt">If you want to delay having a period, finish the strip of pills you are taking. Start the next strip the next day without a break. Take this strip the usual way. After the second strip, leave seven pill- free days as usual, then start your next strip of pills in the normal way. When you use the second strip, you may have some unexpected bleeding or spotting on the days that you take the pill, but don&rsquo;t worry.</p><p>&nbsp;</p><p><!--[if !supportLists]-->3.9&nbsp; <!--[endif]-->When you want to get pregnant</p><p style="margin-left:11.0pt; margin-right:22.25pt">If you are planning a baby, it&rsquo;s best to use another method of contraception after stopping Marvelon until you have had a proper period. Your doctor or midwife relies on the date of your</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:11.25pt">last natural period before you get pregnant to tell you when your baby is due. However, it will not cause you or the baby any harm if you get pregnant straight away.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:11.0pt; margin-right:28.4pt; text-align:justify">Like all medicines, Marvelon can cause side effects, although not everybody gets them. If you get any side effect, particularly if severe and persistent, or have any change to your health that you think may be due to Marvelon, please talk to your doctor<strong>.</strong></p><p><strong>&nbsp;</strong></p><p style="margin-left:11.0pt; margin-right:10.9pt">An increased risk of blood clots in your veins (venous thromboembolism (VTE)) or blood clots in your arteries (arterial thromboembolism (ATE)) is present for all women taking combined hormonal contraceptives. For more detailed information on the different risks from taking combined hormonal contraceptives please see section 2 &ldquo;What you need to know before you use Marvelon&rdquo;.</p><p><!--[if !supportLists]-->4.1&nbsp; <!--[endif]-->Serious side effects &ndash; see a doctor straight away Signs of deep vein thrombosis include:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->swelling of one leg or along a vein in the leg or foot especially when accompanied by:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->pain or tenderness in the leg which may be felt only when standing or walking;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->increased warmth in the affected leg;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->change in colour of the skin on the leg e.g. turning pale, red or blue.</p><p>&nbsp;</p><p>Signs of a pulmonary embolism:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden unexplained breathlessness or rapid breathing;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden cough without an obvious cause, which may bring up blood;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sharp chest pain which may increase with deep breathing;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe light headedness or dizziness;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->rapid or irregular heartbeat;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe pain in your stomach.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:17.95pt">If you are unsure, talk to a doctor as some of these symptoms such as coughing or being short of breath may be mistaken for a milder condition such as a respiratory tract infection (e.g. a &lsquo;common cold&rsquo;).</p><p>&nbsp;</p><p>Signs of retinal vein thrombosis (blood clot in the eye):</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->symptoms most commonly occur in one eye:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->immediate loss of vision or</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->painless blurring of vision which can progress to loss of vision.</p><p>&nbsp;</p><p>Signs of heart attack:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->chest pain, discomfort, pressure, heaviness;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sensation of squeezing or fullness in the chest, arm or below the breastbone;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->fullness, indigestion or choking feeling;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->upper body discomfort radiating to the back, jaw, throat, arm and stomach;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sweating, nausea, vomiting or dizziness;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->extreme weakness, anxiety, or shortness of breath;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->rapid or irregular heartbeats.</p><p>&nbsp;</p><p>Signs of a stroke:</p><p>&nbsp;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden weakness or numbness of the face, arm or leg, especially on one side of the body;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden confusion, trouble speaking or understanding;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden trouble seeing in one or both eyes;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden trouble walking, dizziness, loss of balance or coordination;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden, severe or prolonged headache with no known cause;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->loss of consciousness or fainting with or without seizure.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:18.6pt">Sometimes the symptoms of stroke can be brief with an almost immediate and full recovery, but you should still seek urgent medical attention as you may be at risk of another stroke.</p><p>&nbsp;</p><p>Signs of blood clots blocking other blood vessels:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->swelling and slight blue discolouration of an extremity;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe pain in your stomach (acute abdomen).</p><p>&nbsp;</p><p>Signs of a severe allergic reaction to Marvelon</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->swelling of the face, lips, mouth, tongue or throat.</p><p>&nbsp;</p><p>Signs of breast cancer include:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->dimpling of the skin;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->changes in the nipple;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->any lumps you can see or feel.</p><p>&nbsp;</p><p>Signs of cancer of the cervix include:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->vaginal discharge that smells and contains blood;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->unusual vaginal bleeding;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->pelvic pain;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->painful sex.</p><p>&nbsp;</p><p>Signs of severe liver problems include:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe pain in your upper abdomen;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->yellow skin or eyes (jaundice).</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:19.7pt">&rarr;<strong>If you think you may have any of these, see a doctor straight away. </strong>You may need to stop taking Marvelon.</p><p>&nbsp;</p><p><!--[if !supportLists]-->4.2&nbsp; <!--[endif]-->Possible side effects</p><p style="margin-left:11.0pt; margin-right:0in"><strong>Common </strong>(may affect up to 1 in 10 people):</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Headache;</p><p style="margin-left:46.4pt; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Putting on weight</strong>;</p><p style="margin-left:46.4pt; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Breast problems</strong>, such as painful or tender breasts;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Depression or mood changes;</p><p style="margin-left:46.4pt; text-indent:-21.75pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Stomach problems, </strong>such as nausea; abdominal pain;</p><p>&nbsp;</p><p style="margin-left:11.0pt"><strong>Uncommon </strong>(may affect up to 1 in 100 people):</p><p style="margin-right:15.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Migraine </strong>(see a doctor as soon as possible if this is your first migraine or it&rsquo;s worse than usual, or if the headache is severe, unusual or long lasting);</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Fluid retention </strong>(swollen hands, ankles or feet &ndash; a sign of fluid retention);</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Decreased sexual desire;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Vomiting</strong>;</p><p>&nbsp;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Diarrhoea</strong>;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Skin problems, such as rash or hives</strong>;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Breast enlargement</strong>;</p><p>&nbsp;</p><p style="margin-left:11.0pt; text-align:justify"><strong>Rare </strong>(may affect up to 1 in 1000 people):</p><p style="margin-right:20.6pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Changes in vaginal secretions&ndash;Irregular vaginal bleeding </strong>- see section 4.3, Bleeding between periods should not last long;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Breasts producing a milky fluid from the nipples;</p><p style="text-indent:-14.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Hypersensitivity reactions</strong>;</p><p style="text-indent:-14.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Discomfort of the eyes if you wear contact lenses</strong>;</p><p style="text-indent:-14.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Erythema nodosum (bruise-like swelling to the shins)</strong>;</p><p style="text-indent:-14.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Erythema multiforme (this is a skin condition)</strong>;</p><p style="text-indent:-14.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Decreased weight</strong>;</p><p style="text-indent:-14.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Increased sexual desire</strong>;</p><p style="text-indent:-14.8pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Harmful blood clots </strong>in a vein or artery for example:</p><p style="margin-left:60.65pt; margin-right:0in; text-indent:-14.25pt"><!--[if !supportLists]-->o&nbsp; <!--[endif]-->in a leg or foot (i.e. DVT);</p><p style="margin-left:60.65pt; text-indent:-14.25pt"><!--[if !supportLists]-->o&nbsp; <!--[endif]-->in a lung (i.e. PE);</p><p style="margin-left:60.65pt; text-indent:-14.25pt"><!--[if !supportLists]-->o&nbsp; <!--[endif]-->heart attack;</p><p style="margin-left:60.65pt; text-indent:-14.25pt"><!--[if !supportLists]-->o&nbsp; <!--[endif]-->stroke;</p><p style="margin-left:60.65pt; margin-right:13.4pt; text-indent:-14.25pt"><!--[if !supportLists]-->o&nbsp; <!--[endif]-->mini-stroke or temporary stroke-like symptoms, known as a transient ischaemic attack (TIA);</p><p style="margin-left:60.65pt; margin-right:0in; text-indent:-14.25pt"><!--[if !supportLists]-->o&nbsp; <!--[endif]-->blood clots in the liver, stomach/intestine, kidneys or eye.</p><p style="margin-left:11.0pt; margin-right:21.8pt; text-align:justify">The chance of having a blood clot may be higher if you have any other conditions that increase this risk. (See section 2 for more information on the conditions that increase risk for blood clots and the symptoms of a blood clot.)</p><p style="margin-left:46.4pt; margin-right:0in; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Severe <strong>allergic reaction </strong>to Marvelon</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Breast cancer</p><p style="margin-left:46.4pt; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Cancer of the cervix</strong></p><p style="margin-left:46.4pt; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Severe <strong>liver problems</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->High blood pressure</p><p style="margin-left:46.4pt; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Gall stones</strong></p><p style="margin-left:46.4pt; margin-right:33.95pt; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Chorea </strong>(a problem with the nervous system causing jerky movements that you can&rsquo;t control)</p><p style="margin-left:46.4pt; margin-right:21.15pt; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Worsening of <strong>systemic lupus erythematosus </strong>(SLE; when your immune system attacks your body causing, for example, joint ache and tiredness)</p><p style="margin-left:46.4pt; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Stomach and intestine problems </strong>such as pancreatitis; Crohn&rsquo;s disease; ulcerative colitis</p><p style="margin-left:46.4pt; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Worsening of <strong>otosclerosis </strong>(a hearing problem)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Problems with blood sugar</p><p style="margin-left:46.4pt; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Worsening of a rare condition called <strong>porphyria</strong></p><p style="margin-left:46.4pt; text-indent:-21.25pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Worsening of <strong>skin problems, </strong>such as brown patches on your face or body <em>(chloasma)</em></p><p style="margin-left:46.4pt; margin-right:0in">blister-like rash, (<em>herpes gestationis)</em></p><p><em>&nbsp;</em></p><p style="margin-left:11.0pt; margin-right:29.25pt; text-align:justify">&rarr;<strong>Tell your doctor, pharmacist or family planning nurse </strong>if you are worried about any side effects which you think may be due to Marvelon. Also tell them if any existing conditions get worse while you are taking Marvelon.</p><p>&nbsp;</p><p><!--[if !supportLists]-->4.3&nbsp; <!--[endif]-->Bleeding between periods should not last long</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:13.35pt">A few women have a little unexpected bleeding or spotting while they are taking Marvelon, especially during the first few months. Normally, this bleeding is nothing to worry about and will stop after a day or two. Keep taking Marvelon as usual; the problem should disappear after the first few strips.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:22.25pt">You may also have unexpected bleeding if you are not taking your pills regularly, so try to take your pill at the same time every day. Also, unexpected bleeding can sometimes be caused by other medicines.</p><p>&nbsp;</p><p style="margin-left:11.0pt">&rarr;<strong>Make an appointment to see your doctor </strong>if you get breakthrough bleeding or spotting that:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->carries on for more than the first few months</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->starts after you&rsquo;ve been taking Marvelon for a while</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->carries on even after you&rsquo;ve stopped taking Marvelon.</p><p>&nbsp;</p><p>Reporting of side effects</p><p style="margin-left:11.0pt; margin-right:11.55pt">If you get any side effects, talk to your doctor, family planning nurse or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA. By reporting side effects you can help provide more information on the safety of this medicine.</p><p style="margin-left:5.0pt; margin-right:-1.0pt">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:11.0pt; margin-right:0in">Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:15.9pt">Do not use Marvelon after the expiry date which is stated on the carton. The expiry date is written on outer pack &amp; inner label.</p><p>&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt">Store Marvelon below 30 &deg;C. Do not freeze.</p><p style="margin-left:11.0pt; margin-right:35.85pt">Store in the original package, in order to protect from light and moisture.</p><p style="margin-left:11.0pt; margin-right:16.45pt">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->1.&nbsp; <!--[endif]-->information What Marvelon contains</p><p style="margin-left:11.0pt; margin-right:13.45pt">The active substances are desogestrel and ethinyl estradiol. Each tablet contains: 0.150 mg of the progestogen desogestrel, and 0.030 mg of the oestrogen ethinyl estradiol.</p><p style="margin-left:11.0pt; margin-right:19.55pt">The other ingredients are: potato starch, povidone, stearic acid, silica colloidal anhydrous, alpha-tocopherol, lactose monohydrate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Marvelon looks like and contents of the pack Each box of Marvelon contains three strips of 21 tablets. Each strip of Marvelon contains 21 white tablets.
The tablets are biconvex, round and 6 mm in diameter. Each tablet is marked TR5 on one side and Organon* on the reverse side.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder and Manufacturer</p><p>&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt">N.V. Organon</p><p style="margin-left:5.0pt; margin-right:-1.0pt">Kloosterstraat 6</p><p style="margin-left:11.0pt; margin-right:251.9pt">5349 AB Oss, The Netherlands</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in December 2018. Version No. (04) 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="text-align:right" dir="RTL">مارفيلون هو أقراص منع الحمل المُركّبة تُؤخذ عن طريق الفم (&#39;حبوب منع الحمل&#39;). تتناولينها أنتِ لتجنّب حدوث الحمل.</p><p style="text-align:right" dir="RTL">تحتوي أقراص منع الحمل هذه ذات الجرعة المنخفضة على نوعين من الهرمونات الجنسية الأنثويّة، هرمون الاستروجين والبروجستيرون. هذه الهرمونات تمنع تحرير البويضة من المبايض لديكِ وبذلكَ تمنع حدوث الحمل. كما يزيد مارفيلون من كثافة السائل (المخاط) الطبيعي الموجود في عنق الرّحم مما يجعل من الصعب على الحيوانات المنوية دخول الرحم.</p><p style="text-align:right" dir="RTL">مارفيلون عبارة عن أقراص لمنع الحمل تُستخدم لمدة ٢١ يومًا &ndash; بحيث تتناولين قرصًا واحدًا كل يوم لمدة ٢١ يومًا، تليها ٧ أيام من الاستراحة لا تتناولين خلالها أي قرص.</p><p style="text-align:right" dir="RTL"><strong>فوائد تناول أقراص منع الحمل</strong> ما يلي:</p><p style="text-align:right" dir="RTL">&bull; هي أحد أكثر الطرق الموثوقة لمنع الحمل وتأثيرها قابل للإلغاء إذا ما استُخدمت بشكل صحيح.<br />&bull; لا تتعارض مع العلاقة الحميمة.<br />&bull; تعمل عادة على انتظام الدورة الشهريّة مع التقليل من النزف والألم المصاحب لها.<br />&bull; قد تساعد في الحدّ من أعراض ما قبل الطمث.</p><p style="text-align:right" dir="RTL">لن يحميك مارفيلون من الأمراض التي تنتقل جنسيًّا، مثل الكِلاميديا أو فيروس نقص المناعة البشرية. إذ يمكن للواقي الذكري فقط أن يُساعد على ذلكِ.</p><p style="text-align:right" dir="RTL"><strong>ينبغي تناول مارفيلون حسب الإرشادات كي يمنع الحمل.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right" dir="RTL"><strong>ملاحظات عامة</strong><br />يجب عليك قبل البدء في استخدام مارفيلون قراءة المعلومات حول جلطات الدم في الفقرة رقم ٢. من المهم بشكل خاص قراءة أعراض تجلط الدم - انظري الفقرة رقم ٢ &quot;جلطات الدم&quot;.</p><p style="text-align:right" dir="RTL">من المهم أن تفهمي فوائد ومخاطر استخدام حبوب منع الحمل قبل البدء في تناولها، أو عند اتخاذ قرار بشأن الاستمرار في تناولها. وعلى الرغم من أن حبوب منع الحمل تناسب معظم النساء الصحيحات، إلا أنّها لا تُناسب الجميع.<br />&larr; <strong>أخبري طبيبك</strong> إذا كان لديك أيّ من الأمراض أو عوامل الخطر المُدرجة في هذه النشرة.</p><p style="text-align:right" dir="RTL"><strong>قبل البدء في تناول حبوب منع الحمل</strong></p><p style="text-align:right" dir="RTL">&bull; سوف یستفسر طبیبك عن تاريخك الصحي وعن المشاکل الصحيّة لدى عائلتك وسيتحقّق من ضغط الدم لديك. قد يحتاج أيضا إلى إجراء فحوص أخرى، مثل فحص الثدي.</p><p style="text-align:right" dir="RTL"><strong>أثناء استخدامك لحبوب منع الحمل</strong><br />&bull; ستحتاجين إلى <strong>فحوصات منتظمة</strong> من قِبل طبيبك أو ممرضة تنظيم الأسرة، وعادة يتم ذلكِ عندما تحتاجين إلى وصفة طبية أخرى من حبوب منع الحمل.<br />&bull; يجب عليك إجراء <strong>فحص</strong> <strong>مسْح عُنق الرّحم بانتظام</strong>.<br />&bull; <strong>افحصي ثدييك</strong> وحلماتك كل شهر بحثًا عن أي تغييرات - أخبري طبيبك إذا شعرت أو لاحظت أيّ شيء غريب، مثل كتلة أو تنقر جلد الثدي.<br />&bull; <strong>إذا كنت بحاجة إلى إجراء فحص دم</strong> أخبري طبيبك بأنك تتناولين حبوب منع الحمل، لأنّ حبوب منع الحمل قد تؤثر على نتائج بعض الفحوصات.<br />&bull; <strong>إذا كنت ستخضعين لعملية جراحيّة</strong>، تأكدي من أن طبيبك يعرف ذلكَ. قد تحتاجين إلى التوقف عن تناول حبوب منع الحمل حوالي ٤-٦ أسابيع قبل العملية. وذلكِ للحد من خطر تجلط الدم (انظري الفقرة رقم ٢&ndash;١). سيخبرك طبيبك متى يمكنك العودة&nbsp; لتناول حبوب منع الحمل مرة أخرى.</p><p style="text-align:right" dir="RTL"><strong>٢&ndash;١ لا تستخدمي مارفيلون</strong><br />يجب عدم استخدام مارفيلون إذا كان لديك أي من الحالات المذكورة أدناه. إذا كان لديك أي من الحالات المذكورة أدناه، يجب أن تخبري طبيبك. سوف يناقش طبيبك استخدام شكل آخر من وسائل تحديد النسل&nbsp; أكثر ملاءمة لكِ. انظري أيضا الفقرة رقم ٢&ndash;٢ &quot;التحذيرات والاحتياطات&quot;.</p><p style="text-align:right" dir="RTL">&bull; إذا كنتِ تعانين (أو عانيتِ في أيّ وقت مضى) من تجلط الدم في الأوعية الدموية في ساقيك (خثار الأوردة العميقة، DVT)، أو في الرئتين (الانسداد الرئوي،&quot;PE&quot;) أو في غير ذلكَ من الأعضاء؛<br />&bull; إذا كنتِ تعلمين أنّ لديكِ اضطرابًا يؤثر على تخثر الدم - على سبيل المثال، نقص بروتين ج C، نقص بروتين س S، نقص أضداد الثرومبين ٣، العامل الخامس لايدن أو أجسام مضادة للفوسفوليبيد؛<br />&bull; إذا كنتِ بحاجة إلى إجراء عملية أو إذا اضطررتِ لعدم الحركة لفترة طويلة (انظري فقرة &#39;جلطات الدم&#39;)؛<br />&bull; إذا تعرّضتِ في أيّ وقت مضى إلى نوبة قلبيّة أو السكتة الدماغية.<br />&bull; إذا كنتِ تعانين (أو عانيت في أيّ وقت مضى) من الذبحة الصدرية (وهي حالة تسبب ألم شديد في الصدر وقد تكون أول علامة على حدوث نوبة قلبية) أو نوبات نقص التروية العابرة [TIA - أعراض السكتة الدماغية المؤقتة])؛<br />&bull; إذا كان لديك أيّ من الأمراض التالية التي قد تزيد من خطر حدوث جلطة في الشرايين:<br />&nbsp; - مرض السكري الحاد مع تضرّر الأوعية الدموية،<br />&nbsp; - ارتفاع ضغط الدم،<br />&nbsp; - مستوًى عالٍ جدا من الدهون في الدم (الكِوليسترول أو الدهون الثلاثية)،<br />&nbsp; - حالة تُعرف باسم فرط هوموسيستين الدم.<br />&bull; إذا كنتِ تعانين (أو عانيت في أيّ وقت مضى) من نوع من الصداع النصفي يسمى &#39;الصداع النصفي مع الهالة&#39;؛<br />&bull; إذا کنتِ تعانين أو عانيت مؤخّرًا من <strong>أمراض کبدیة حادة؛</strong><br />&bull; إذا كان لديكِ في أي وقت مضى <strong>ورم في الكِبد</strong>؛<br />&bull; إذا كان لديكِ أو عانيتِ في السابق من <strong>التهاب البنكرياس</strong> (التهاب البنكرياس) المرتبط بمستويات عالية من<br />&nbsp; المواد الدهنية في الدم.<br />&bull; <strong>الحمل</strong> المعروف أو المشتبه به.<br />&bull; إذا كان لديكِ <strong>سرطان</strong> يتأثر بالهرمونات الجنسية - مثل بعض سرطانات الثدي، سرطان بطانة الرحم أو المبيض؛<br />&bull; إذا كان لديك نزيف مهبلي لم يشرح لكِ الطبيب سببه؛<br />&bull; إذا كان لديك حساسية (رد فعل تحسّسي) نحو أيّ من المكوّنات في مارفيلون.</p><p style="text-align:right" dir="RTL">&bull; إذا كان لديكِ التهاب الكبد الوبائي نوع ج C وتتناولين الأدوية التي تحتوي على أومبيتاسفير/باريتابريفير/رينونافير وداسابوفير (انظر أيضا البند ٢&ndash;٣&nbsp; أدوية أخرى ومارفيلون).</p><p style="text-align:right" dir="RTL">&larr; إذا كنتِ تعانين من أيّ مما ذكر أعلاه، أو تعرضت لها للمرّة ألأولى أثناء تناولكِ مارفيلون، راجعي طبيبك في أقرب وقت ممكن. لا تتناولي مارفيلون.</p><p style="text-align:right" dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:10.5pt;margin-top:72.5pt;width:455.5pt;height:117.55pt;z-index:251644416;
 visibility:visible;mso-height-percent:200;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-bottom:3.6pt;mso-height-percent:200;mso-width-relative:margin;
 mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><u><span lang=AR-SA style='font-size:14.0pt;line-height:
    107%;font-family:"Traditional Arabic",serif'>اطلبي العناية الطبية العاجلة</span></u><span
    lang=AR-SA style='font-size:14.0pt;line-height:107%;font-family:"Traditional Arabic",serif'><br>
    - إذا لاحظتِ علاماتٍ محتملة لتجلط دموي قد تعني أنّك تعانين من تجلط الدم في
    الساق (أي تخثر الأوردة العميقة)، وتجلط الدم في الرئة (أي الانسداد الرئوي)،
    والنوبة القلبية أو السكتة الدماغية (انظري فقرة<span
    style='mso-spacerun:yes'>  </span>&quot;جلطات الدم&quot; أدناه).</span><span
    dir=LTR style='font-size:14.0pt;line-height:107%;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><span lang=AR-SA style='font-size:14.0pt;line-height:
    107%;font-family:"Traditional Arabic",serif'>للحصول على وصف أعراض هذه
    الآثار الجانبية الخطيرة يرجى قراءة فقرة &quot;كيفية التعرّف على الجلطة
    الدّموية&quot;.</span><span dir=LTR style='font-size:14.0pt;line-height:
    107%;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><!--[if !vml]--><img width="612" height="161" alt="Text Box: اطلبي العناية الطبية العاجلة
- إذا لاحظتِ علاماتٍ محتملة لتجلط دموي قد تعني أنّك تعانين من تجلط الدم في الساق (أي تخثر الأوردة العميقة)، وتجلط الدم في الرئة (أي الانسداد الرئوي)، والنوبة القلبية أو السكتة الدماغية (انظري فقرة  &quot;جلطات الدم&quot; أدناه).
للحصول على وصف أعراض هذه الآثار الجانبية الخطيرة يرجى قراءة فقرة &quot;كيفية التعرّف على الجلطة الدّموية&quot;.
" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[endif]--><strong>٢&ndash;٢ </strong><strong>&nbsp;التحذيرات والاحتياطات</strong><br />متى يجب عليك الاتصال بطبيبك؟<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p style="text-align:right" dir="RTL"><strong>أخبري طبيبك إذا كان أي من الحالات التالية تنطبق عليك.</strong><br />يجب عليك أيضًا أن تخبري طبيبك إذا تعرّضت للحالة، أو تفاقمت الحالة أثناء استخدام مارفيلون .</p><p style="text-align:right" dir="RTL">&bull; إذا كان لديكِ في أي وقت مضى مشاكل في <strong>قلبك أو الدورة الدموية أو تخثر الدم.</strong><br />&bull; إذا كنتِ مصابة <strong>بمرض السكري.</strong><br />&bull; إذا كنتِ تعانين من <strong>مشاكل في الكِلى أو الكِبد.</strong><br />&bull; إذا تعرّضتِ في أيّ وقت مضى <strong>للاكتئاب الشديد</strong>.<br />&bull; إذا كنتِ تعانين من <strong>الصداع النصفي.</strong><br />&bull; إذا سبق وتعرّضتِ <strong>أثناء الحمل أو أثناء استخدام حبوب منع الحمل</strong> إلى حالات، مثل:<br />&nbsp; - حكة في الجسم بأكمله (حكة)،<br />&nbsp; - اليرقان الذي لم يحدث بسبب العدوى،<br />&nbsp; - حصى المرارة،<br />&nbsp; - الذئبة الحمراء الشاملة (SLE)<br />&nbsp; - الطفح الجلدي على شكل نفطات، يُسمى هربس الحمل،<br />&nbsp; - مشكلة في السمع تسمى تصلب الأذن،<br />&nbsp; - حالات نادرة أخرى تسمى البورفيريا ووذمة وعائية وراثية.<br />&bull; إذا كان لديكِ بقع بنية على وجهك أو جسمك (كلف) - إذا كان الأمر كذلك تجنبي التعرض للكِثير من أشعة الشمس أو الأشعة فوق البنفسجية.<br />&bull; إذا كان لديكِ مرض كراون أو التهاب القولون التقرحي (مرض التهاب الأمعاء المزمن).<br />&bull; إذا كان لديكِ الذئبة الحمراء الشاملة (مرض الذئبة الحمراء - مرض يؤثر على نظام الدفاع الطبيعي الخاص بك).<br />&bull; إذا كان لديكِ متلازمة انحلال الدم اليوريميّة (HUS - اضطراب تخثر الدم مما يُسبب فشل الكِلى).<br />&bull; إذا كان لديكِ فقر الدم المنجلي (مرض وراثي يُصيب خلايا الدم الحمراء).<br />&bull; إذا كان لديكِ مستويات مرتفعة من الدهون في الدم (ارتفاع مستوى الدهون الثلاثية في الدم) أو تاريخ عائلي إيجابي لهذه الحالة. ويرتبط ارتفاع مستوى الدهون الثلاثية مع زيادة خطر التهاب البنكرياس (التهاب البنكرياس).<br />&bull; إذا كنتِ بحاجة إلى إجراء عملية، أو لازمتِ السرير لفترة طويلة (انظري فقرة رقم ٢ &#39;جلطات الدم&#39;).<br />&bull; إذا كنتِ قد وضعت مولودًا للتّو، فأنتِ في خطر متزايد من حدوث جلطات الدم. يجب عليك أن تسألي طبيبك كيف يمكنك البدء في استخدام مارفيلون بعد وقت قصير من الولادة (انظري فقرة ٢&ndash;٢&ndash;١ حبوب منع الحمل والتجلط).<br />&bull; إذا كان لديكِ التهاب في الأوردة تحت الجلد (التهاب الوريد الخثاري السطحي).<br />&bull; إذا كان لديكِ عروق الدوالي.</p><p style="text-align:right" dir="RTL"><strong>٢&ndash;٢&ndash;١ حبوب منع الحمل والتجلط<br />جلطات الدم</strong></p><p style="text-align:right" dir="RTL">استخدام وسائل منع الحمل الهرمونية المُركّبة مثل مارفيلون، يزيد من خطر إصابتك بتجلط الدم مقارنة مع عدم استخدامها. وفي حالات نادرة، يمكن لجلطات الدم أن تؤدي إلى إغلاق الأوعية الدموية بالكِامل وبالتالي حدوث مشاكل خطيرة.</p><p style="text-align:right" dir="RTL">يمكن أن تتكون الجلطات الدموية في:<br />&bull; الأوردة (ويُشار إليها في هذه الحالة باسم &quot;تخثر وريدي&quot;، &quot;الجلطات الدموية الوريدية&quot; أو VTE)<br />&bull; الشرايين (ويُشار إليها باسم &quot;تخثر الشرايين&quot;، &quot;الجلطات الدموية الشريانية&quot; أو ATE).</p><p style="text-align:right" dir="RTL">التعافي من جلطات الدم قد لا يكون بشكل كامل دائمًا. ونادرًا، قد تكون هناك آثار دائمة خطيرة، أو نادرًا جدًّا، قد تكون قاتلة.</p><p style="text-align:right" dir="RTL"><strong>من المهم أن نتذكر أن الخطر الكُلِّي لحدوث تجلط الدم الضار بسبب مارفيلون يعتبر قليلًا.</strong></p><p style="text-align:right" dir="RTL"><strong>كيفية التعرف على أعراض الجلطة الدموية</strong></p><p style="text-align:right" dir="RTL">اطلبي العناية الطبية العاجلة إذا لاحظتِ أيّ من العلامات أو الأعراض التالية.</p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL"><strong>&nbsp;</strong></p><table style="width:595px" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="background-color:#cccccc; border-color:black; height:25.8pt; width:177.15pt"><p style="text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:-1.0pt; margin-right:9.65pt; text-align:right" dir="RTL">ما السبب المحتمل وراء حدوث هذه الأعراض؟</p></td><td style="background-color:#cccccc; border-color:black; height:25.8pt; width:269.35pt"><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL"><br />هل تواجهين أيّ من هذه العلامات؟</p></td></tr><tr><td style="border-color:black; height:142.25pt; vertical-align:top; width:177.15pt"><p style="margin-left:15.75pt; margin-right:59.1pt; text-align:right; text-indent:-.25in" dir="RTL">&nbsp;</p><p style="margin-left:15.75pt; margin-right:59.1pt; text-align:right; text-indent:-.25in" dir="RTL">تخثّر الأوردة العميقة</p></td><td style="height:142.25pt; vertical-align:top; width:269.35pt"><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:-.7pt; margin-right:5.05pt; text-align:right" dir="RTL">تورم في ساق واحدة أو على طول الوريد في الساق أو القدم خاصة<br />عندما يكون مصحوبا بما يلي:</p><p style="margin-left:-.7pt; margin-right:5.05pt; text-align:right" dir="RTL">&nbsp;&nbsp; &bull; الألم أو الإيلام في الساق والذي قد تشعرين به عند الوقوف أو المشي<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقط،</p><p style="margin-left:-.7pt; margin-right:5.05pt; text-align:right" dir="RTL">&nbsp;&nbsp; &bull; الإحساس بزيادة في حرارة الرجل المصابة</p><p style="margin-left:-.7pt; margin-right:5.05pt; text-align:right" dir="RTL">&nbsp;&nbsp; &bull; تغيير لون جلد الساق على سبيل المثال: تحوله إلى اللون &nbsp;الأحمر أو &nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp; الأزرق الشاحب،</p></td></tr><tr><td style="border-color:black; height:198.5pt; vertical-align:top; width:177.15pt"><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;انسداد الشريان الرئوي<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p></td><td style="height:198.5pt; vertical-align:top; width:269.35pt"><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; ضيق النّفس المفاجئ بدون سبب معلوم أو التنفس السريع،</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; السعال المفاجئ دون سبب واضح، والذي قد يصاحبه خروج دم،</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; ألم حاد في الصدر قد يزيد مع التنفس العميق،</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; الشعور بدوار شديد أو دوخة،</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; سرعة أو عدم انتظام ضربات القلب،</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; ألم شديد في معدتك.</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">إذا لم تكوني متأكدة، تحدثي إلى الطبيب لأن بعض هذه الأعراض مثل السعال أو صعوبة التنفس قد تحدث في حالة أقل خطورة مثل عدوى الجهاز التنفسي (على سبيل المثال &#39;نزلة برد&#39;).</p></td></tr><tr><td style="border-color:black; height:71.05pt; vertical-align:top; width:177.15pt"><p style="margin-left:27.6pt; margin-right:23.1pt; text-align:right; text-indent:-.25in" dir="RTL"><br />تخثر الوريد في الشبكية<br />(تجلط الدم في العين)</p></td><td style="height:71.05pt; vertical-align:top; width:269.35pt"><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">أعراض تحدث أكثر شيوعًا في عين واحدة:<br />&bull; فقدان فوري للرؤية أو</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; عدم وضوح الرؤية غير المؤلم الذي يمكن أن يتطوّر إلى فقدان الرؤية.</p></td></tr><tr><td style="border-color:black; height:149.65pt; vertical-align:top; width:177.15pt"><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبة القلبيّة</p></td><td style="height:149.65pt; vertical-align:top; width:269.35pt"><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; ألم في الصدر، عدم الراحة، ضغط، ثقل؛</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; الإحساس بالضغط أو الامتلاء في الصدر أو الذراع أو تحت عظمة<br />&nbsp; الصدر.</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; الشعور بالامتلاء، وعسر الهضم أو الشعور بالاختناق.</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; الانزعاج في الجزء العلوي من الجسم يمتدّ إلى الظهر والفك والحلق والذراع &nbsp;والمعدة.</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; التعرق والغثيان والقيء والدّوار.</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; ضعف شديد أو قلق أو ضيق في التنفس.</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; ضربات القلب السريعة أو غير المنتظمة.</p></td></tr><tr><td style="border-color:black; height:197.6pt; vertical-align:top; width:177.15pt"><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">السكتة الدماغيّة</p></td><td style="height:197.6pt; vertical-align:top; width:269.35pt"><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; ضعف مفاجئ أو خدر في الوجه، الذراع أو الساق، وبخاصة على جانب<br />&nbsp; واحد من الجسم.</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; الارتباك المفاجئ، صعوبة في الكلام أو الفهم.</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; مشكلة مفاجئة في الرؤية في إحدى العينين أو كلتاهما.</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; صعوبة مفاجئة في المشي، والدوخة، وفقدان التوازن أو التنسيق.</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; صداع مفاجئ أو حاد أو مطول بدون سبب معروف.</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; فقدان الوعي أو الإغماء مع أو بدون نوبات.</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">في بعض الأحيان تكون أعراض السكتة الدماغية قصيرة مع تعافي فوري وكامل تقريبا، ولكِن يجب أن تسعين للحصول على عناية طبية عاجلة إذ قد تكونين عرضة لخطر حدوث سكتة دماغيّة أخرى.</p></td></tr><tr><td style="border-color:black; height:62.4pt; vertical-align:top; width:177.15pt"><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">جلطات دموية أدت إلى انسداد أوعية دموية أخرى</p></td><td style="height:62.4pt; vertical-align:top; width:269.35pt"><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; تورم وتغير طفيف في لون أحد الأطراف إلى اللون الأزرق؛</p><p style="margin-left:-1.0pt; margin-right:5.1pt; text-align:right" dir="RTL">&bull; ألم شديد في معدتك (اعتلال البطن الحاد)</p></td></tr></tbody></table><p style="text-align:right" dir="RTL"><strong>&nbsp;</strong></p><p style="text-align:right" dir="RTL"><strong>جلطات الدم التي تحدث في الوريد<br />ماذا يمكن أن يحدث إذا تشكلت جلطة دموية في الوريد؟</strong><br />&bull; ارتبط استخدام وسائل منع الحمل الهرمونية المُركّبة مع زيادة في خطر حدوث الجلطات الدموية في الوريد (تخثر وريدي). ومع ذلك، هذه الآثار الجانبية نادرة.<br />في معظم الأحيان، تحدث هذه الأثار في السنة الأولى من استخدام وسائل منع الحمل الهرمونية المُركّبة.<br />&bull; إذا حدثت جلطة دموية في الوريد في الساق أو القدم، يمكن أن تسبب تخثر الوريد العميق (DVT).<br />&bull; إذا انتقلت الجلطة الدموية من الساق واستقرت في الرئة يمكن أن تسبب انسدادا رئويًّا.<br />&bull; نادرًا ما تحدث الجلطة الوريدية في عضو آخر مثل العين (تخثر الوريد الشبكي).</p><p style="text-align:right" dir="RTL"><strong>متى يكون خطر الإصابة بتجلط الدم في الوريد أعلى؟</strong><br />يكون خطر الإصابة بتجلط الدم في الوريد هو الأعلى خلال السنة الأولى من استخدام وسائل منع الحمل الهرمونية للمرة الأولى. قد يكون الخطر أيضا أعلى إذا عدت إلى استخدام وسائل منع الحمل الهرمونية المركبة (نفس الُمنتج أو منتج مختلف) بعد انقطاع يصل إلى 4 أسابيع أو أكثر.</p><p style="text-align:right" dir="RTL">بعد مرور السنة الأولى، يقل خطر الإصابة بتجلط الدم لكِنه يظل دائمًا أعلى قليلًا مما لو كنتِ لا تستخدمين وسائل منع الحمل الهرمونية المُركّبة.<br />عند التوقف عن استخدام مارفيلون يعود خطر الإصابة بتجلط الدم إلى وضعه الطبيعي في غضون بضعة أسابيع.</p><p style="text-align:right" dir="RTL"><strong>ما خطر الإصابة بتجلط الدم؟</strong><br />يعتمد خطر الإصابة بتجلط الدم على مقدار الخطر الطبيعي لديك في الإصابة بتخثّر الأوردة VTE &nbsp;وعلى نوع وسيلة منع الحمل الهرمونية المُركّبة التي تستخدمينها.</p><p style="text-align:right" dir="RTL">الخطر الكِلي لحدوث تجلط الدم في الساق أو الرئة (DVT أو PE) مع مارفيلون قليل.</p><p style="text-align:right" dir="RTL">&bull; تحدث جلطة دموية لدى امرأتين من أصل ١٠٠٠٠ امرأة غير حامل ولم يستخدمن أي من وسائل منع الحمل الهرمونية المُركّبة &nbsp;&nbsp;<br />&bull; تحدث جلطة دموية لدى ٥-٧ نساء من أصل ١٠٠٠٠ امرأة ممن يستخدمن وسائل منع الحمل الهرمونية المُركّبة التي تحتوي على الليفونورجيستريل، نوريثيستيرون، أو نورجستيمات.<br />&bull; تحدث جلطة دموية لدى ٩-١٢ امرأة من أصل ١٠٠٠٠ امرأة ممن يستخدمن وسائل منع الحمل الهرمونية المُركّبة التي تحتوي على ديسوجيستريل مثل مارفيلون.<br />&bull; قد يتفاوت خطر حدوث جلطة دموية وفقًا لتاريخك الطبي الشخصي (انظري&quot;العوامل التي تزيد من خطر تجلط الدم&quot; أدناه).</p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:233.75pt"><p style="text-align:right" dir="RTL">الحالة</p></td><td style="vertical-align:top; width:233.75pt"><p style="text-align:right" dir="RTL"><strong>خطر الإصابة بتجلط الدم في سنة</strong></p></td></tr><tr><td style="vertical-align:top; width:233.75pt"><p style="text-align:right" dir="RTL">النساء اللائي <strong>لا يستخدمن</strong> الهرمونات المُركّبة لمنع الحمل على شكل أقراص / لصقات / حلقات مهبليّة ولسن حوامل</p></td><td style="vertical-align:top; width:233.75pt"><p style="text-align:right" dir="RTL">حوالي امرأتين من بين١٠٠٠٠ امرأة</p></td></tr><tr><td style="vertical-align:top; width:233.75pt"><p style="text-align:right" dir="RTL">النساء اللائي يستخدمن وسائل منع الحمل الهرمونية المُركّبة التي تحتوي على <strong>الليفونورجيستريل، نوريثيستيرون أو نورجستيمات</strong></p></td><td style="vertical-align:top; width:233.75pt"><p style="text-align:right" dir="RTL">حوالي ٥-٧ امرأة من بين١٠٠٠٠ امرأة</p></td></tr><tr><td style="vertical-align:top; width:233.75pt"><p style="text-align:right" dir="RTL">النساء اللائي يستخدمن مارفيلون</p></td><td style="vertical-align:top; width:233.75pt"><p style="text-align:right" dir="RTL">حوالي ٩-١٢ امرأة من بين١٠٠٠٠ امرأة</p></td></tr></tbody></table><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL"><strong>العوامل التي تزيد من خطر حدوث تجلط الدم في الوريد لديك:</strong><br />خطر حدوث تجلط الدم مع مارفيلون قليل ولكِن هناك بعض الحالات تزيد من ذلكِ الخطر. خطرك أعلى إذا:<br />&bull; &nbsp;كان لديك زيادة كبيرة في الوزن (مؤشر كتلة الجسم أو BMI أكثر من ٣٠ كجم/م٢).<br />&bull;&nbsp; أُصيب أحد أفراد عائلتك المباشرين بتجلط دموي في الساق أو الرئة أو أي عضو آخر في سن مبكرة (على سبيل المثال، دون سن ال ٥٠ تقريبا). في هذه الحالة يمكن أن يكون لديك اضطراب وراثي في تخثر الدم.</p><p style="text-align:right" dir="RTL">&bull; كنتِ بحاجة إلى إجراء عملية، أو اضطررتِ إلى عدم المشي لفترة طويلة بسبب إصابة أو مرض، أو لديك جبيرة على ساقك. قد تحتاجين إلى التوقف عن استخدام مارفيلون لعدة أسابيع قبل الجراحة أو أثناء فترات عدم الحركة. إذا كنتِ بحاجة إلى التوقف عن استخدام مارفيلون اسألي طبيبك متى يمكنكِ البدء في استخدامه مرة أخرى.<br />&bull; مع تقدمك في السن (لا سيّما أكثر من ٣٥ سنة).<br />&bull; إذا كنتِ قد أنجبت مولودًا قبل أقل من بضعة أسابيع.</p><p style="text-align:right" dir="RTL">يزداد خطر الإصابة بتجلط الدم مع ازدياد عدد عوامل الخطر لديك.</p><p style="text-align:right" dir="RTL">قد يزيد السفر الجوي (الذي تزيد مدته عن ٤ ساعات) بشكل مؤقت من خطر حدوث جلطة دموية، خاصة إذا كان لديك بعض العوامل الأخرى المذكورة.</p><p style="text-align:right" dir="RTL">من المهم إخبار طبيبك إذا كان أي من هذه الحالات ينطبق عليكِ، حتى لو كنتِ غير متأكدة. قد يقرر طبيبك أن تتوقفي عن استخدام مارفيلون.</p><p style="text-align:right" dir="RTL">إذا تغيّر أي من الحالات المذكورة أعلاه أثناء استخدام مارفيلون، على سبيل المثال بإصابة أحد أفراد العائلة المقربين بتجلط الدم دون سبب معروف؛ أو بازدياد الوزن لديك، أخبري طبيبكِ بذلك.</p><p style="text-align:right" dir="RTL"><strong><u>جلطات الدم التي تحدث في الشريان</u></strong><br /><br /><strong>ماذا يمكن أن يحدث إذا تشكلت جلطة دموية في الشريان؟</strong><br />كما هو الحال مع الجلطة الدموية التي تتشكل في الوريد، قد تُسبّب الجلطة في الشريان مشاكل خطيرة. على سبيل المثال، فإنها يمكن أن تُسبّب نوبة قلبية أو السكتة الدماغية.</p><p style="text-align:right" dir="RTL"><strong>العوامل التي تزيد من خطر حدوث جلطة دموية في الشريان</strong></p><p style="text-align:right" dir="RTL">من المهم أن نلاحظ أن خطر الإصابة بأزمة قلبية أو السكتة الدماغية مع استخدام مارفيلون قليل جدا ولكِن يمكن أن يزيد:</p><p style="text-align:right" dir="RTL">&bull; مع التقدّم في العمر (بعد حوالي ٣٥ عاما من العمر).<br />&bull; <strong>إذا كنتِ تدخنين</strong>. يُنصح أن تتوقفي عن التدخين عند استخدام وسائل منع الحمل الهرمونية المُركّبة مثل مارفيلون. إذا كنتِ غير قادرة على التوقف عن التدخين وقد تجاوزت ِ ٣٥ &nbsp;عامًا من العمر، قد ينصحك طبيبك باستخدام نوع مختلف من وسائل منع الحمل.<br />&bull; إذا كان لديك زيادة في الوزن.<br />&bull; إذا كان لديك ارتفاع في ضغط الدم.<br />&bull; إذا أصيب أحد أفراد عائلتك المباشرين بأزمة قلبية أو سكتة دماغية في سن مبكرة (أقل من حوالي ٥٠ سنة). في هذه الحالة قد يكون لديك أيضا خطر أكبر في حدوث نوبة قلبية أو السكتة الدماغية؛<br />&bull; إذا كان لديك، أو لدى أي شخص في عائلتك المباشرة، مستوى عال من الدهون في الدم (الكِوليسترول أو الدهون الثلاثية)؛<br />&bull; إذا كنتِ مصابة بالصداع النصفي، وخاصة الصداع النصفي مع الهالة؛<br />&bull; إذا كان لديكِ مشكلة في قلبك (اضطراب الصمام، اضطراب في ضربات القلب يُسمى الرجفان الأذيني)؛<br />&bull; إذا كنتِ مصابة بمرض السّكري.</p><p style="text-align:right" dir="RTL">قد يزداد خطر حدوث الجلطة الدموية أكثر إذا كان لديك أكثر من واحد من هذه العوامل أو إذا كان أي منها شديد بشكل خاص.</p><p style="text-align:right" dir="RTL">إذا تغيّرت أيّ من الحالات المذكورة أعلاه أثناء استخدامك مارفيلون، على سبيل المثال بدأت بالتدخين، أو أُصيب أحد أفراد عائلتك المقربين بجلطة دموية بدون سبب معروف؛ أو ازداد وزنك بشكل كبير، أخبري طبيبك.</p><p style="text-align:right" dir="RTL"><strong>٢&ndash;٢&ndash;٢ حبوب منع الحمل والسرطان</strong><br />تُقلّل حبوب منع الحمل من خطر الإصابة بسرطان المبيض والرحم إذا ما استخدمت على المدى الطويل. لكِنّها، على ما يبدو تزيد قليلًا من خطر الإصابة <strong>بسرطان عنق الرحم</strong> أيضًا - على الرغم من أن ذلك قد يُعزى إلى ممارسة الجنس دون الواقي الذكري بدلًا من استخدام حبوب منع الحمل نفسها. وينبغي أن تخضع جميع النساء <strong>لفحص مسحة عنق الرحم</strong>.</p><p style="text-align:right" dir="RTL">إذا كنتِ مصابة <strong>بسرطان الثدي</strong>، أو أصبت به في الماضي، يجب أن لا تتناولي حبوب منع الحمل. حبوب منع الحمل تزيد قليلًا من خطر الإصابة بسرطان الثدي. يزداد هذا الخطر كلما طالت فترة استخدام حبوب منع الحمل، ولكِنّه يعود إلى وضعه الطبيعي في غضون نحو ١٠ سنوات بعد التوقف عن استخدامها. لأن سرطان الثدي نادر الحدوث عند النساء تحت سن ٤٠ عامًا، فإنّ العدد الاضافي من حالات سرطان الثدي لدى السيدات اللواتي يستخدمن حبوب منع الحمل هو قليل.</p><p style="text-align:right" dir="RTL">فمثلًا:<br />&bull; من بين ١٠٠٠٠ امرأة <strong>لم يتناولن حبوب منع الحمل أبدًا</strong>، ستُصاب حوالي ١٦ امرأة بسرطان الثدي في الوقت الذي يبلغن فيه سن ٣٥ عامًا.<br />&bull; من بين ١٠٠٠٠ امرأة <strong>يتناولن حبوب منع الحمل لمدة 5 سنوات في أوائل العشرينات من أعمارهن</strong>، ستُصاب حوالي <strong>١٧-١٨</strong> منهن بسرطان الثدي عند بلوغهن ٣٥ عامًا من العمر.<br />&bull; من بين ١٠٠٠٠ امرأة <strong>لم يتناولن حبوب منع الحمل أبدًا</strong>، فإن حوالي <strong>١٠٠</strong> امرأة منهن ستصاب بسرطان الثدي عند بلوغهن سن ٤٥ عامًا.<br />&bull; من بين ١٠٠٠٠ امرأة <strong>يتناولن حبوب منع الحمل لمدة ٥ سنوات في أوائل الثلاثينات من أعمارهنّ</strong>، ستُصاب حوالي <strong>١١٠ </strong>منهن بسرطان الثدي عند بلوغهن سن &nbsp;٤٥ عاما.</p><p style="text-align:right" dir="RTL"><strong>يكون خطر الإصابة بسرطان الثدي لديك أعلى:</strong></p><p style="text-align:right" dir="RTL">&bull; إذا أُصيبت إحدى قريباتك (أم أو شقيقة أو جدّة) بسرطان الثدي؛<br />&bull; إذا كنتِ تعانين من زيادة الوزن بشكل خطير.</p><p style="text-align:right" dir="RTL">&larr; <strong>راجعي الطبيب في أقرب وقت ممكن إذا لاحظتِ أي تغيرات في ثدييك</strong>، مثل تغيرات في الجلد، , تغيرات في الحلمة أو إذا شعرت بوجود أو رأيت أي كتل.</p><p style="text-align:right" dir="RTL">كذلكِ ارتبط استخدام حبوب منع الحمل بأمراض الكِبد، مثل اليرقان وأورام الكِبد غير السرطانية، ولكِن هذا أمر نادر الحدوث. كما ارتبط أيضًا بشكل نادرٍ جدا، مع بعض أشكال سرطان الكِبد لدى النساء الذين استخدمن الحبوب لفترة طويلة.</p><p style="text-align:right" dir="RTL">&larr; <strong>راجعي الطبيب في أقرب وقت ممكن إذا كنت تعانين من ألم شديد في معدتك أو اصفرار في البشرة أو العينين </strong>(اليرقان). قد تحتاجين إلى التوقف عن تناول مارفيلون.</p><p style="text-align:right" dir="RTL"><strong>2-2-3 اضطرابات نفسية</strong><br />بعض النساء اللاتي يستخدمن وسائل منع الحمل الهرمونية بما في ذلك مارفيلون قد أبلغن عن اكتئاب أو مزاج مكتئب. &nbsp;قد يكون الاكتئاب خطيرًا وقد يؤدي أحيانًا إلى أفكار انتحاريّة. إذا كنتِ تعانين من تغيرات المزاج والأعراض الاكتئابية ، اتصلي بطبيبك للحصول على مزيد من المشورة الطبية في أقرب وقت ممكن.</p><p style="text-align:right" dir="RTL"><strong>٢&ndash;٣ &nbsp;أدوية أخرى ومارفيلون</strong><br />أخبري طبيبك أو الصيدلي أو ممرضة تنظيم الأسرة إذا كنتِ تستخدمين أو استخدمتِ مؤخرًا أو قد تستخدمين أي أدوية أو منتجات أعشاب أخرى بما في ذلك تلك التي لم توصف لكِ. كذلك، أخبري أي طبيب أو طبيب أسنان يصف لكِ دواءً آخر (أو الصيدلي) أنّك تستخدمين مارفيلون. وذلك لأنّ مارفيلون يمكن أن يؤثر أيضًا على مدى كفاءة الأدوية الأخرى، مما يؤدي إلى زيادة في التأثير (على سبيل المثال، سيكلوسبورين) أو انخفاض في التأثير (على سبيل المثال، لاموتريجين). ذكّري طبيبك إذا كنتِ تتناولين هذه الأدوية في حال تطلب علاجك تعديل في الجرعة.</p><p style="text-align:right" dir="RTL">تحققي أيضًا من جميع نشرات المعلومات التي تصاحب الأدوية لمعرفة ما إذا كان يمكن تناولها مع وسائل منع الحمل الهرمونية.</p><p style="text-align:right" dir="RTL"><strong>قد تعيق بعض الأدوية مارفيلون عن العمل بشكل صحيح. وتشمل هذه الأدوية المستخدمة لعلاج:</strong></p><p style="text-align:right" dir="RTL">&bull; <strong>الصّرع</strong> (بريميدون، فينيتوينز، الفينوباربيتال، كاربامازيبين، أوكسكاربازيبين، توبيراميت، فيلبامات، مودافينيل)؛<br />&bull; <strong>السُّلّ</strong> (ريفامبيسين)؛<br />&bull; <strong>عدوى فيروس نقص المناعة البشرية</strong> (ريتونافير، نلفينافير، نيفيرابين، إيفافيرنز)؛<br />&bull; <strong>عدوى فيروس الالتهاب الكِبدي الوبائي</strong><strong> </strong><strong>&nbsp;نوع ج </strong><strong>C</strong> (على سبيل المثال، بوسبريفير، تيلابريفير)؛<br />&bull; <strong>الأمراض المُعدية الأخرى</strong> (على سبيل المثال، غريسيوفولفين)؛<br />&bull; <strong>ارتفاع ضغط الدم في الأوعية الدموية في الرئتين</strong> (بوسنتان)؛<br />&bull; <strong>الاكتئاب</strong> (العلاج العشبي <strong>نبتة سانت جون</strong>).</p><p style="text-align:right" dir="RTL">إذا كنتِ تتناولين أدوية أو منتجات عشبية التي قد تُقلل من فعاليّة مارفيلون، ينبغي استخدام وسيلة أخرى من وسائل منع الحمل.&nbsp; وبما أن تأثير أي دواء آخر على مارفيلون قد يستمر لمدة تصل إلى ٢٨يومًا بعد التوقف عن الدواء، فمن الضروري استخدام وسائل منع الحمل الاضافية خلال هذه المدة.</p><p style="text-align:right" dir="RTL">لا تستخدم مارفيلون إذا كان لديك التهاب الكبد الوبائي ج C، , و تتناول الأدوية التي تحتوي على أومبيتاسفير/باريتابريفير/ريتونافير وداسابوفير هذا قد يؤدي إلى ارتفاع نتائج فحوصات الدم المتعلقة بوظيفة الكبد نتائج (زيادة في إنزيم الكبد ALT).&nbsp; سوف يصف الطبيب نوعًا آخرَ من وسائل منع الحمل قبل بدء العلاج بهذه الأدوية. يمكن إعادة استخدام مارفيلون بعد حوالي 2 أسابيع بعد الانتهاء من هذا العلاج. انظر البند 2-1 &quot;لا تستخدم مارفيلون&quot;.</p><p style="text-align:right" dir="RTL"><strong>٢&ndash;٤ &nbsp;مارفيلون مع الطعام والشراب</strong><br />لا توجد تعليمات خاصة حول تناول الطعام والشراب أثناء استخدام مارفيلون.</p><p style="text-align:right" dir="RTL"><strong>٢&ndash;٥ الحمل والرضاعة الطبيعية</strong><br />لا تستخدمي مارفيلون إذا كنتِ حاملًا. إذا كنتِ تعتقدينين أنك قد تكوني حاملًا، فقومي بإجراء اختبار الحمل للتأكد من أنك حامل بالفعل قبل التوقف عن تناول مارفيلون.</p><p style="text-align:right" dir="RTL">لا يُنصح باستخدام مارفيلون أثناء الرضاعة الطبيعية. اسألي طبيبك أو ممرضة تنظيم الأسرة عن وسائل منع الحمل البديلة. الرضاعة الطبيعية قد لا تمنع حدوث الحمل.</p><p style="text-align:right" dir="RTL"><strong>٢&ndash;٦ &nbsp;القيادة واستخدام الآلات </strong><br />مارفيلون ليس له تأثير معروف على القدرة على القيادة أو استخدام الآلات.</p><p style="text-align:right" dir="RTL"><strong>٢&ndash;٧ &nbsp;مارفيلون يحتوي على اللاكتوز</strong><br />إذا سبق وأخبرك طبيبك أن لديك عدم تحمّل لبعض السكريات، استشيري طبيبك قبل استخدام مارفيلون.</p><p style="text-align:right" dir="RTL"><strong>٢&ndash;٨ الاستخدام لدى المراهقين</strong><br />لا تتوفر بيانات سريريّة حول الفعاليّة والسلامة لدى المراهقين دون 18 عامًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right" dir="RTL"><strong>٠٣ &nbsp;كيفية استخدام مارفيلون</strong></p><p style="text-align:right" dir="RTL"><strong>٣&ndash;١ &nbsp;كيفية التناول </strong></p><p style="text-align:right" dir="RTL">لمنع الحمل، تناولي هذا الدواء دومًا كما هو موضح في هذه النشرة أو حسب ارشادات طبيبك أو ممرضة تنظيم الأسرة أو الصيدلي. تحققي مع طبيبك، ممرضة تنظيم الأسرة أو الصيدلي إذا لم تكوني متأكدة.</p><p style="text-align:right" dir="RTL"><strong>تناولي مارفيلون كل يوم لمدة ٢١ يومًا</strong><br />يتوفّر مارفيلون في شرائط يحتوي كل منها على ٢١ قرصًا من أقراص منع الحمل، مع تقويم لكل يوم من أيام الأسبوع مقابل كل قرص.<br />&bull; تناولي القرص في نفس الوقت من كل يوم.<br />&bull; ابدئي بتناول حبوب منع الحمل حسب تقويمها الصحیح من الأسبوع.<br />&bull; اتبعي اتجاه الأسهم على الشريط. تناولي حبة واحدة كل يوم، حتى الانتهاء من جميع حبوب منع الحمل وعددها ٢١.<br />&bull; ابتلعي كل حبة كاملة، مع الماء إذا لزم الأمر. لا تمضغي حبوب منع الحمل.</p><p style="text-align:right" dir="RTL"><strong>يلي ذلك سبعة أيام خالية من حبوب منع الحمل </strong></p><p style="text-align:right" dir="RTL">بعد أن تتناولي جميع حبوب منع الحمل ٢١ حبة في الشريط، لديك سبعة أيام لن تتناولي خلالها أي حبوب منع الحمل. وإذا تناولت آخر حبة في الشريط الأول يوم الجمعة، سوف تبدأين في تناول الحبوب من الشريط الثاني يوم السبت من الأسبوع الذي يلي فترة الاستراحة.</p><p style="text-align:right" dir="RTL">في غضون بضعة أيام من تناول آخر حبة من الشريط، يجب أن يحدث لديك نزيف شبيه بالدورة نتيجة انسحاب الدواء. قد لا ينتهي هذا النزيف عندما يحين الوقت للبدء في تناول الحبوب من الشريط التالي. لا تحتاجين إلى استخدام وسائل منع حمل إضافية خلال هذه الأيام السبعة الخالية من حبوب منع الحمل - طالما أنّك قد تناولت حبوب منع الحمل بشكل صحيح وبدأتِ باستخدام حبوب منع الحمل في الشريط التالي في الوقت المحدد.</p><p style="text-align:right" dir="RTL"><strong>ثم ابدئي بتناول حبوب منع الحمل من الشريط التالي </strong><br />ابدئي في تناول حبوب منع الحمل من الشريط التالي من مارفيلون بعد انتهاء السبعة أيام الخالية من حبوب منع الحمل - حتى لو استمر النزيف. ابدئي دائمًا الشريط الجديد في الوقت المحدد.</p><p style="text-align:right" dir="RTL">طالما أنكِ تتناولين مارفيلون بشكل صحيح، سوف تبدأين دائمًا كل شريط جديد في نفس اليوم من كل أسبوع.</p><p style="text-align:right" dir="RTL"><strong>٣&ndash;٢ البدء باستخدام مارفيلون<br />عند استخدامك مارفيلون لأول مرة أو عند العودة لاستخدامه مرة أخرى بعد فترة انقطاع</strong><br /><strong>إما</strong> أن تتناولي أول حبة منع حمل من مارفيلون في أول أيام الحيض من الدورة الشهرية المقبلة. بهذه الطريقة، سيكون لديك حماية من الحمل مع أول حبة تتناولينها.</p><p style="text-align:right" dir="RTL"><strong>أو</strong> إذا كان الحيض قد بدأ بالفعل يمكنك تناول مارفيلون بدءًا من اليوم الخامس من الحيضّ (على أن يبدأ حساب أيام الحيض بدءًا من اليوم الأول لنزول الدم) حتى وإن لم يتوقف النزيف.&nbsp; يجب عليك أيضًا استخدام وسائل منع حمل إضافية، مثل الواقي الذكري، إلى ما بعد تناولكِ السبعة حبوب الأولى بشكل صحيح.</p><p style="text-align:right" dir="RTL"><strong>تغيير نوع حبوب منع الحمل من نوع آخر إلى مارفيلون</strong><br />&bull; <strong>إذا كنتِ حاليًّا تتناولين حبوب منع الحمل لمدة ٢١ يومًا</strong>: ابدئي في تناول مارفيلون في اليوم التالي بعد نهاية الشريط السابق. سيكون لديك حماية من الحمل مع أول حبة تتناولينها لكن لن يحدث لكِ نزيف الحيض حتى بعد الانتهاء من الشريط الأول من مارفيلون.</p><p style="text-align:right" dir="RTL">&bull; <strong>إذا كنتِ حاليًّا تتناولين حبوب منع الحمل لمدة ٢٨ يوما:</strong> ابدئي في تناول مارفيلون في اليوم التالي من أخر حبة نشطة تتناولينها. سيكون لديك حماية من الحمل مع أول حبة تتناولينها لكن لن يحدث لكِ نزيف الحيض حتى بعد الانتهاء من الشريط الأول من مارفيلون.</p><p style="text-align:right" dir="RTL">&bull; <strong>أو إذا كنتِ تتناولين حبوب منع الحمل البروجستيرونية فقط </strong>(حبوب منع الحمل المنمنمة أو المُصغرة أو الميني بل): ابدئي مارفيلون في اليوم الأول من بدء النزيف (الحيض)، حتى لو كنت قد تناولت من الحبوب البروجستيرونية في ذلك اليوم. سيكون لديك حماية فورية من الحمل. إذا لم يكن لديك عادة أي نزيف أثناء تناولكِ حبوب منع الحمل التي تحتوي على بروجستيرون فقط، يمكنك التوقف عن تناولها في أي يوم ومن ثمّ البدء في تناول مارفيلون في اليوم التالي. سوف تحتاجين إلى استخدام وسائل منع حمل إضافية، مثل الواقي الذكري، لمدة سبعة أيام.</p><p style="text-align:right" dir="RTL"><strong>تغيير إلى مارفيلون من حقن بروجستيرون فقط، أو اللولب الرّحمي الذي يحتوي على زرع البروجستيرون (اللولب)</strong></p><p style="text-align:right" dir="RTL">ابدئي في تناول مارفيلون عندما يحين موعد الحقن التالي أو في اليوم الذي يتم فيه إزالة الزرع أو اللولب. تأكدي من أنك تستخدمين أيضًا وسيلة إضافية لمنع الحمل، مثل الواقي الذكري، للأيام السبعة الأولى التي تبدأين فيها بتناول مارفيلون.</p><p style="text-align:right" dir="RTL"><strong>البدء باستخدام مارفيلون بعد الإجهاض أو الإسقاط</strong><br />إذا كنتِ قد تعرضتِ للإجهاض أو الإسقاط، قد يخبرك طبيبك أن تبدأي في تناول مارفيلون على الفور. وهذا يعني أنه سيكون لديك حماية من الحمل مع تناولكِ لأول حبة من حبوب منع الحمل.</p><p style="text-align:right" dir="RTL"><strong>منع الحمل بعد الولادة </strong><br />إذا كان لديكِ طفل رضيع، استشيري طبيبك حول وسائل منع الحمل الملائمة لكِ.</p><p style="text-align:right" dir="RTL">إذا كنت لا تمارسين الرضاعة الطبيعية:<br />&bull; يمكنك البدء في تناول مارفيلون بعد ثلاثة أسابيع من الولادة أو،<br />&bull; يمكنك البدء في تناول مارفيلون بعد أكثر من ثلاثة أسابيع من الولادة ولكِنك تحتاجين في هذه الحالة&nbsp; إلى استخدام وسائل منع حمل إضافية، مثل الواقي الذكري إلى ما بعد تناولكِ لأول سبع حبوب منع حمل&nbsp; بشكل صحيح.</p><p style="text-align:right" dir="RTL">&bull; إذا كنتِ قد مارستِ العلاقة الحميمة بعد الولادة، فهناك احتمال أن تكوني حاملًا، لذا يجب عليك استخدام شكل آخر من وسائل منع الحمل مثل الواقي الذكري. في هذه الحالة، ابدئي في تناول حبوب منع الحمل مارفيلون في أول يوم من أيام الحيض المُقبل.</p><p style="text-align:right" dir="RTL"><strong>٣&ndash;٣ &nbsp;في حال نسيان إحدى الجرعات </strong><br />إذا نسيت أن تتناولي أحد حبوب منع الحمل، فاتبعي الإرشادات التالية:</p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1028" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:134.7pt;margin-top:9.2pt;width:152.15pt;
 height:20.15pt;z-index:251647488;visibility:visible;mso-width-percent:400;
 mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
 mso-width-percent:400;mso-width-relative:margin;mso-height-relative:margin'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#_x0000_s1028'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=center dir=RTL style='text-align:center;
    line-height:12.0pt;mso-line-height-rule:exactly;direction:rtl;unicode-bidi:
    embed'><span lang=AR-SA style='font-family:"Traditional Arabic",serif'>متى
    كان موعد الجرعة التي نسيت أن تتناولينها؟</span><span dir=LTR
    style='font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><!--[if !vml]--><img width="40%" alt="Text Box: متى كان موعد الجرعة التي نسيت أن تتناولينها؟" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[endif]--><!--[if gte vml 1]><v:shape
 id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:365pt;margin-top:9.2pt;width:62.5pt;
 height:26pt;z-index:251646464;visibility:visible;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-bottom:3.6pt;mso-width-relative:margin;
 mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" filled="f" stroked="f">
 <v:textbox style='mso-next-textbox:#Text_x0020_Box_x0020_2'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><span lang=AR-SA style='font-family:"Traditional Arabic",serif;
    color:white'>ابدئي هنا</span><span dir=LTR style='font-family:"Traditional Arabic",serif;
    color:white'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><!--[if !vml]--><img width="86" height="37" alt="Text Box: ابدئي هنا" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><!--[endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t66" coordsize="21600,21600" o:spt="66" adj="5400,5400" path="m@0,l@0@1,21600@1,21600@2@0@2@0,21600,,10800xe">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="val #0"/>
  <v:f eqn="val #1"/>
  <v:f eqn="sum 21600 0 #1"/>
  <v:f eqn="prod #0 #1 10800"/>
  <v:f eqn="sum #0 0 @3"/>
 </v:formulas>
 <v:path o:connecttype="custom" o:connectlocs="@0,0;0,10800;@0,21600;21600,10800"
  o:connectangles="270,180,90,0" textboxrect="@4,@1,21600,@2"/>
 <v:handles>
  <v:h position="#0,#1" xrange="0,21600" yrange="0,10800"/>
 </v:handles>
</v:shapetype><v:shape id="Arrow_x003a__x0020_Left_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t66" style='position:absolute;left:0;text-align:left;
 margin-left:348.5pt;margin-top:-.8pt;width:90.5pt;height:44pt;z-index:251645440;
 visibility:visible;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQAnG2iHjgIAAC0FAAAOAAAAZHJzL2Uyb0RvYy54bWysVFtv2jAUfp+0/2D5fQ1ksLZRQ4WoOk1C
LVI79dk4Donk22xDYL9+n50AvexpGg/GJ+f+ne/45navJNkJ51ujSzq+GFEiNDdVqzcl/fl8/+WK
Eh+Yrpg0WpT0IDy9nX3+dNPZQuSmMbISjiCI9kVnS9qEYIss87wRivkLY4WGsjZOsQDRbbLKsQ7R
lczy0ehb1hlXWWe48B5f73olnaX4dS14eKxrLwKRJUVtIZ0unet4ZrMbVmwcs03LhzLYP1ShWKuR
9BTqjgVGtq79EEq13Blv6nDBjcpMXbdcpB7QzXj0rpunhlmRegE43p5g8v8vLH/YrRxpq5LmlGim
MKK5c6YryFLUgeQRoM76AnZPduUGyeMau93XTsV/9EH2CdTDCVSxD4Tj43g8uf46BfYcuun06mqU
UM/O3tb58F0YReKlpBKJUw0JULZb+oC0sD/axYzeyLa6b6VMwsEvpCM7hiGDG5XpnpGdEsl8gAIl
pV/sBWHeuEpNOtSYX6IqwhkYWEsGV64sMPF6QwmTG1CbB5fqeePt3WZ9yjyZXOaLSW/UsEr09Uxj
6mPm3vxjFbGzO+ab3iWliC6sUG3AeshWlRS4nSNJHbUiEXzAJ06pn0u8rU11wGCd6RnvLb9vkWQJ
RFbMgeJoF2sbHnHU0gADM9woaYz7/bfv0R7Mg5aSDisDfH5tmRMA+ocGJ6/Hk0ncsSRMppc5BPda
s36t0Vu1MBjYGA+E5eka7YM8Xmtn1Au2ex6zQsU0R+5+EoOwCP0q433gYj5PZtgry8JSP1keg0ec
IrzP+xfm7ECxAHo8mON6seIdyXrb6KnNfBtM3SYGnnHFBKOAnUyzHN6PuPSv5WR1fuVmfwAAAP//
AwBQSwMEFAAGAAgAAAAhANlc8b7fAAAACQEAAA8AAABkcnMvZG93bnJldi54bWxMj81OwzAQhO9I
vIO1SNxap/ykaRqnqgi9gQQNF25uvI0j4nUUu214e5YT3HZ3RrPfFJvJ9eKMY+g8KVjMExBIjTcd
tQo+6t0sAxGiJqN7T6jgGwNsyuurQufGX+gdz/vYCg6hkGsFNsYhlzI0Fp0Ocz8gsXb0o9OR17GV
ZtQXDne9vEuSVDrdEX+wesAni83X/uQUvFTP3f0j7qrKJm/buvZm9Rlflbq9mbZrEBGn+GeGX3xG
h5KZDv5EJoheQbpacpeoYLZIQbAhW2Z8OPCQPoAsC/m/QfkDAAD//wMAUEsBAi0AFAAGAAgAAAAh
ALaDOJL+AAAA4QEAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAU
AAYACAAAACEAOP0h/9YAAACUAQAACwAAAAAAAAAAAAAAAAAvAQAAX3JlbHMvLnJlbHNQSwECLQAU
AAYACAAAACEAJxtoh44CAAAtBQAADgAAAAAAAAAAAAAAAAAuAgAAZHJzL2Uyb0RvYy54bWxQSwEC
LQAUAAYACAAAACEA2Vzxvt8AAAAJAQAADwAAAAAAAAAAAAAAAADoBAAAZHJzL2Rvd25yZXYueG1s
UEsFBgAAAAAEAAQA8wAAAPQFAAAAAA==
" adj="5251" fillcolor="black" strokecolor="#2f528f" strokeweight="1pt"/><v:shape
 id="_x0000_s1034" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:244.75pt;margin-top:240.55pt;width:152.1pt;
 height:30pt;z-index:251653632;visibility:visible;mso-width-percent:400;
 mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-vertical-relative:page;mso-width-percent:400;
 mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#_x0000_s1034'/>
 <w:wrap anchory="page"/>
</v:shape><v:line id="Straight_x0020_Connector_x0020_5" o:spid="_x0000_s1029"
 style='position:absolute;left:0;text-align:left;z-index:251648512;
 visibility:visible' from="230pt,30.9pt" to="230pt,38.35pt" o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" strokeweight="1.25pt">
 <v:stroke joinstyle="miter"/>
</v:line><v:line id="Straight_x0020_Connector_x0020_6" o:spid="_x0000_s1030"
 style='position:absolute;left:0;text-align:left;z-index:251649536;
 visibility:visible;mso-width-relative:margin;mso-height-relative:margin'
 from="124pt,38.35pt" to="333pt,38.35pt" o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" strokeweight="1pt">
 <v:stroke joinstyle="miter"/>
</v:line><v:shapetype id="_x0000_t32" coordsize="21600,21600" o:spt="32"
 o:oned="t" path="m,l21600,21600e" filled="f">
 <v:path arrowok="t" fillok="f" o:connecttype="none"/>
 <o:lock v:ext="edit" shapetype="t"/>
</v:shapetype><v:shape id="Straight_x0020_Arrow_x0020_Connector_x0020_7"
 o:spid="_x0000_s1031" type="#_x0000_t32" style='position:absolute;left:0;
 text-align:left;margin-left:333pt;margin-top:38.85pt;width:0;height:16.5pt;
 z-index:251650560;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" strokeweight="1pt">
 <v:stroke endarrow="block" joinstyle="miter"/>
</v:shape><v:shape id="Straight_x0020_Arrow_x0020_Connector_x0020_8" o:spid="_x0000_s1032"
 type="#_x0000_t32" style='position:absolute;left:0;text-align:left;
 margin-left:116.75pt;margin-top:46.6pt;width:16.5pt;height:0;rotation:90;
 z-index:251651584;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" adj="-257891,-1,-257891" strokeweight="1pt">
 <v:stroke endarrow="block" joinstyle="miter"/>
</v:shape><v:shape id="Straight_x0020_Arrow_x0020_Connector_x0020_197" o:spid="_x0000_s1043"
 type="#_x0000_t32" style='position:absolute;left:0;text-align:left;
 margin-left:125.75pt;margin-top:54pt;width:0;height:15pt;z-index:251662848;
 visibility:visible;mso-width-relative:margin;mso-height-relative:margin'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" strokeweight="1pt">
 <v:stroke endarrow="block" joinstyle="miter"/>
</v:shape><v:shape id="_x0000_s1045" type="#_x0000_t32" style='position:absolute;
 left:0;text-align:left;margin-left:326.45pt;margin-top:61.4pt;width:13.05pt;
 height:0;rotation:90;z-index:251664896;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" adj="-680607,-1,-680607" strokeweight="1pt">
 <v:stroke endarrow="block" joinstyle="miter"/>
</v:shape><v:shape id="_x0000_s1033" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:33.65pt;margin-top:240.3pt;width:152.4pt;
 height:31pt;z-index:251652608;visibility:visible;mso-width-percent:400;
 mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-vertical-relative:page;mso-width-percent:400;
 mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQC3dLWKJQIAAEsEAAAOAAAAZHJzL2Uyb0RvYy54bWysVNuO2yAQfa/Uf0C8N3Zu3cSKs9pmm6rS
9iLt9gMwxjEqMBRI7PTrd8BJGm3bl6p+QAwzHGbOmfHqtteKHITzEkxJx6OcEmE41NLsSvrtaftm
QYkPzNRMgRElPQpPb9evX606W4gJtKBq4QiCGF90tqRtCLbIMs9boZkfgRUGnQ04zQKabpfVjnWI
rlU2yfO3WQeutg648B5P7wcnXSf8phE8fGkaLwJRJcXcQlpdWqu4ZusVK3aO2VbyUxrsH7LQTBp8
9AJ1zwIjeyd/g9KSO/DQhBEHnUHTSC5SDVjNOH9RzWPLrEi1IDneXmjy/w+Wfz58dUTWJV1SYphG
iZ5EH8g76MkkstNZX2DQo8Ww0OMxqpwq9fYB+HdPDGxaZnbizjnoWsFqzG4cb2ZXVwccH0Gq7hPU
+AzbB0hAfeN0pA7JIIiOKh0vysRUOB5OpvPZfIEujr7pcnqTJ+kyVpxvW+fDBwGaxE1JHSqf0Nnh
wYeYDSvOIfExD0rWW6lUMtyu2ihHDgy7ZJu+VMCLMGVIhzzNJ/OBgL9C5On7E4SWAdtdSV3SxSWI
FZG296ZOzRiYVMMeU1bmxGOkbiAx9FWfBJue5amgPiKxDobuxmnETQvuJyUddnZJ/Y89c4IS9dGg
OMvxbBZHIRmz+c0EDXftqa49zHCEKmmgZNhuQhqfyJuBOxSxkYnfqPaQySll7NhE+2m64khc2ynq
1z9g/QwAAP//AwBQSwMEFAAGAAgAAAAhACJ7LY3gAAAACgEAAA8AAABkcnMvZG93bnJldi54bWxM
j8tuwjAQRfeV+g/WVOqu2EFJHyEOqpDYsGuKWpYmHmJDbEexgfD3na7a3Yzm6s451XJyPbvgGG3w
ErKZAIa+Ddr6TsL2c/30Ciwm5bXqg0cJN4ywrO/vKlXqcPUfeGlSx6jEx1JJMCkNJeexNehUnIUB
Pd0OYXQq0Tp2XI/qSuWu53MhnrlT1tMHowZcGWxPzdlJiKdsXXyH49bsNjfTHHf2y25WUj4+TO8L
YAmn9BeGX3xCh5qY9uHsdWS9hJeMVJKE/E3QQIE8z8hlL6Eo5gJ4XfH/CvUPAAAA//8DAFBLAQIt
ABQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAAAAAAAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10u
eG1sUEsBAi0AFAAGAAgAAAAhADj9If/WAAAAlAEAAAsAAAAAAAAAAAAAAAAALwEAAF9yZWxzLy5y
ZWxzUEsBAi0AFAAGAAgAAAAhALd0tYolAgAASwQAAA4AAAAAAAAAAAAAAAAALgIAAGRycy9lMm9E
b2MueG1sUEsBAi0AFAAGAAgAAAAhACJ7LY3gAAAACgEAAA8AAAAAAAAAAAAAAAAAfwQAAGRycy9k
b3ducmV2LnhtbFBLBQYAAAAABAAEAPMAAACMBQAAAAA=
">
 <v:textbox style='mso-next-textbox:#_x0000_s1033'/>
 <w:wrap anchory="page"/>
</v:shape><![endif]--><!--[if !vml]--></p><table align="left" cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td colspan="5">&nbsp;</td><td style="vertical-align:top" rowspan="2" colspan="2"><img width="123" height="64" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png" /></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td style="vertical-align:top" rowspan="2" colspan="3"><img width="288" height="54" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png" /></td></tr><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="background-color:white; border-color:black; vertical-align:top" rowspan="2" colspan="2"><!--[endif]--><!--[if !mso]--><table style="width:100%" cellspacing="0" cellpadding="0"><tbody><tr><td><!--[endif]--><p style="text-align:center" dir="RTL">قبل أكثر من ١٢ ساعة<br />أو نسيت تناول أكثر من حبة</p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td><td>&nbsp;</td><td style="background-color:white; border-color:black; vertical-align:top" colspan="3"><!--[endif]--><!--[if !mso]--><table style="width:100%" cellspacing="0" cellpadding="0"><tbody><tr><td><!--[endif]--><p style="text-align:center" dir="RTL">قبل أقل من ١٢ ساعة</p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td></tr><tr><td>&nbsp;</td></tr></tbody></table><p><!--[endif]--></p><p>&nbsp;</p><p style="text-align:right" dir="RTL">&nbsp;</p><p>&nbsp;</p><p style="text-align:right" dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_s1035" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:245.7pt;
 margin-top:12.7pt;width:152.45pt;height:64.5pt;z-index:251654656;visibility:visible;
 mso-width-percent:400;mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
 mso-width-percent:400;mso-width-relative:margin;mso-height-relative:margin'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#_x0000_s1035'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoListParagraphCxSpFirst dir=RTL style='margin-top:0in;
    margin-right:7.45pt;margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;
    text-align:right;text-indent:-7.05pt;mso-list:l1 level1 lfo1;direction:
    rtl;unicode-bidi:embed'><![if !supportLists]><span style='font-size:10.0pt;
    line-height:107%;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:10.0pt;line-height:107%;
    font-family:"Traditional Arabic",serif'>تناولي الحبة التي نسيتيها فور أن
    تتذكريها، ثم استمري في تناول الحبوب كالمعتاد. قد يعني ذلك أن تتناولي حبتين
    في نفس اليوم.</span><span dir=LTR style='font-size:10.0pt;line-height:107%;
    font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpLast dir=RTL style='margin-top:0in;margin-right:
    7.45pt;margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;text-align:
    right;text-indent:-7.05pt;mso-list:l1 level1 lfo1;direction:rtl;unicode-bidi:
    embed'><![if !supportLists]><span style='font-size:10.0pt;line-height:107%;
    font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-size:10.0pt;line-height:107%;font-family:"Traditional Arabic",serif'>لا
    تقلقي إذ لن يقل تأثير منع الحمل لديك.</span><span dir=LTR style='font-size:
    10.0pt;line-height:107%;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><!--[if !vml]--><img width="40%" alt="Text Box: •	تناولي الحبة التي نسيتيها فور أن تتذكريها، ثم استمري في تناول الحبوب كالمعتاد. قد يعني ذلك أن تتناولي حبتين في نفس اليوم.
•	لا تقلقي إذ لن يقل تأثير منع الحمل لديك.
" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png" /><!--[endif]--><!--[if gte vml 1]><v:shape id="_x0000_s1036"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:27.15pt;margin-top:12.7pt;width:151.85pt;height:123.5pt;z-index:251655680;
 visibility:visible;mso-width-percent:400;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-bottom:3.6pt;mso-width-percent:400;mso-width-relative:margin;
 mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#_x0000_s1036'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoListParagraphCxSpFirst dir=RTL style='margin-top:0in;
    margin-right:14.55pt;margin-bottom:8.0pt;margin-left:0in;mso-add-space:
    auto;text-align:right;text-indent:-.25in;line-height:12.0pt;mso-line-height-rule:
    exactly;mso-list:l1 level1 lfo1;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:10.0pt;font-family:"Traditional Arabic",serif'>تناولي
    آخر حبة نسيتِ أن تتناولينها على الفور.</span><span dir=LTR
    style='font-size:10.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='margin-top:0in;
    margin-right:14.55pt;margin-bottom:8.0pt;margin-left:0in;mso-add-space:
    auto;text-align:right;text-indent:-.25in;line-height:12.0pt;mso-line-height-rule:
    exactly;mso-list:l1 level1 lfo1;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:10.0pt;font-family:"Traditional Arabic",serif'>اتركي
    الحبوب الأخرى التي نسيتيها في مكانها.</span><span dir=LTR style='font-size:
    10.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='margin-top:0in;
    margin-right:14.55pt;margin-bottom:8.0pt;margin-left:0in;mso-add-space:
    auto;text-align:right;text-indent:-.25in;line-height:12.0pt;mso-line-height-rule:
    exactly;mso-list:l1 level1 lfo1;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:10.0pt;font-family:"Traditional Arabic",serif'>استمري
    في تناول الحبوب كالمعتاد. قد يعني ذلك أن تتناولي حبتين في نفس اليوم.</span><span
    dir=LTR style='font-size:10.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='margin-top:0in;
    margin-right:14.55pt;margin-bottom:8.0pt;margin-left:0in;mso-add-space:
    auto;text-align:right;text-indent:-.25in;line-height:12.0pt;mso-line-height-rule:
    exactly;mso-list:l1 level1 lfo1;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:10.0pt;font-family:"Traditional Arabic",serif'>التزمي
    الحرص باستخدام وسائل منع حمل إضافية (كالواقي الذكري) خلال السبعة أيام
    التالية.</span><span dir=LTR style='font-size:10.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='margin-top:0in;
    margin-right:14.55pt;margin-bottom:8.0pt;margin-left:0in;mso-add-space:
    auto;text-align:right;text-indent:-.25in;line-height:12.0pt;mso-line-height-rule:
    exactly;mso-list:l1 level1 lfo1;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:10.0pt;font-family:"Traditional Arabic",serif'>تفقدي
    عدد الحبوب المُتبقيّة في الشريط بعد تناولك لآخر حبة نسيت أن تتناولينها.</span><span
    dir=LTR style='font-size:10.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpLast dir=RTL style='margin-top:0in;margin-right:
    .4pt;margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;text-align:
    right;text-indent:-.25in;line-height:12.0pt;mso-line-height-rule:exactly;
    mso-list:l1 level1 lfo1;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    dir=RTL></span><span style='font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span dir=RTL></span><span dir=RTL></span><span lang=AR-SA
    style='font-size:10.0pt;font-family:"Traditional Arabic",serif'><span
    dir=RTL></span><span dir=RTL></span><span
    style='mso-spacerun:yes'>  </span></span><span dir=LTR style='font-size:
    10.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><!--[if !vml]--><img width="40%" alt="Text Box: •	تناولي آخر حبة نسيتِ أن تتناولينها على الفور.
•	اتركي الحبوب الأخرى التي نسيتيها في مكانها.
•	استمري في تناول الحبوب كالمعتاد. قد يعني ذلك أن تتناولي حبتين في نفس اليوم.
•	التزمي الحرص باستخدام وسائل منع حمل إضافية (كالواقي الذكري) خلال السبعة أيام التالية.
•	تفقدي عدد الحبوب المُتبقيّة في الشريط بعد تناولك لآخر حبة نسيت أن تتناولينها.
•	  
" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image006.png" /><!--[endif]--></p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_s1046"
 type="#_x0000_t32" style='position:absolute;left:0;text-align:left;
 margin-left:-114.7pt;margin-top:24.4pt;width:20pt;height:0;rotation:90;
 z-index:251665920;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" adj="-205254,-1,-205254" strokeweight="1pt">
 <v:stroke endarrow="block" joinstyle="miter"/>
</v:shape><v:shapetype id="_x0000_t34" coordsize="21600,21600" o:spt="34"
 o:oned="t" adj="10800" path="m,l@0,0@0,21600,21600,21600e" filled="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="val #0"/>
 </v:formulas>
 <v:path arrowok="t" fillok="f" o:connecttype="none"/>
 <v:handles>
  <v:h position="#0,center"/>
 </v:handles>
 <o:lock v:ext="edit" shapetype="t"/>
</v:shapetype><v:shape id="_x0000_s1050" type="#_x0000_t34" style='position:absolute;
 left:0;text-align:left;margin-left:107.1pt;margin-top:44.9pt;width:9.8pt;
 height:.1pt;rotation:90;flip:x;z-index:251670016;visibility:visible'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" adj=",127774800,-418665" strokeweight="1pt">
 <v:stroke endarrow="block"/>
</v:shape><v:line id="_x0000_s1051" style='position:absolute;left:0;
 text-align:left;z-index:251671040;visibility:visible;mso-width-relative:margin;
 mso-height-relative:margin' from="-97.05pt,40.05pt" to="111.95pt,40.05pt"
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" strokeweight="1pt">
 <v:stroke joinstyle="miter"/>
</v:line><v:shape id="_x0000_s1048" type="#_x0000_t32" style='position:absolute;
 left:0;text-align:left;margin-left:113.75pt;margin-top:38.6pt;width:22.5pt;
 height:0;rotation:90;z-index:251667968;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" adj="-189120,-1,-189120" strokeweight="1pt">
 <v:stroke endarrow="block" joinstyle="miter"/>
</v:shape><![endif]--><!--[if !vml]--></p><table align="left" cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="vertical-align:top" rowspan="2"><img width="11" height="29" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png" /></td></tr><tr><td>&nbsp;</td><td colspan="3">&nbsp;</td><td style="vertical-align:top" rowspan="3"><img width="11" height="33" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image008.png" /></td></tr><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td colspan="2">&nbsp;</td><td style="vertical-align:top"><img width="286" height="15" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image009.png" /></td></tr></tbody></table><p><!--[endif]-->&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="text-align:right" dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_s1037"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:259.05pt;margin-top:22.5pt;width:152.15pt;height:21.5pt;z-index:251656704;
 visibility:visible;mso-width-percent:400;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-bottom:3.6pt;mso-width-percent:400;mso-width-relative:margin;
 mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#_x0000_s1037'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=center dir=RTL style='text-align:center;
    direction:rtl;unicode-bidi:embed'><span lang=AR-SA style='font-size:10.0pt;
    line-height:107%;font-family:"Traditional Arabic",serif'>تبقّى ٧ سبع حبوب
    أو أكثر</span><span dir=LTR style='font-size:10.0pt;line-height:107%;
    font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><!--[if !vml]--><img width="40%" alt="Text Box: تبقّى ٧ سبع حبوب أو أكثر" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image010.png" /><!--[endif]--><!--[if gte vml 1]><v:shape
 id="_x0000_s1038" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:25.85pt;margin-top:22pt;width:151.4pt;height:22pt;
 z-index:251657728;visibility:visible;mso-width-percent:400;
 mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
 mso-width-percent:400;mso-width-relative:margin;mso-height-relative:margin'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#_x0000_s1038'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=center dir=RTL style='text-align:center;
    direction:rtl;unicode-bidi:embed'><span lang=AR-SA style='font-size:10.0pt;
    line-height:107%;font-family:"Traditional Arabic",serif'>تبقّى أقل من ٧ سبع
    حبوب </span><span dir=LTR style='font-size:10.0pt;line-height:107%;
    font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><!--[if !vml]--><img width="40%" alt="Text Box: تبقّى أقل من ٧ سبع حبوب " src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image011.png" /><!--[endif]--><!--[if gte vml 1]><v:shape
 id="Straight_x0020_Arrow_x0020_Connector_x0020_194" o:spid="_x0000_s1041"
 type="#_x0000_t32" style='position:absolute;left:0;text-align:left;
 margin-left:352pt;margin-top:11.8pt;width:0;height:15pt;z-index:251660800;
 visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" strokeweight="1pt">
 <v:stroke endarrow="block" joinstyle="miter"/>
</v:shape><v:shape id="Straight_x0020_Arrow_x0020_Connector_x0020_196" o:spid="_x0000_s1042"
 type="#_x0000_t32" style='position:absolute;left:0;text-align:left;
 margin-left:689.2pt;margin-top:0;width:0;height:15pt;z-index:251661824;
 visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" strokeweight="1pt">
 <v:stroke endarrow="block" joinstyle="miter"/>
</v:shape><![endif]--><!--[if !vml]--></p><table align="left" cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td colspan="2">&nbsp;</td><td style="vertical-align:top" rowspan="2"><img width="11" height="23" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image012.png" /></td></tr><tr><td>&nbsp;</td><td style="vertical-align:top" rowspan="2"><img width="11" height="23" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image013.png" /></td></tr><tr><td>&nbsp;</td></tr></tbody></table><p><!--[endif]--></p><p>&nbsp;</p><p style="text-align:right" dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_s1040"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:36.05pt;margin-top:28.55pt;width:152.15pt;height:120.25pt;
 z-index:251659776;visibility:visible;mso-width-percent:400;
 mso-wrap-distance-top:3.6pt;mso-wrap-distance-bottom:3.6pt;
 mso-width-percent:400;mso-width-relative:margin;mso-height-relative:margin'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#_x0000_s1040'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoListParagraphCxSpFirst dir=RTL style='margin-top:0in;
    margin-right:7.45pt;margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;
    text-align:right;text-indent:-7.05pt;line-height:normal;mso-list:l0 level1 lfo2;
    direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:10.0pt;font-family:"Traditional Arabic",serif'>لا
    تنسي اتخاذ الاحتياطات اللازمة خلال الأيام السبعة المقبلة.</span><span
    dir=LTR style='font-size:10.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='margin-top:0in;
    margin-right:7.45pt;margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;
    text-align:right;text-indent:-7.05pt;line-height:normal;mso-list:l0 level1 lfo2;
    direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:10.0pt;font-family:"Traditional Arabic",serif'>عندما
    تنتهي من تناول الحبوب في الشريط، اتركي فترة 7 أيام الخالية من الحبوب قبل
    البدء باستخدام الشريط اللاحق.</span><span dir=LTR style='font-size:10.0pt;
    font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpLast dir=RTL style='margin-top:0in;margin-right:
    7.45pt;margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;text-align:
    right;text-indent:-7.05pt;line-height:normal;mso-list:l0 level1 lfo2;
    direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:10.0pt;font-family:"Traditional Arabic",serif'>إذا
    نسيت أن تتناولي حبة أو أكثر من حبوب الأسبوع الأول في الشريط (اليوم ١-٧)،
    ومارست العلاقة الحميمة خلال هذا الأسبوع، من المحتمل أن تحملي. استشيري
    طبيبك، ممرضة تنظيم الأسرة أو الصيدلي في أسرع وقت ممكن.</span><span dir=LTR
    style='font-size:10.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><!--[if !vml]--><img width="40%" alt="Text Box: •	لا تنسي اتخاذ الاحتياطات اللازمة خلال الأيام السبعة المقبلة.
•	عندما تنتهي من تناول الحبوب في الشريط، اتركي فترة 7 أيام الخالية من الحبوب قبل البدء باستخدام الشريط اللاحق.
•	إذا نسيت أن تتناولي حبة أو أكثر من حبوب الأسبوع الأول في الشريط (اليوم ١-٧)، ومارست العلاقة الحميمة خلال هذا الأسبوع، من المحتمل أن تحملي. استشيري طبيبك، ممرضة تنظيم الأسرة أو الصيدلي في أسرع وقت ممكن.
" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image014.png" /><!--[endif]--><!--[if gte vml 1]><v:shape id="_x0000_s1047"
 type="#_x0000_t32" style='position:absolute;left:0;text-align:left;
 margin-left:355.7pt;margin-top:-3.05pt;width:0;height:15pt;z-index:251666944;
 visibility:visible;mso-width-relative:margin;mso-height-relative:margin'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" strokeweight="1pt">
 <v:stroke endarrow="block" joinstyle="miter"/>
</v:shape><![endif]--><!--[if !vml]--></p><table align="left" cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="11" height="23" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image015.png" /></td></tr></tbody></table><p><!--[endif]--><!--[if gte vml 1]><v:shape id="_x0000_s1039" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:-195.05pt;
 margin-top:27.65pt;width:151.85pt;height:129.8pt;z-index:251658752;
 visibility:visible;mso-width-percent:400;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-bottom:3.6pt;mso-width-percent:400;mso-width-relative:margin;
 mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoListParagraphCxSpFirst dir=RTL style='margin-top:0in;
    margin-right:7.9pt;margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;
    text-align:right;text-indent:-.1in;line-height:12.0pt;mso-line-height-rule:
    exactly;mso-list:l0 level1 lfo2;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:10.0pt;font-family:"Traditional Arabic",serif'>لا
    تنسي اتخاذ الاحتياطات اللازمة خلال الأيام السبعة المقبلة.</span><span
    dir=LTR style='font-size:10.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='margin-top:0in;
    margin-right:7.9pt;margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;
    text-align:right;text-indent:-.1in;line-height:12.0pt;mso-line-height-rule:
    exactly;mso-list:l0 level1 lfo2;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:10.0pt;font-family:"Traditional Arabic",serif'>عندما
    تنتهي من تناول الحبوب في الشريط، ابدأي في تناول الحبوب من الشريط اللاحق
    بدون انقطاع. </span><span dir=LTR style='font-size:10.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='margin-top:0in;
    margin-right:7.9pt;margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;
    text-align:right;text-indent:-.1in;line-height:12.0pt;mso-line-height-rule:
    exactly;mso-list:l0 level1 lfo2;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:10.0pt;font-family:"Traditional Arabic",serif'>إذا
    لم يحدث لديك نزيف نتيجة انسحاب الدواء بعد الانتهاء من الشريط الثاني، قومي
    بعمل اختبار الحمل قبل أن تبدأي باتناول الحبوب من الشريط المقبل. </span><span
    dir=LTR style='font-size:10.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpLast dir=RTL style='margin-top:0in;margin-right:
    7.9pt;margin-bottom:8.0pt;margin-left:0in;mso-add-space:auto;text-align:
    right;text-indent:-.1in;line-height:12.0pt;mso-line-height-rule:exactly;
    mso-list:l0 level1 lfo2;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:10.0pt;font-family:"Traditional Arabic",serif'>إذا
    نسيت أن تتناولي حبة أو أكثر من حبوب الأسبوع الأول في الشريط (اليوم ١-٧)،
    ومارست العلاقة الحميمة خلال هذا الأسبوع، من المحتمل أن تحملي. استشيري
    طبيبك، ممرضة تنظيم الأسرة أو الصيدلي في أسرع وقت ممكن.</span><span dir=LTR
    style='font-size:10.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><!--[if !vml]--><img width="40%" alt="Text Box: •	لا تنسي اتخاذ الاحتياطات اللازمة خلال الأيام السبعة المقبلة.
•	عندما تنتهي من تناول الحبوب في الشريط، ابدأي في تناول الحبوب من الشريط اللاحق بدون انقطاع. 
•	إذا لم يحدث لديك نزيف نتيجة انسحاب الدواء بعد الانتهاء من الشريط الثاني، قومي بعمل اختبار الحمل قبل أن تبدأي باتناول الحبوب من الشريط المقبل. 
•	إذا نسيت أن تتناولي حبة أو أكثر من حبوب الأسبوع الأول في الشريط (اليوم ١-٧)، ومارست العلاقة الحميمة خلال هذا الأسبوع، من المحتمل أن تحملي. استشيري طبيبك، ممرضة تنظيم الأسرة أو الصيدلي في أسرع وقت ممكن.
" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image016.png" /><!--[endif]--><!--[if gte vml 1]><v:shape id="Straight_x0020_Arrow_x0020_Connector_x0020_202"
 o:spid="_x0000_s1044" type="#_x0000_t32" style='position:absolute;left:0;
 text-align:left;margin-left:136.5pt;margin-top:-4.05pt;width:0;height:15pt;
 z-index:251663872;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" strokeweight="1pt">
 <v:stroke endarrow="block" joinstyle="miter"/>
</v:shape><v:shape id="_x0000_s1049" type="#_x0000_t34" style='position:absolute;
 left:0;text-align:left;margin-left:-101.6pt;margin-top:2.7pt;width:12.6pt;
 height:.1pt;rotation:90;flip:x;z-index:251668992;visibility:visible'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" adj=",91573200,-328371" strokeweight="1pt">
 <v:stroke endarrow="block"/>
</v:shape><![endif]--><!--[if !vml]--></p><table align="left" cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td colspan="2">&nbsp;</td><td style="vertical-align:top" rowspan="3"><img width="11" height="23" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image017.png" /></td></tr><tr><td>&nbsp;</td><td style="vertical-align:top"><img width="11" height="19" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image018.png" /></td></tr><tr><td>&nbsp;</td></tr></tbody></table><p><!--[endif]--></p><p>&nbsp;</p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL"><strong>&nbsp;</strong></p><p style="text-align:right" dir="RTL"><strong>&nbsp;</strong></p><p style="text-align:right" dir="RTL"><strong>&nbsp;</strong></p><p>&nbsp;</p><p style="text-align:right" dir="RTL"><strong>إذا نسيتِ أن تتناولي أيّ من الحبوب في الشريط، ولم يحدث لديك نزيف الحيض خلال الأيام السبعة الخالية من الحبوب</strong>، قد تكوني حاملًا. <strong>اتصلي بطبيبك أو بعيادة تنظيم الأسرة، أو قومي بإجراء اختبار الحمل بنفسك.</strong></p><p style="text-align:right" dir="RTL">إذا بدأتِ بتناول حبوب منع الحمل من شريط جديد في وقت متأخر، أو جعلت المدة الخالية من حبوب منع الحمل تطول أكثر من سبعة أيام، قد لا تكوني محمية من الحمل. إذا كنتِ قد مارست العلاقة الحميمة خلال الأيام السبعة الأخيرة، استشيري طبيبك أو ممرضة تنظيم الأسرة أو الصيدلي. قد تحتاجين إلى استخدام منع الحمل في حالات الطوارئ.</p><p style="text-align:right" dir="RTL">يجب عليك أيضًا استخدام وسائل منع الحمل الإضافية، مثل الواقي الذكري، لمدة سبعة أيام.</p><p style="text-align:right" dir="RTL"><strong>٣&ndash;٤ &nbsp;حبوب منع الحمل المفقودة<br />إذا فقدتِ إحدى حبوب منع الحمل،</strong></p><p style="text-align:right" dir="RTL"><strong>إمّا</strong> أن تتناولي حبة منع الحمل الأخيرة من الشريط بدلًا من الحبة المفقودة. ثم تتابعين تناول بقية حبوب منع الحمل الأخرى في أيامها الصحيحة. سوف تكون الدورة الشهرية لديك أقصر بيوم واحد من المعتاد، ولكن لن تتأثر حمايتك من الحمل. بعد انتهاء السبعة أيام الخالية من حبوب منع الحمل سيكون لديك يوم بدء جديد، أبكر بيوم واحد.</p><p style="text-align:right" dir="RTL"><strong>أو</strong> إذا كنتِ لا ترغبين في تغيير يوم بداية الدورة لديكِ، قومي بتناول حبة من حبوب منع الحمل من شريط احتياطي آخر. ثم تناولي بقية حبوب منع الحمل الأخرى من الشريط الحالي كالمعتاد. يمكنك الاحتفاظ بالشريط الاحتياطي لاستخدامه عند اللزوم.</p><p style="text-align:right" dir="RTL"><strong>٣&ndash;٥ &nbsp;إذا كنتِ تعانين من التقيؤ أو لديك إسهال</strong></p><p style="text-align:right" dir="RTL">إذا كنتِ تعانين من التقيؤ أو لديكِ إسهال قد لا يحصل جسمكِ على جرعة الهرمونات المعتادة من حبوب منع الحمل.</p><p style="text-align:right" dir="RTL">إذا تقيّأتِ في غضون <strong>٣ إلى ٤</strong> ساعات بعد تناول حبة منع الحمل، يُعد ذلك كأنك نسيت تناول أحد الحبوب. يجب اتباع الارشادات الخاصة بنسيان تناول أحد الحبوب - انظري الفقرة ٣&ndash;٣ ، إذا نسيتِ تناول أحد الحبوب.</p><p style="text-align:right" dir="RTL">إذا كان لديكِ <strong>إسهال شديد لأكثر من ١٢ ساعة بعد تناول مارفيلون</strong> اتبعي التعليمات الخاصة إذا كنتِ نسيتِ تناول حبة منع الحمل لمدة أكثر من ١٢ ساعة &nbsp;- انظري الفقرة ٣&ndash;٣ ، إذا نسيتِ تناول أحد الحبوب.</p><p style="text-align:right" dir="RTL"><strong>&larr;</strong><strong> تحدثي مع طبيبكِ إذا استمر اضطراب معدتكِ أو ازداد سوءًا. قد ينصحكِ / تنصحكِ باستخدام نوع آخر من وسائل منع الحمل.</strong></p><p style="text-align:right" dir="RTL"><strong>٣&ndash;٦ &nbsp;لم يحدث لكِ نزف الحيض - هل يمكن أن تكوني حاملًا؟</strong><br />أحيانًا، قد لا يحدث لديكِ النزف الناجم عن انسحاب الدواء. وهذا قد يعني أنك حامل، ولكن هذا أمر مستبعد جدا إذا كنتِ قد تناولت حبوب منع الحمل بشكل صحيح. ابدئي بتناول حبوب منع الحمل من الشريط التالي في الوقت المعتاد. إذا كنتِ تعتقدين أنكِ قد تعرضين نفسكِ لخطر الحمل (على سبيل المثال، عن طريق نسيان تناول بعض حبوب منع الحمل أو تناول أدوية أخرى)، أو إذا لم يحدث لديك نزف للمرة الثانية،&nbsp; يجب عليكِ إجراء اختبار الحمل. يمكنك شراء الاختبار من الصيدلي أو الحصول على اختبار مجاني من عيادة تنظيم الأسرة أو الجراحة. إذا كنت حاملًا، توقفي عن تناول مارفيلون وراجعي الطبيب.</p><p style="text-align:right" dir="RTL"><strong>٣&ndash;٧ &nbsp;يجب أن لا يحدث ضررًا بسبب تناول أكثر من حبة واحدة من حبوب منع الحمل </strong></p><p style="text-align:right" dir="RTL">من غير المحتمل أن يؤدي تناول أكثر من حبة من حبوب منع الحمل إلى أي ضرر، ولكِن قد تصابين &nbsp;بالغثيان أو القيء أو قد يحدث لديك بعض النزيف المهبلي. استشيري طبيبك إذا تعرضتِ لأي ٍّمن هذه الأعراض.</p><p style="text-align:right" dir="RTL"><strong>٣&ndash;٨ &nbsp;يمكنكِ تأخير النزيف الحيضي </strong><br />إذا كنتِ ترغبين في تأخير نزف الحيض، تناولي جميع حبوب منع الحمل في الشريط كالمعتاد، ثم ابدئي في تناول الحبوب من الشريط التالي دون انقطاع. استمري في تناول الحبوب بالطريقة المعتادة. بعد الانتهاء من الشريط الثاني، اتركي سبعة أيام خالية من حبوب منع الحمل كالمعتاد، ثم ابدئي في تناول الحبوب من الشريط التالي بالطريقة المعتادة. قد يحدث لديك عند البدء في استخدام الشريط الثاني، بعض النزيف غير المتوقع أو دم مُتقطع مع استمراركِ في تناول حبوب منع الحمل، فلا داعي للقلق.</p><p style="text-align:right" dir="RTL"><strong>٣&ndash;٩ &nbsp;عند رغبتكِ في الإنجاب </strong><br />إذا كنتِ تخططين لإنجاب طفلٍ، فمن الأفضل استخدام طريقة أخرى لمنع الحمل بعد التوقف عن استخدام مارفيلون حتى يحدث نزف الحيض. یعتمد طبیبك أو القابلة علی تاریخ آخر دورة شهرية حدثت لكِ بشكل طبيعي في تحديد وقت الولادة المتوقع. ومع ذلك، فإنه لن يحدث لكِ أو لطفلكِ أيّ ضرر إذا أصبحت&nbsp; حاملًا على الفور دون حدوث الدورة الشهرية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right" dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب مارفيلون آثارًا جانبية، ولكنها لا تحدث لدى جميع المرضى. إذا حدث لديكِ أيّ أثر جانبي، خاصة إذا كان شديدًا ومستمرًا ، أو أي تغيير في صحتك وتعتقدين أنه قد يكون بسبب مارفيلون، فيرجى التحدث إلى طبيبك.</p><p style="text-align:right" dir="RTL">تواجه جميع النساء اللاتي يتناولن وسائل منع الحمل الهرمونية المركبة زيادة خطر الجلطات الدموية في الأوردة (الجلطات الدموية الوريدية)، أو جلطات الدم في الشرايين (الجلطات الدموية الشريانية). للحصول على معلومات أكثر تفصيلًا عن المخاطر المختلفة لاستعمال موانع الحمل الهرمونية المركبة، يرجى الاطلاع على الفقرة رقم &quot;٢&quot; ما تحتاجين إلى معرفته قبل استخدام مارفيلون.</p><p style="text-align:right" dir="RTL">٤<strong>&ndash;١ الآثار الجانبية الخطيرة -&nbsp; يجب طلب المساعدة الطبية فورًا</strong></p><p style="text-align:right" dir="RTL"><strong>علامات الجلطة الدموية الوريدية:</strong></p><p style="margin-left:0in; margin-right:21.45pt; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تورم في ساق واحدة أو على طول الوريد في الساق أو القدم وخاصة عندما يكون مصحوبًا بــ:</p><p style="margin-left:0in; margin-right:21.45pt; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم في الساق أو ألم عند لمس الساق والذي يكون محسوسًا فقط عند الوقوف أو المشي؛</p><p style="margin-left:0in; margin-right:21.45pt; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الإحساس بزيادة في حرارة الرجل المصابة؛</p><p style="margin-left:0in; margin-right:21.45pt; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]-->تغير لون جلد الساق كأن تصبح ذات لون أحمر، أو أزرق شاحب.<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p style="text-align:right" dir="RTL"><strong>علامات الجلطة الرئوية:</strong></p><p style="margin-left:0in; margin-right:.2in; text-align:right; text-indent:-14.2pt" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->انقطاع التنفس المفاجئ وغير المبرر أو التنفس السريع؛</p><p style="margin-left:0in; margin-right:.2in; text-align:right; text-indent:-14.2pt" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->سُعال مفاجئ بدون سبب واضح والذي يمكن أن يتسبب في خروج دم؛</p><p style="margin-left:0in; margin-right:.2in; text-align:right; text-indent:-14.2pt" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم حاد في الصدر والذي قد يزداد مع التنفس العميق؛</p><p style="margin-left:0in; margin-right:.2in; text-align:right; text-indent:-14.2pt" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الشعور بالدّوار أو الدوخة؛</p><p style="margin-left:0in; margin-right:.2in; text-align:right; text-indent:-14.2pt" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضربات القلب السريعة أو غير المنتظمة؛</p><p style="margin-left:0in; margin-right:.2in; text-align:right; text-indent:-14.2pt" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم شديد في المعدة.</p><p style="margin-right:.2in; text-align:right; text-indent:-14.2pt" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL">إذا كنتِ غير متأكدة، تحدثي إلى طبيبك لأنّ بعض هذه العلامات مثل السعال أو ضيق في التنفس قد تفسر بالخطأ على أنها علامات لحالات أقل خطورة مثل عدوى الجهاز التنفسي (كالرشح مثلا).</p><p style="text-align:right" dir="RTL"><strong>علامات الجلطة الدموية في وريد الشبكية (جلطة في العين):</strong></p><p style="margin-left:0in; margin-right:21.45pt; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تحدث معظم العلامات في عين واحدة:</p><p style="margin-left:0in; margin-right:21.45pt; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فقدان فوري للرؤية؛</p><p style="margin-left:0in; margin-right:21.45pt; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->عدم وضوح في الرؤية غير مؤلم والذي قد يتطور إلى فقدان الرؤية.</p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL"><strong>علامات النوبة القلبية:</strong></p><p style="margin-left:0in; margin-right:21.45pt; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم، شعور بالضيق، أو الضغط، أو الثقل في الصدر؛</p><p style="margin-left:0in; margin-right:21.45pt; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->شعور بالضغط أو الإمتلاء في الصدر، الذراع، أو تحت عظم الثدي</p><p style="margin-left:0in; margin-right:21.45pt; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الشعور بعدم الراحة في الجزء العلوي للجسم ويمتد إلى الظهر، الفك، الحلق، الذراع، والمعدة؛</p><p style="margin-left:0in; margin-right:21.45pt; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التعرق، الغثيان، القيء، أو الدوخة؛</p><p style="margin-left:0in; margin-right:21.45pt; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضعف شديد، أرق، أو ضيق في التنفس؛</p><p style="margin-left:0in; margin-right:21.45pt; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->نبض قلب متسارع أو غير منتظم.<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p style="text-align:right" dir="RTL"><strong>علامات السكتة الدماغية:</strong></p><p style="margin-left:0in; margin-right:.2in; text-align:right; text-indent:-14.2pt" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضعف أو خدر مفاجئ في الوجه، الذراع، أو الساق، بالذات في جهة واحدة من الجسم؛</p><p style="margin-left:0in; margin-right:.2in; text-align:right; text-indent:-14.2pt" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->تشوش مفاجئ، صعوبة في النطق أو الفهم؛</p><p style="margin-left:0in; margin-right:.2in; text-align:right; text-indent:-14.2pt" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->اضطراب في الرؤية مفاجئ إمّا في عين واحدة أو كلا العينين؛</p><p style="margin-left:0in; margin-right:.2in; text-align:right; text-indent:-14.2pt" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->صعوبة في المشي فجأة، دُوار، أو فقدان الإتزان، أو عدم التناسق في الحركة؛</p><p style="margin-left:0in; margin-right:.2in; text-align:right; text-indent:-14.2pt" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->صداع شديد أو طويل الأمد بشكل فجائي وبغير سبب واضح؛</p><p style="margin-left:0in; margin-right:.2in; text-align:right; text-indent:-14.2pt" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp; <!--[endif]-->فقدان الوعي، أو الإغماء مع أو بدون تشنجات.</p><p style="margin-left:0in; margin-right:.2pt; text-align:right" dir="RTL">مع أنه في بعض الأحيان تكون علامات السكتة الدماغية محدودة مع شفاء تام وفوري، إلا أنه يجب عليكِ طلب المساعدة الطبية فورًا لأنكِ قد تكونين عرضة لسكتة دماغية أخرى.</p><p style="text-align:right" dir="RTL"><strong>&nbsp;</strong></p><p style="text-align:right" dir="RTL"><strong>علامات الجلطة الدموية التي تسد أوعية دموية أخرى:</strong></p><p style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تورم مع ازرقاق طفيف في اللون لأحد الأطراف ؛</p><p style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم شديد في المعدة.<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p style="text-align:right" dir="RTL"><strong>علامات فرط الحساسية الشديدة تجاه مارفيلون:</strong></p><p style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in" dir="RTL"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تورم الوجه، الشفاه، الفم، اللسان، أو الحلق.</p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL"><strong>علامات سرطان الثدي وتشمل:</strong><br />&bull; تنقّر الجلد؛<br />&bull; تغيرات في الحلمة؛<br />&bull; أي كتل يمكنك أن ترينها أو تشعرين بها.<br /><br /><strong>علامات سرطان عنق الرحم وتشمل:</strong><br />&bull; الإفرازات المهبلية لها رائحة وتحتوي على الدم؛<br />&bull; نزيف مهبلي غير عادي؛<br />&bull; ألم في الحوض؛<br />&bull; ألم أثناء العلاقة الحميمة.<strong> </strong></p><p style="text-align:right" dir="RTL"><strong>علامات مشاكل الكبد الشديدة وتشمل:</strong><br />&bull; ألم شديد في الجزء العلوي من البطن.<br />&bull; اصفرار الجلد أو العينين (اليرقان).</p><p style="text-align:right" dir="RTL"><strong>&larr;</strong><strong> إذا كنتِ تعتقدين أنك تعانين من أيّ من هذه الأمور، يُرجى مراجعة الطبيب على الفور. </strong>قد<strong> </strong>تحتاجين إلى التوقف عن تناول مارفيلون.</p><p style="text-align:right" dir="RTL"><strong>٤&ndash;٢ &nbsp;الآثار الجانبيّة المحتملة</strong></p><p style="text-align:right" dir="RTL"><strong>شائعة </strong>(قد تُؤثر على ما يصل إلى ١ من كل ١٠ نساء):<br /><strong>&bull; صداع؛<br />&bull; زيادة الوزن؛<br />&bull; مشاكل في الثدي، مثل الوجع أو الألم عن اللمس؛<br />&bull; الاكتئاب أو تغيرات المزاج؛<br />&bull; مشاكل في المعدة، </strong>مثل الغثيان. وجع البطن؛</p><p style="text-align:right" dir="RTL"><strong>غير شائعة </strong>(قد تؤثر على ما يصل إلى ١ من كل ١٠٠امرأة):<br /><strong>&bull; الصداع النصفي </strong>(راجعي الطبيب في أقرب وقت ممكن إذا كان هذا هو أول صداع نصفي يصيبك أو أنه أسوأ من المعتاد، أو إذا كان الصداع شديدًا أو غير عادي أو طويل الأمد).<br /><strong>&bull; احتباس السوائل </strong>(تورم اليدين والكِاحلين أو القدمين - علامة على احتباس السوائل).<br /><strong>&bull; انخفاض الرغبة الجنسية.<br />&bull; القيء.<br />&bull; إسهال؛<br />&bull; مشاكل في الجلد، مثل الطفح الجلدي أو الشرى؛<br />&bull; تضخّم الثدي؛</strong></p><p style="text-align:right" dir="RTL"><strong>نادرة</strong> (قد تؤثر على ما يصل إلى١ من بين ١٠٠٠ امرأة):<br />&bull; <strong>التغيرات في إفرازات المهبل - نزيف مهبلي غير منتظم</strong> - انظري الفقرة رقم 4.3، النزيف بين الدورة الطمثيّة يجب أن لا يدوم طويلًا؛<br />&bull; <strong>إفراز حليبي من حلمة الثدي</strong>.<br />&bull; <strong>ردود فعل تحسّسية.</strong><br />&bull; <strong>انزعاج في العينين إذا ارتديتِ العدسات اللاصقة.</strong><br />&bull; <strong>حمامي عقدية (تورم في الكِاحلين شبيه بالكِدمة).<br />&bull; حمامي عديدة الأشكال (حالة تصيب الجلد).<br />&bull; انخفاض الوزن.</strong><br />&bull; <strong>زيادة الرغبة الجنسية.<br />&bull; جلطات الدم الضارة في الوريد أو الشريان</strong> على سبيل المثال:<br />&nbsp;&nbsp; o في الساق أو القدم (أي DVT)؛<br />&nbsp;o&nbsp;&nbsp; في الرئة (أي PE).<br />&nbsp;o&nbsp;&nbsp; نوبة قلبية.<br />o&nbsp;&nbsp; &nbsp;السكتة الدماغية.<br />&nbsp;o&nbsp;&nbsp; السكتة الدماغية البسيطة أو أعراض تشبه السكتة الدماغية المؤقتة، والمعروفة باسم نوبات نقص تروية عابرة (TIA)؛<br />&nbsp;&nbsp; o جلطات دموية في الكبد، المعدة / الأمعاء، الكِلى أو العين.</p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL">قد تكون فرصة حدوث جلطة دموية أعلى إذا كان لديك أي حالة أخرى تزيد من هذا الخطر. (انظري الفقرة رقم ٢ لمزيد من المعلومات حول العوامل التي تزيد من خطر الجلطات الدموية وأعراض تجلط الدم).</p><p style="text-align:right" dir="RTL">&bull; رد فعل <strong>تحسسي شديد نحو مارفيلون</strong><br />&bull; <strong>سرطان الثدي</strong><br />&bull; <strong>سرطان عنق الرحم</strong><br />&bull; مشاكل <strong>الكبد الشديدة</strong><br />&bull; <strong>ضغط دم مرتفع</strong><br />&bull; <strong>حصى المرارة</strong><br />&bull; <strong>الكِوريا</strong> (مشكلة في الجهاز العصبي تسبب حركات تتشنجي لا يمكنك السيطرة عليها)<br />&bull; تفاقم <strong>الذئبة الحمامية الشاملة</strong> (SLE؛ عندما يهاجم الجهاز المناعي جسدك مُسبّبًا، على سبيل المثال، آلام المفاصل والتعب)<br />&bull; <strong>مشاكل في المعدة والأمعاء</strong> مثل التهاب البنكرياس. مرض كراون؛ التهاب القولون التقرحي<br />&bull; تفاقم <strong>تصلب الأذن</strong> (مشكلة في السمع)<br />&bull; مشاكل في <strong>نسبة السكر في الدم</strong><br />&bull; تفاقم حالة نادرة تسمى <strong>البورفيريا</strong><br />&bull; تفاقم <strong>مشاكل الجلد</strong>، مثل بقع بنية على وجهك أو جسمك (كَلَف)؛ طفح جلدي على شكل بثور، (هربس الحمل)</p><p style="text-align:right" dir="RTL">&larr; <strong>أخبر طبيبك أو الصيدلي أو ممرضة تنظيم الأسرة</strong> إذا كنت قلقة بشأن أي آثار جانبية تعتقدين أنّ تتعلّق بمارفيلون. أخبريهم أيضا إذا تفاقمت لديك أي من الآثار أثناء استخدامك مارفيلون.</p><p style="text-align:right" dir="RTL"><strong>٣&ndash;٤ ينبغي ألا يستمر النزيف في منتصف الدورة الطمثيّة &nbsp;<br />يحدث لدى </strong>عدد قليل من النساء نزيف خفيف غير متوقع &nbsp;أو تبقيع أثناء استخدامهن مارفيلون، وخاصة خلال الأشهر القليلة الأولى. لا يدعو هذا النزيف إلى القلق ويتوقف عادة بعد يوم أو يومين. استمري في تناول مارفيلون كالمعتاد. يجب أن تختفي المشكلة بعد استخدام عدد قليل من الشرائط.</p><p style="text-align:right" dir="RTL">قد يحدث لديك أيضا نزيف غير متوقع إذا كنتِ لا تتناولين حبوب منع الحمل بانتظام، ولذلك تناولي حبوب منع الحمل في نفس الوقت كل يوم. كما يمكن أيضًا، أن يحدث نزيف غير متوقع في بعض الأحيان بسبب أدوية أخرى.</p><p style="text-align:right" dir="RTL">&rarr; <strong>حددي موعد لمراجعة الطبيب</strong> إذا تعرضت لنزيف في منتصف الدورة الطمثيّة أو تبقيع إذا:<br />&bull; اِسْتَمَرَّ لأكثر من الأشهر القليلة الأولى<br />&bull; بَدَأَ بعد استخدامك مارفيلون لفترة من الوقت<br />&bull; اِسْتَمَرَّ حتى بعد توقفكِ عن استخدام مارفيلون.</p><p style="text-align:right" dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong><br />إذا تعرّضتِ لأيّ آثار جانبيّة، تحدثي مع طبيبك أو ممرضة تنظيم الأسرة أو الصيدلي. ويشمل ذلك أيّ آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرة عن طريق &quot;المركز الوطني للتيقظ والسلامة الدوائية، التابع لهيئة الغذاء والدواء السعودية&quot;. عن طريق الإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right" dir="RTL">يُحفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p style="text-align:right" dir="RTL">لا تستخدمي مارفيلون بعد تاريخ انتهاء الصلاحية المُدوّن على العلبة. تاريخ انتهاء الصلاحية مُدوّن على العلبة الخارجية والملصق الداخلي.</p><p style="text-align:right" dir="RTL">يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية.لا يُجمد</p><p style="text-align:right" dir="RTL">يُحفظ في العبوة الأصلية لحمايته من الضوء والرطوبة</p><p style="text-align:right" dir="RTL">لا تتخلصي من أيّ أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسألي الصيدلي عن كيفية التخلّص من الأدوية التي لم تعودي تستخدميها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right" dir="RTL"><strong>ماذا يحتوي مارفيلون</strong><br />المواد الفعالة هي ديسوجيستريل وإثينيل إستراديول. يحتوي كل قرص على: ٠٫١٥٠ ملغم من بروجيسترون ديسوجيستريل، و ٠٫٠٣٠ ملغم من استروجين إثينيل إستراديول.<br />المكونات الأخرى هي:<br />نشا البطاطس، البوفيدون، حامض الستياريك، السيليكا الغروية اللامائية، ألفا توكوفيرول، اللاكتوز مونوهيدرات</p><p style="text-align:right" dir="RTL">&nbsp;</p><p style="text-align:right" dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>كيف تبدو أقراص مارفيلون وما محتويات العلبة</strong><br />تحتوي كل علبة من علب مارفيلون على ثلاثة شرائط يتكون كل منها من ٢١ حبة.<br />يحتوي كل شريط من مارفيلون على ٢١ قرصًا أبيض اللون.<br />الأقراص دائرية الشكل ومحدبة الوجهين، يبلغ قطر كل منها ٦ ملم. طُبع على أحد الوجهين في كل قرص الرمز TR5 وعلى الوجه الآخر كلمة أورغانون*.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right" dir="RTL"><strong>الشركة المالكة لحقوق التسويق والشركة الصانعة:</strong></p><p style="text-align:right" dir="RTL">إن في أورجانون</p><p style="text-align:right" dir="RTL">كلوستيرسترات 6،</p><p style="text-align:right" dir="RTL">5349 إيه بي أوس،</p><p style="text-align:right" dir="RTL">هولندا</p><p style="text-align:right" dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ ديسمبر 2018الاصدار رقم (4)
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marvelon
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Desogestrel 0.150 mg Ethinylestradiol 0.030 mg

Excipient with known effect: lactose.
For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets.

Tablets are round, biconvex and 6 mm in diameter.  They are coded on one side TR5 and on the reverse side Organon*.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt">Oral contraception.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:5.05pt">The decision to prescribe Marvelon should take into consideration the individual woman&rsquo;s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Marvelon compares with other CHCs (see sections 4.3 and 4.4).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>4.2.2&nbsp;&nbsp;&nbsp; How to start Marvelon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><em>N</em><em>o preceding hormonal contraceptive use [in the past month]:</em></p><p>&nbsp;</p><p>It is preferable that tablet intake from the first pack is started on the first day of menstruation in which case no extra contraceptive precautions are necessary.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:14.8pt">If menstruation has already begun, (that is 2, 3, or 4 days previously), tablet taking should commence on day 5 of the menstrual period. In this case additional contraceptive precautions must be taken for the first 7 days of tablet taking.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:18.65pt">If menstruation began more than 5 days previously then the patient should be advised to wait until her next menstrual period before starting to take Marvelon.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><em>Changing from a 21 day pill or another 22 day pill to Marvelon:</em></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:2.15pt">All tablets in the old pack should be finished. The first Marvelon tablet is taken the next day i.e. no gap is left between taking tablets nor does the patient need to wait for her period to begin. Tablets should be taken as instructed in &lsquo;How to take Marvelon&rsquo;. Additional contraceptive precautions are not required. The patient will not have a period until the end of the first Marvelon pack, but this is not harmful, nor does it matter if she experiences some bleeding on tablet-taking days.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><em>Changing from a combined Every Day Pill (28 day tablets) to Marvelon:</em></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:4.2pt">Marvelon should be started after taking the last <em>active </em>tablet from the &lsquo;Every Day Pill&rsquo; pack (i.e. after taking 21 or 22 tablets). The first Marvelon tablet is taken the next day i.e. no gap is left between taking tablets nor does the patient need to wait for her period to begin.&nbsp; One tablet is taken daily at the same time, without interruption for 21 days, followed by a 7 day tablet-free period.&nbsp; Each subsequent pack is started after the 7 day tablet-free period has elapsed.</p><p style="margin-left:5.0pt; margin-right:14.05pt">Additional contraceptive precautions are not required.&nbsp; Remaining tablets from the Every Day (ED) pack should be discarded. The patient will not have a period until the end of the first Marvelon pack, but this is not harmful, nor does it matter if she experiences some bleeding on tablet-taking days.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><em>Changing from a Progestogen -only Pill (POP or Mini Pill) to Marvelon:</em></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:3.25pt">The first Marvelon tablet should be taken on the first day of the period, even if the patient has already taken a mini pill on that day. &nbsp;One tablet is taken daily at the same time, without interruption for 21 days, followed by a 7 day tablet-free period. &nbsp;Each subsequent pack is started after the 7 day tablet-free period has elapsed. Additional contraceptive precautions are not then required.&nbsp; All the remaining Progestogen-only pills in the mini pill pack should be discarded.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:5.4pt">If the patient is taking a (mini) pill, then she may not always have a period, especially when she is breast feeding. The first Marvelon tablet should be taken on the day after stopping the mini pill. All remaining pills in the mini pill packet must be discarded. Additional contraceptive precautions must be taken for the first seven days.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:36.7pt"><em>Changi</em><em>n</em><em>g from a progestogen-only injection, implant or from a progestogen- releasing intrauterine system [IUS]:</em></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:8.85pt">The woman may switch any day from an implant (or the IUS on the day of its removal, from an injectable when the next injection would be due). Additional contraceptive precautions must be taken for the first seven days.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><em>Post-Partum Administration:</em></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:6.0pt">Following childbirth hormonal contraceptive administration to non-breast feeding mothers should be started 21 days post-partum in which case no additional contraceptive precautions are required. If intercourse has taken place post-partum, hormonal contraceptive use should be delayed until the first day of the menstrual period.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:45.55pt">If post-partum administration of Marvelon begins more than 21 days after delivery then additional contraceptive precautions are required for the first 7 days.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:1.95pt; text-align:justify">N.B. Mothers who are breast feeding should be advised not to use the combined pill since this may reduce the amount of breast-milk, but may be advised instead to use a progestogen-only pill (POP).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:48.5pt">After miscarriage or abortion administration should start immediately in which case no additional contraceptive precautions are required.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><em>Additional contraceptive precautions:</em></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:8.95pt">When additional contraceptive precautions are required the patient should be advised either not to have sex, or to use a cap plus spermicide, or for her partner to use a condom.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:5.5pt">Rhythm methods should not be advised as the pill disrupts the usual cyclical changes associated with the natural menstrual cycle e.g. changes in temperature and cervical mucus.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><em>How to skip a period:</em></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:2.6pt">To skip a period, a new pack of Marvelon should be started on the day after finishing the current pack (the patient skips the tablet-free days). Tablet-taking should be continued in the usual way. During the use of the second pack she may experience slight spotting or breakthrough bleeding but contraceptive protection will not be diminished provided there are no tablet omissions. The next pack of Marvelon is started after the usual 7 tablet-free days, regardless of whether the period has completely finished or not.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>4.2.3&nbsp;&nbsp;&nbsp; Management of missed tablets</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><em>Advice in case of missed pills</em></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt">The reliability of Marvelon may be reduced if tablets are forgotten:</p><p style="margin-left:5.0pt; margin-right:27.75pt">If the forgotten tablet is taken within 12 hours, no further precautions are necessary, further tablets should be taken at the usual time.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:2.55pt">If one or more tablets are forgotten for more than 12 hours, contraceptive protection will be reduced. The patient should take the last forgotten tablet, even if this means taking two tablets in one day, and then continue to take tablets at the normal time. Additional contraceptive precautions should be taken for the next seven days, and the patient should follow &lsquo;the 7-day rule&rsquo;.</p><p>&nbsp;</p><p><em>The 7-Day rule</em></p><p style="margin-left:5.0pt; margin-right:-1.0pt"><em>If any one tablet is forgotten for more than 12 hours</em></p><p style="margin-left:5.0pt; margin-right:-1.0pt"><em>I</em><em>f the patient has vomiting or diarrhoea for more than 12 hours</em></p><p style="margin-left:5.0pt; margin-right:-1.0pt"><em>I</em><em>f the patient is taking any of the drugs listed under &lsquo;Interactions&rsquo;:</em></p><p style="margin-left:5.0pt; margin-right:4.95pt">The patient should continue to take her tablets as usual and additional contraceptive precautions must be taken for the next 7 days.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:2.05pt">But - if these 7 days run beyond the end of the current pack, the next pack must be started as soon as the current one is finished, i.e. no gap should be left between packs. (This prevents an extended break in tablet taking which may increase the risk of the ovaries releasing an egg and thus reducing contraceptive protection). The patient will not have a period until the end of 2 packs but this is not harmful nor does it matter if she experiences some bleeding on tablet taking days.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><em>Advice in case of Vomiting or severe diarrhoea</em></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:5.9pt">In case of severe gastro-intestinal disturbance, absorption may not be complete and additional contraceptive measures should be taken. Unless diarrhoea is extremely severe, it does not affect steroidal absorption.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:24.8pt">If vomiting occurs within 3-4 hours after tablet taking, or in cases of severe or prolonged diarrhoea, the advice concerning missed tablets, as given in Section 4.2.3, is applicable. If the woman does not want to change her normal tablet-taking schedule, she has to take the extra tablet(s) needed from another pack.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>4.2.4&nbsp;&nbsp;&nbsp; Paediatric population</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:7.4pt">The safety and efficacy of desogestrel in adolescents below 18 years has not yet been established. No data are available.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4.3	Contraindications

Combined hormonal contraceptives (CHCs) should not be used in the presence of any of the conditions listed below. Should any of the conditions appear for the first time during CHC use, the product should be stopped immediately.
•	Presence or risk of venous thromboembolism (VTE)
o Venous thromboembolism – current VTE (on anticoagulants) or history of (e.g. deep venous thrombosis [DVT] or pulmonary embolism [PE]).
o Known hereditary or acquired predisposition for venous thromboembolism, such as APC-resistance, (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency.
o Major surgery with prolonged immobilisation (see section 4.4).
o A high risk of venous thromboembolism due to the presence of multiple risk factors
(see section 4.4).
•	Presence or risk of arterial thromboembolism (ATE)
o Arterial thromboembolism – current arterial thromboembolism, history of arterial thromboembolism (e.g. myocardial infarction) or prodromal condition (e.g. angina pectoris)

o Cerebrovascular disease – current stroke, history of stroke or prodromal condition (e.g. transient ischaemic attack, TIA).
o Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant).
o History of migraine with focal neurological symptoms.
o A high risk of arterial thromboembolism due to multiple risk factors (see section 4.4) or
to the presence of one serious risk factor such as:
•	diabetes mellitus with vascular symptoms
•	severe hypertension
•	severe dyslipoproteinaemia
•	Pancreatitis or a history thereof if associated with severe hypertriglyceridaemia.
•	Presence or history of severe hepatic disease as long as liver function values have not returned to normal.
•	Presence or history of liver tumours (benign or malignant).
•	Known or suspected estrogen-dependent tumours, (See 4.4 Special warnings and special precautions for use: The Pill and Cancer).
•	Endometrial hyperplasia.
•	Undiagnosed vaginal bleeding.
•	Known or suspected pregnancy.
•	Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
•Marvelon is contraindicated for concomitant use with medicinal products containing
ombitasvir/paritaprevir/ritonavir and dasabuvir (see sections 4.4 and 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and precautions for use</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>4.4.1&nbsp;&nbsp;&nbsp; Warnings</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:11.65pt">If any of the conditions or risk factors mentioned below is present, the suitability of Marvelon should be discussed with the woman.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:20.0pt">In the event of aggravation, or first appearance of any of these conditions or risk factors, the woman should be advised to contact her doctor to determine whether the use of Marvelon should be discontinued.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Circulatory Disorders</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:20.0pt"><strong><u>Risk of venous thromboembolism (VTE)</u></strong></p><p style="margin-left:5.0pt; margin-right:-1.0pt">&nbsp;</p><p style="margin-left:27.45pt; margin-right:11.75pt; text-indent:-.25in">&middot;&nbsp;&nbsp;&nbsp; The use of any combined hormonal contraceptive (CHC) increases the risk of venous thromboembolism (VTE) compared with no use. <strong>Products that contain levonorgestrel, norgestimate or norethisterone are associated with the lowest risk of VTE. Other products such as Marvelon may have up to twice this level of risk. The decision to</strong></p><p style="margin-left:27.45pt; margin-right:2.35pt"><strong>use any product other than one with the lowest VTE risk should be taken only after a discussion with the woman to ensure she understands the risk of VTE with</strong></p><p style="margin-left:27.45pt; margin-right:11.65pt"><strong>Marvelon, how her current risk factors influence this risk, and that her VTE risk is highest in the first ever year of use.&nbsp; There is also some evidence that the risk is</strong></p><p style="margin-left:27.45pt; margin-right:-1.0pt"><strong>increased when a CHC is re-started after a break in use of 4 weeks or more</strong>.</p><p>&nbsp;</p><p style="margin-left:27.45pt; margin-right:3.05pt; text-align:justify; text-indent:-.25in">&middot;&nbsp;&nbsp;&nbsp; In women who do not use a CHC and are not pregnant about 2 out of 10,000 will develop a VTE over the period of one year. However, in any individual woman the risk may be far higher, depending on her underlying risk factors (see below).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:27.45pt; margin-right:-1.0pt">It is estimated1 that out of 10,000 women who use a CHC containing desogestrel between</p><p style="margin-left:27.45pt; margin-right:11.95pt">9 and 12 women will develop a VTE in one year; this compares with about 62 in women who use a levonorgestrel-containing CHC.</p><p style="margin-left:27.45pt; margin-right:24.7pt">In both cases, the number of VTEs per year is fewer than the number expected during pregnancy or in the postpartum period.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:9.55pt; margin-right:-1.0pt">&middot;&nbsp;&nbsp;&nbsp; VTE may be fatal in 1-2% of cases.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p style="margin-left:98.5pt; margin-right:-1.0pt"><strong>Number of VTE events per 10,000 women in one year</strong></p><p style="margin-left:98.5pt; margin-right:-1.0pt"><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_137" o:spid="_x0000_s1115" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:73.6pt;
 margin-top:166.85pt;width:313.65pt;height:248.55pt;z-index:251661312;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:margin;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page'>
 <v:imagedata src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
 <o:lock v:ext="edit" aspectratio="f"/>
 <w:wrap type="square" anchorx="margin" anchory="margin"/>
</v:shape><![endif]--><!--[if !vml]--><img width="418" height="331" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.0pt; margin-right:10.2pt">Extremely rarely, thrombosis has been reported to occur in CHC users in other blood vessels, e.g. hepatic, mesenteric, renal or retinal veins and arteries.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:10.2pt"><strong><u>Risk factors for VTE</u></strong></p><p style="margin-left:5.0pt; margin-right:-1.0pt"><strong><u>&nbsp;</u></strong></p><p style="margin-left:5.0pt; margin-right:2.3pt">The risk for venous thromboembolic complications in CHC users may increase substantially in a woman with additional risk factors, particularly if there are multiple risk factors (see table).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:11.0pt; margin-right:20.4pt">Marvelon is contraindicated if a woman has multiple risk factors that put her at high risk of venous thrombosis (see section 4.3). If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors &ndash; in this case her total risk of VTE should be considered. If the balance of benefits and risks is considered to be negative a CHC should not be prescribed (see section 4.3).</p><p style="margin-left:5.0pt; margin-right:17.25pt">&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.0pt; margin-right:20.1pt"><!--[if gte vml 1]><v:group id="Group_x0020_89"
 o:spid="_x0000_s1113" style='position:absolute;left:0;text-align:left;
 margin-left:84pt;margin-top:-2.1pt;width:2in;height:.1pt;z-index:-251659264;
 mso-position-horizontal-relative:page' coordorigin="1680,-42" coordsize="2880,2"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEA4EH4O30DAACLCAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWysVttu4zYQfS/QfyD42MLRJYojG6ss
tr4EC2y3wdr7AbREW0IpUiXpS1r03zszkmI5qbtAWz/YQ83o8MzhDMfv3p9qxQ7SusrojEc3IWdS
56ao9C7jX9fLUcqZ80IXQhktM/4sHX//8P1378R0Z0VTVjkDBO2mIuOl9800CFxeylq4G9NIDb6t
sbXwsLS7oLDiCMi1CuIwHAe1qDR/OEPNhRdsb6t/AaVM/qssZkIfhANIlU+HTzqOKv/vyGKqD4+2
WTVPFpnnnw9PllVFxkE5LWqQiAedowuDZfDqrd0Z4LS1Ncab7Zad4ATC8TgNAesZ7PvbOE7DFk+e
PMsxII1TCsgxIr7v3Hn5yzcA8nLxTxBAsaUCxoAemcjvStYp1Eeb9qM1+4alk9fp48uE8gmOyLVi
gGqPvQRXtGGb48+mADnF3hsqkv9dKRCadB4lcUf6RSLUmDOUmFxXxHFNq8zbYgAZOlmWVkpsATbp
T+rzoY93zaUm7XMS5BwC5fVNKd5k0lfLtTygcPfOP0pDtScOn5ynqt0VYNGJFR3/NeiwrRW0948j
FrIItqKvVrHdS1jUh/0QsHXIjoy27kB7rLgPIqzkbvz3WLd9GGLFAyyszZ6hKHvS+Ul3rMFiAm+u
kCqmMQ57ag3c4CRJf0CAIMzwSizs/Tq2fafbwsrcM0Xt7unbZtxytsn4ppWkER6Z4RZosiPUEFYT
PqjNQa4NuTwya+uvJ3b2Kj2Mag9xwKp1Ay3cgG6Xl02R6+BktVlWStEpKI1UojCJEuLijKoK9CId
Z3ebmbLsIDA1+mA2gHYRBi2uC0IrpSgWne1FpVob4hWJC/XXaYCVSFf6H5NwskgXaQLtNl6MknA+
H31YzpLReBnd381v57PZPPoTqUXJtKyKQmpk14+XKHlzd9dVbo0zW3+TmzqAC7TKZT9iYMBE4XnA
XGRxkeySPm+TDS5pkBaQS/9L2aE83RzwpxVdBv70kymeUdIN/ELvWtOWCcxYMEpjf+fsCJMz4+63
vbCSM/VRu4xPoiSBcvC0SO7uY1jYoWcz9AidA1TGPYd6R3PmYQWv7Btb7UrYKaJD1uYDXJ/bCrsb
2LackJ1yfuWflaTDJOZSF0/Cii/AWVEPST36uuqEgQh4/Zzc3slV8wVaocVtsyc5KLCbGsGrMdz5
6G8Dzvrh+uEvAAAA//8DAFBLAwQUAAYACAAAACEAnE5eIeIGAAA6HAAAGgAAAGNsaXBib2FyZC90
aGVtZS90aGVtZTEueG1s7FlPbxtFFL8j8R1Ge2/j/42jOlXs2A20aaPYLepxvB7vTjO7s5oZJ/UN
tUckJERBHKjEjQMCKrUSl/JpAkVQpH4F3szsrnfiNUnbCCpoDvHu29+8/+/Nm93LV+5FDB0SISmP
O171YsVDJPb5hMZBx7s1GlxY95BUOJ5gxmPS8eZEelc233/vMt7wGU3GHIvJKCQRQcAolhu444VK
JRtra9IHMpYXeUJieDblIsIKbkWwNhH4CAREbK1WqbTWIkxjbxM4Ks2oz+BfrKQm+EwMNRuCYhyB
9JvTKfWJwU4Oqhoh57LHBDrErOMBzwk/GpF7ykMMSwUPOl7F/Hlrm5fX8Ea6iKkVawvrBuYvXZcu
mBzUjEwRjHOh1UGjfWk7528ATC3j+v1+r1/N+RkA9n2w1OpS5NkYrFe7Gc8CyF4u8+5VmpWGiy/w
ry/p3O52u812qotlakD2srGEX6+0Gls1B29AFt9cwje6W71ey8EbkMW3lvCDS+1Ww8UbUMhofLCE
1gEdDFLuOWTK2U4pfB3g65UUvkBBNuTZpUVMeaxW5VqE73IxAIAGMqxojNQ8IVPsQ072cDQWFGsB
eIPgwhNL8uUSSctC0hc0UR3vwwTHXgHy8tn3L589Qcf3nx7f/+n4wYPj+z9aRs6qHRwHxVUvvv3s
z0cfoz+efPPi4RfleFnE//rDJ7/8/Hk5EMpnYd7zLx//9vTx868+/f27hyXwLYHHRfiIRkSiG+QI
7fMIDDNecTUnY/FqK0YhpsUVW3EgcYy1lBL+fRU66BtzzNLoOHp0ievB2wLaRxnw6uyuo/AwFDNF
SyRfCyMHuMs563JR6oVrWlbBzaNZHJQLF7Mibh/jwzLZPRw78e3PEuibWVo6hvdC4qi5x3CscEBi
opB+xg8IKbHuDqWOX3epL7jkU4XuUNTFtNQlIzp2smmxaIdGEJd5mc0Qb8c3u7dRl7Myq7fJoYuE
qsCsRPkRYY4br+KZwlEZyxGOWNHh17EKy5QczoVfxPWlgkgHhHHUnxApy9bcFGBvIejXMHSs0rDv
snnkIoWiB2U8r2POi8htftALcZSUYYc0DovYD+QBpChGe1yVwXe5WyH6HuKA45Xhvk2JE+7Tu8Et
GjgqLRJEP5mJklheJdzJ3+GcTTExrQaautOrIxr/XeNmFDq3lXB+jRta5fOvH5Xo/ba27C3Yvcpq
ZudEo16FO9mee1xM6NvfnbfxLN4jUBDLW9S75vyuOXv/+ea8qp7PvyUvujA0aD2L2EHbjN3Ryql7
Shkbqjkj16UZvCXsPZMBEPU6c7ok+SksCeFSVzIIcHCBwGYNElx9RFU4DHECQ3vV00wCmbIOJEq4
hMOiIZfy1ngY/JU9ajb1IcR2DonVLp9Ycl2Ts7NGzsZoFZgDbSaorhmcVVj9UsoUbHsdYVWt1Jml
VY1qpik60nKTtYvNoRxcnpsGxNybMNQgGIXAyy0432vRcNjBjEy0322MsrCYKJxniGSIJySNkbZ7
OUZVE6QsV5YM0XbYZNAHx1O8VpDW1mzfQNpZglQU11ghLovem0Qpy+BFlIDbyXJkcbE4WYyOOl67
WWt6yMdJx5vCORkuowSiLvUciVkAb5h8JWzan1rMpsoX0WxnhrlFUIVXH9bvSwY7fSARUm1jGdrU
MI/SFGCxlmT1rzXBredlQEk3OpsW9XVIhn9NC/CjG1oynRJfFYNdoGjf2du0lfKZImIYTo7QmM3E
Pobw61QFeyZUwusO0xH0Dbyb0942j9zmnBZd8Y2YwVk6ZkmI03arSzSrZAs3DSnXwdwV1APbSnU3
xr26Kabkz8mUYhr/z0zR+wm8fahPdAR8eNErMNKV0vG4UCGHLpSE1B8IGBxM74Bsgfe78BiSCt5K
m19BDvWvrTnLw5Q1HCLVPg2QoLAfqVAQsgdtyWTfKcyq6d5lWbKUkcmogroysWqPySFhI90DW3pv
91AIqW66SdoGDO5k/rn3aQWNAz3kFOvN6WT53mtr4J+efGwxg1FuHzYDTeb/XMV8PFjsqna9WZ7t
vUVD9IPFmNXIqgKEFbaCdlr2r6nCK261tmMtWVxrZspBFJctBmI+ECXwDgnpf7D/UeEz+wVDb6gj
vg+9FcHHC80M0gay+oIdPJBukJY4hsHJEm0yaVbWtenopL2WbdbnPOnmck84W2t2lni/orPz4cwV
59TieTo79bDja0tb6WqI7MkSBdI0O8iYwJR9ydrFCRoH1Y4HX5Mg0PfgCr5HeUCraVpN0+AKPjLB
sGS/DHW89CKjwHNLyTH1jFLPMI2M0sgozYwCw1n6DSajtKBT6c8m8NlO/3go+0ICE1z6RSVrqs7n
vs2/AAAA//8DAFBLAwQUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5n
cy9fcmVscy9kcmF3aW5nMS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8k
UezbG+hFQfCyMLPsN7NN+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZy
lMYpJFIoLnEYcw4nxpIa0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7
YZgUnr16WHT5RwTLpRcWoIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEA
u+VIlAUBAAAeAgAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQA
BgAIAAAAIQCtMD/xwQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQA
BgAIAAAAIQDgQfg7fQMAAIsIAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3Mv
ZHJhd2luZzEueG1sUEsBAi0AFAAGAAgAAAAhAJxOXiHiBgAAOhwAABoAAAAAAAAAAAAAAAAA2gUA
AGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoA
AAAAAAAAAAAAAAAA9AwAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVs
c1BLBQYAAAAABQAFAGcBAAD3DQAAAAA=
">
 <v:shape id="Freeform_x0020_90" o:spid="_x0000_s1114" style='position:absolute;
  left:1680;top:-42;width:2880;height:2;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="2880,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l2880,e" filled="f" strokeweight=".82pt">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;2880,0"
   o:connectangles="0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="193" height="1" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[endif]-->1 These incidences were estimated from the totality of the epidemiological study data, using relative risks for the different products compared with levonorgestrel-containing CHCs.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:18.35pt">2 Mid-point of range of 5-7 per 10,000 WY, based on a relative risk for CHCs containing levonorgestrel versus non-use of approximately 2.3 to 3.6</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:-1.0pt"><strong>Table: Risk factors for VTE</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:30.5pt; vertical-align:top; width:196.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt"><strong>Risk factor</strong></p></td><td style="border-color:black; height:30.5pt; vertical-align:top; width:274.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt"><strong>Comment</strong></p></td></tr><tr><td style="border-color:black; height:68.5pt; vertical-align:top; width:196.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:23.75pt">Obesity (body mass index over 30 kg/m&sup2;)</p></td><td style="height:68.5pt; vertical-align:top; width:274.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Risk increases substantially as BMI rises.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:9.95pt">Particularly important to consider if other risk factors also present.</p></td></tr><tr><td style="border-color:black; height:244.45pt; vertical-align:top; width:196.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:6.9pt">Prolonged immobilisation, major surgery, any surgery to the legs or pelvis, neurosurgery, or major trauma</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.1pt; margin-right:9.55pt">Note:&nbsp; Temporary immobilisation including air travel &gt;4 hours can also be a risk factor for VTE, particularly in women with other risk factors.</p></td><td style="height:244.45pt; vertical-align:top; width:274.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:5.25pt">In these situations it is advisable to discontinue use of the patch/pill/ring (in the case of elective surgery at least four weeks in advance) and not resume until two weeks after complete remobilisation. Another method of contraception should be used to avoid unintentional pregnancy.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Antithrombotic treatment should be considered if</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Marvelon has not been discontinued in advance.</p></td></tr><tr><td style="border-color:black; height:72.5pt; vertical-align:top; width:196.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:7.25pt">Positive family history (venous thromboembolism ever in a sibling or parent especially at a relatively early age e.g. before 50).</p></td><td style="height:72.5pt; vertical-align:top; width:274.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:7.7pt">If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any CHC use.</p></td></tr><tr><td style="border-color:black; height:72.5pt; vertical-align:top; width:196.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:14.6pt">Other medical conditions associated with VTE</p></td><td style="height:72.5pt; vertical-align:top; width:274.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:23.65pt">Cancer, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease (Crohn&rsquo;s disease or ulcerative colitis) and sickle cell disease</p></td></tr><tr><td style="border-color:black; height:30.6pt; vertical-align:top; width:196.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Increasing age</p></td><td style="height:30.6pt; vertical-align:top; width:274.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Particularly above 35 years</p></td></tr></tbody></table><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:11.0pt; margin-right:8.9pt">There is no consensus about the possible role of varicose veins and superficial thrombophlebitis in the onset or progression of venous thrombosis.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:11.0pt; margin-right:10.2pt">The increased risk of thromboembolism in pregnancy, and particularly the 6-week period of the puerperium, must be considered (for information on &ldquo;Pregnancy and lactation&rdquo; see section 4.6).</p><p>&nbsp;</p><p><strong><u>Symptoms of VTE (deep vein thrombosis and pulmonary embolism)</u></strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:23.85pt">In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt">Symptoms of deep vein thrombosis (DVT) can include:</p><p style="margin-left:29.0pt; margin-right:-1.0pt">&ndash; unilateral swelling of the leg and/or foot or along a vein in the leg;</p><p style="margin-left:29.0pt; margin-right:-1.0pt">&ndash; pain or tenderness in the leg which may be felt only when standing or walking;</p><p style="margin-left:5.0pt; margin-right:82.05pt; text-indent:24.0pt">&ndash; increased warmth in the affected leg; red or discoloured skin on the leg. Symptoms of pulmonary embolism (PE) can include:</p><p style="margin-left:29.0pt; margin-right:-1.0pt">&ndash; sudden onset of unexplained shortness of breath or rapid breathing;</p><p style="margin-left:29.0pt; margin-right:-1.0pt">&ndash; sudden coughing which may be associated with haemoptysis;</p><p style="margin-left:29.0pt; margin-right:-1.0pt">&ndash; sharp chest pain;</p><p style="margin-left:29.0pt; margin-right:-1.0pt">&ndash; severe light headedness or dizziness;</p><p style="margin-left:29.0pt; margin-right:-1.0pt">&ndash; rapid or irregular heartbeat.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:2.35pt">Some of these symptoms (e.g. &ldquo;shortness of breath&rdquo;, &ldquo;coughing&rdquo;) are non-specific and might be misinterpreted as more common or less severe events (e.g. respiratory tract infections).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:60.05pt">Other signs of vascular occlusion can include: sudden pain, swelling and slight blue discoloration of an extremity.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:14.7pt">If the occlusion occurs in the eye symptoms can range from painless blurring of vision which can progress to loss of vision. Sometimes loss of vision can occur almost immediately.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:14.7pt"><strong><u>Risk of arterial thromboembolism (ATE)</u></strong></p><p style="margin-left:5.0pt; margin-right:-1.0pt">&nbsp;</p><p style="margin-left:5.0pt; margin-right:24.6pt">Epidemiological studies have associated the use of CHCs with an increased risk for arterial thromboembolism (myocardial infarction) or for cerebrovascular accident (e.g. transient ischaemic attack, stroke). Arterial thromboembolic events may be fatal.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:14.7pt"><strong><u>Risk factors for ATE</u></strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:7.35pt">The risk of arterial thromboembolic complications or of a cerebrovascular accident in CHC users increases in women with risk factors (see table). Marvelon is contraindicated if a woman has one serious or multiple risk factors for ATE that puts her at high risk of arterial thrombosis (see section 4.3). If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors - in this case her total risk should be considered.&nbsp; If the balance of benefits and risks is considered to be negative a CHC should not be prescribed (see section 4.3).</p><p>&nbsp;</p><p style="margin-left:11.0pt; margin-right:-1.0pt"><strong>Table: Risk factors for ATE</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:20.4pt; vertical-align:top; width:196.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt"><strong>Risk factor</strong></p></td><td style="border-color:black; height:20.4pt; vertical-align:top; width:274.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt"><strong>Comment</strong></p></td></tr><tr><td style="border-color:black; height:20.5pt; vertical-align:top; width:196.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Increasing age</p></td><td style="height:20.5pt; vertical-align:top; width:274.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Particularly above 35 years</p></td></tr><tr><td style="border-color:black; height:82.55pt; vertical-align:top; width:196.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Smoking</p></td><td style="height:82.55pt; vertical-align:top; width:274.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:2.15pt">Women should be advised not to smoke if they wish to use a CHC.&nbsp; Women over 35 who continue to smoke should be strongly advised to use a different method</p><p style="margin-left:5.1pt; margin-right:-1.0pt">of contraception.</p></td></tr><tr><td style="border-color:black; height:20.5pt; vertical-align:top; width:196.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Hypertension</p></td><td style="height:20.5pt; vertical-align:top; width:274.9pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:74.4pt; vertical-align:top; width:196.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:23.5pt">Obesity (body mass index over 30 kg/m2)</p></td><td style="height:74.4pt; vertical-align:top; width:274.9pt"><p style="margin-left:5.1pt; margin-right:13.55pt">Risk increases substantially as BMI increases. Particularly important in women with additional risk</p><p style="margin-left:5.1pt; margin-right:-1.0pt">factors</p></td></tr><tr><td style="border-color:black; height:62.5pt; vertical-align:top; width:196.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:7.25pt">Positive family history (arterial thromboembolism ever in a sibling or parent especially at relatively early age e.g. below 50).</p></td><td style="height:62.5pt; vertical-align:top; width:274.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:7.7pt">If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any CHC use.</p></td></tr><tr><td style="border-color:black; height:82.55pt; vertical-align:top; width:196.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:-1.0pt">Migraine</p></td><td style="height:82.55pt; vertical-align:top; width:274.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:5.85pt">An increase in frequency or severity of migraine during CHC use (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation.</p></td></tr><tr><td style="border-color:black; height:82.45pt; vertical-align:top; width:196.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:14.6pt">Other medical conditions associated with adverse vascular events</p></td><td style="height:82.45pt; vertical-align:top; width:274.9pt"><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.1pt; margin-right:13.9pt">Diabetes mellitus, hyperhomocysteinaemia, valvular heart disease and atrial fibrillation, dyslipoproteinaemia and systemic lupus erythematosus.</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:11.0pt; margin-right:30.85pt"><strong><u>Symptoms of ATE</u></strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:11.0pt; margin-right:30.85pt">In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.</p><p style="margin-left:11.0pt; margin-right:-1.0pt">Symptoms of a cerebrovascular accident can include:</p><p style="margin-left:35.0pt; margin-right:-1.0pt">- sudden numbness or weakness of the face, arm or leg, especially on one side of the body;</p><p style="margin-left:35.0pt; margin-right:-1.0pt">- sudden trouble walking, dizziness, loss of balance or coordination;</p><p style="margin-left:35.0pt; margin-right:-1.0pt">- sudden confusion, trouble speaking or understanding;</p><p style="margin-left:35.0pt; margin-right:-1.0pt">- sudden trouble seeing in one or both eyes;</p><p style="margin-left:35.0pt; margin-right:-1.0pt">- sudden, severe or prolonged headache with no known cause;</p><p style="margin-left:35.1pt; margin-right:-1.0pt">- loss of consciousness or fainting with or without seizure.</p><p>&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt">Temporary symptoms suggest the event is a transient ischaemic attack (TIA).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt">Symptoms of myocardial infarction (MI) can include:</p><p style="margin-left:40.4pt; margin-right:22.85pt; text-indent:-11.4pt">- &nbsp;pain, discomfort, pressure, heaviness, sensation of squeezing or fullness in the chest, arm, or below the breastbone;</p><p style="margin-left:29.0pt; margin-right:-1.0pt">- &nbsp;discomfort radiating to the back, jaw, throat, arm, stomach;</p><p style="margin-left:29.0pt; margin-right:-1.0pt">- &nbsp;feeling of being full, having indigestion or choking;</p><p style="margin-left:29.0pt; margin-right:-1.0pt">- &nbsp;sweating, nausea, vomiting or dizziness;</p><p style="margin-left:29.0pt; margin-right:-1.0pt">- &nbsp;extreme weakness, anxiety, or shortness of breath;</p><p style="margin-left:29.0pt; margin-right:-1.0pt">- &nbsp;rapid or irregular heartbeats.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tumours</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:75.9pt; margin-right:30.05pt; text-indent:-35.5pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increased risk of cervical cancer in long term users of combined oral contraceptives has been reported in some studies, but there continues to be controversy about the extent to which this is attributable to the confounding effects of sexual behaviour and other factors such as human papilloma virus (HPV).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:75.9pt; margin-right:8.55pt; text-indent:-35.5pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A meta-analysis from 54 epidemiological studies reported that there is a slightly increased relative risk (RR = 1.24) of having breast cancer diagnosed in women who are currently using combined oral contraceptives (COCs). The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in COC users, the biological effects of COCs or a combination of both. The additional breast cancers diagnosed in current users of COCs or in women who have used COCs in the last ten years are more likely to be localised to the breast than those in women who never used COCs.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:75.9pt; margin-right:2.45pt; text-indent:-35.5pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast cancer is rare among women under 40 years of age whether or not they take COCs. Whilst this background risk increases with age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer (see bar chart).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:75.9pt; margin-right:6.5pt; text-indent:-35.5pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The most important risk factor for breast cancer in COC users is the age women discontinue the COC; the older the age at stopping, the more breast cancers are diagnosed. Duration of use is less important and the excess risk gradually disappears during the course of the 10 years after stopping COC use such that by</p><p style="margin-left:75.9pt; margin-right:-1.0pt">10 years there appears to be no excess.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:75.9pt; margin-right:13.5pt; text-indent:-35.5pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The possible increase in risk of breast cancer should be discussed with the user and weighed against the benefits of COCs taking into account the evidence that they offer substantial protection against the risk of developing certain other cancers (e.g. ovarian and endometrial cancer).</p><p>&nbsp;</p><p style="margin-left:197.0pt; margin-right:7.7pt">Estimated cumulative numbers of breast cancers per 10,000 women diagnosed in 5 years of use and up to 10 years after stopping COCs, compared with numbers of breast cancers diagnosed in 10,000 women who had never used COCs</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:148.15pt; margin-right:-1.0pt"><!--[if gte vml 1]><v:group id="Group_x0020_12" o:spid="_x0000_s1036"
 style='position:absolute;left:0;text-align:left;margin-left:243.8pt;
 margin-top:5.15pt;width:307.1pt;height:179.65pt;z-index:-251658240;
 mso-position-horizontal-relative:page' coordorigin="4876,103" coordsize="6142,3593"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:group id="Group_x0020_87" o:spid="_x0000_s1037" style='position:absolute;
  left:5146;top:3618;width:290;height:2' coordorigin="5146,3618" coordsize="290,2"
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_88" o:spid="_x0000_s1038" style='position:absolute;
   left:5146;top:3618;width:290;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="290,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l290,e" filled="f" strokecolor="#7e0000" strokeweight="2.5pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;290,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_85" o:spid="_x0000_s1039"
  style='position:absolute;left:5146;top:3594;width:290;height:48'
  coordorigin="5146,3594" coordsize="290,48" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_86" o:spid="_x0000_s1040" style='position:absolute;
   left:5146;top:3594;width:290;height:48;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="290,48" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l290,r,48l,48,,xe" filled="f" strokeweight=".2875mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3594;290,3594;290,3642;0,3642;0,3594"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_83" o:spid="_x0000_s1041"
  style='position:absolute;left:5436;top:3615;width:290;height:2'
  coordorigin="5436,3615" coordsize="290,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:shape id="Freeform_x0020_84" o:spid="_x0000_s1042" style='position:absolute;
   left:5436;top:3615;width:290;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="290,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l290,e" filled="f" strokecolor="#dc9bb2" strokeweight="2.86pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;290,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_81" o:spid="_x0000_s1043"
  style='position:absolute;left:5436;top:3587;width:290;height:55'
  coordorigin="5436,3587" coordsize="290,55" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQATS84cxQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pa8JA
EMXvQr/DMoXedBNLS0ndiEiVHqRQLYi3ITv5g9nZkF2T+O07h0JvM7w37/1mtZ5cqwbqQ+PZQLpI
QBEX3jZcGfg57eZvoEJEtth6JgN3CrDOH2YrzKwf+ZuGY6yUhHDI0EAdY5dpHYqaHIaF74hFK33v
MMraV9r2OEq4a/UySV61w4alocaOtjUV1+PNGdiPOG6e04/hcC2398vp5et8SMmYp8dp8w4q0hT/
zX/Xn1bwBVZ+kQF0/gsAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQATS84cxQAAANsAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
">
  <v:shape id="Freeform_x0020_82" o:spid="_x0000_s1044" style='position:absolute;
   left:5436;top:3587;width:290;height:55;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="290,55" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l290,r,55l,55,,xe" filled="f" strokeweight=".28786mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3587;290,3587;290,3642;0,3642;0,3587"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_79" o:spid="_x0000_s1045"
  style='position:absolute;left:6158;top:3455;width:293;height:187'
  coordorigin="6158,3455" coordsize="293,187" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_80" o:spid="_x0000_s1046" style='position:absolute;
   left:6158;top:3455;width:293;height:187;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="293,187" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l293,r,187l,187,,e" fillcolor="#7e0000" stroked="f">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3455;293,3455;293,3642;0,3642;0,3455"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_77" o:spid="_x0000_s1047"
  style='position:absolute;left:6158;top:3455;width:293;height:187'
  coordorigin="6158,3455" coordsize="293,187" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:shape id="Freeform_x0020_78" o:spid="_x0000_s1048" style='position:absolute;
   left:6158;top:3455;width:293;height:187;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="293,187" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l293,r,187l,187,,xe" filled="f" strokeweight=".29317mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3455;293,3455;293,3642;0,3642;0,3455"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_75" o:spid="_x0000_s1049"
  style='position:absolute;left:6451;top:3435;width:288;height:206'
  coordorigin="6451,3435" coordsize="288,206" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_76" o:spid="_x0000_s1050" style='position:absolute;
   left:6451;top:3435;width:288;height:206;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="288,206" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l288,r,207l,207,,e" fillcolor="#dc9bb2" stroked="f">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3435;288,3435;288,3642;0,3642;0,3435"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_73" o:spid="_x0000_s1051"
  style='position:absolute;left:6451;top:3435;width:288;height:206'
  coordorigin="6451,3435" coordsize="288,206" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_74" o:spid="_x0000_s1052" style='position:absolute;
   left:6451;top:3435;width:288;height:206;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="288,206" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l288,r,207l,207,,xe" filled="f" strokeweight=".29422mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3435;288,3435;288,3642;0,3642;0,3435"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_71" o:spid="_x0000_s1053"
  style='position:absolute;left:7174;top:3121;width:290;height:521'
  coordorigin="7174,3121" coordsize="290,521" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_72" o:spid="_x0000_s1054" style='position:absolute;
   left:7174;top:3121;width:290;height:521;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="290,521" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l290,r,521l,521,,e" fillcolor="#7e0000" stroked="f">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3121;290,3121;290,3642;0,3642;0,3121"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_69" o:spid="_x0000_s1055"
  style='position:absolute;left:7174;top:3121;width:290;height:521'
  coordorigin="7174,3121" coordsize="290,521" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_70" o:spid="_x0000_s1056" style='position:absolute;
   left:7174;top:3121;width:290;height:521;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="290,521" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l290,r,521l,521,,xe" filled="f" strokeweight=".30269mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3121;290,3121;290,3642;0,3642;0,3121"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_67" o:spid="_x0000_s1057"
  style='position:absolute;left:7464;top:3068;width:288;height:574'
  coordorigin="7464,3068" coordsize="288,574" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_68" o:spid="_x0000_s1058" style='position:absolute;
   left:7464;top:3068;width:288;height:574;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="288,574" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l288,r,574l,574,,e" fillcolor="#dc9bb2" stroked="f">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3068;288,3068;288,3642;0,3642;0,3068"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_65" o:spid="_x0000_s1059"
  style='position:absolute;left:7464;top:3068;width:288;height:574'
  coordorigin="7464,3068" coordsize="288,574" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_66" o:spid="_x0000_s1060" style='position:absolute;
   left:7464;top:3068;width:288;height:574;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="288,574" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l288,r,574l,574,,xe" filled="f" strokeweight=".30375mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3068;288,3068;288,3642;0,3642;0,3068"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_63" o:spid="_x0000_s1061"
  style='position:absolute;left:8186;top:2463;width:290;height:1178'
  coordorigin="8186,2463" coordsize="290,1178" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_64" o:spid="_x0000_s1062" style='position:absolute;
   left:8186;top:2463;width:290;height:1178;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="290,1178" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l291,r,1179l,1179,,e" fillcolor="#7e0000" stroked="f">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,2463;291,2463;291,3642;0,3642;0,2463"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_61" o:spid="_x0000_s1063"
  style='position:absolute;left:8186;top:2463;width:290;height:1178'
  coordorigin="8186,2463" coordsize="290,1178" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_62" o:spid="_x0000_s1064" style='position:absolute;
   left:8186;top:2463;width:290;height:1178;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="290,1178" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l291,r,1179l,1179,,xe" filled="f" strokeweight=".30656mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,2463;291,2463;291,3642;0,3642;0,2463"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_59" o:spid="_x0000_s1065"
  style='position:absolute;left:8477;top:2334;width:288;height:1308'
  coordorigin="8477,2334" coordsize="288,1308" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:shape id="Freeform_x0020_60" o:spid="_x0000_s1066" style='position:absolute;
   left:8477;top:2334;width:288;height:1308;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="288,1308" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l288,r,1308l,1308,,e" fillcolor="#dc9bb2" stroked="f">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,2334;288,2334;288,3642;0,3642;0,2334"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_57" o:spid="_x0000_s1067"
  style='position:absolute;left:8477;top:2334;width:288;height:1308'
  coordorigin="8477,2334" coordsize="288,1308" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_58" o:spid="_x0000_s1068" style='position:absolute;
   left:8477;top:2334;width:288;height:1308;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="288,1308" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l288,r,1308l,1308,,xe" filled="f" strokeweight=".87pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,2334;288,2334;288,3642;0,3642;0,2334"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_55" o:spid="_x0000_s1069"
  style='position:absolute;left:9199;top:1758;width:290;height:1884'
  coordorigin="9199,1758" coordsize="290,1884" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_56" o:spid="_x0000_s1070" style='position:absolute;
   left:9199;top:1758;width:290;height:1884;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="290,1884" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l291,r,1884l,1884,,e" fillcolor="#7e0000" stroked="f">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,1758;291,1758;291,3642;0,3642;0,1758"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_53" o:spid="_x0000_s1071"
  style='position:absolute;left:9199;top:1758;width:290;height:1884'
  coordorigin="9199,1758" coordsize="290,1884" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_54" o:spid="_x0000_s1072" style='position:absolute;
   left:9199;top:1758;width:290;height:1884;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="290,1884" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l291,r,1884l,1884,,xe" filled="f" strokeweight=".30728mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,1758;291,1758;291,3642;0,3642;0,1758"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_51" o:spid="_x0000_s1073"
  style='position:absolute;left:9490;top:1513;width:290;height:2129'
  coordorigin="9490,1513" coordsize="290,2129" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:shape id="Freeform_x0020_52" o:spid="_x0000_s1074" style='position:absolute;
   left:9490;top:1513;width:290;height:2129;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="290,2129" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l290,r,2129l,2129,,e" fillcolor="#dc9bb2" stroked="f">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,1513;290,1513;290,3642;0,3642;0,1513"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_49" o:spid="_x0000_s1075"
  style='position:absolute;left:9490;top:1513;width:290;height:2129'
  coordorigin="9490,1513" coordsize="290,2129" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_50" o:spid="_x0000_s1076" style='position:absolute;
   left:9490;top:1513;width:290;height:2129;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="290,2129" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l290,r,2129l,2129,,xe" filled="f" strokeweight=".30728mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,1513;290,1513;290,3642;0,3642;0,1513"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_47" o:spid="_x0000_s1077"
  style='position:absolute;left:10212;top:937;width:293;height:2705'
  coordorigin="10212,937" coordsize="293,2705" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDkyUA2xQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pa8JA
FMTvhX6H5RV6azaxWCR1FRGVHoJQI0hvj+wzCWbfhuyaP9++KxR6HGbmN8xyPZpG9NS52rKCJIpB
EBdW11wqOOf7twUI55E1NpZJwUQO1qvnpyWm2g78Tf3JlyJA2KWooPK+TaV0RUUGXWRb4uBdbWfQ
B9mVUnc4BLhp5CyOP6TBmsNChS1tKypup7tRcBhw2Lwnuz67XbfTTz4/XrKElHp9GTefIDyN/j/8
1/7SCuYzeHwJP0CufgEAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQDkyUA2xQAAANsAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
">
  <v:shape id="Freeform_x0020_48" o:spid="_x0000_s1078" style='position:absolute;
   left:10212;top:937;width:293;height:2705;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="293,2705" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l293,r,2705l,2705,,e" fillcolor="#7e0000" stroked="f">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,937;293,937;293,3642;0,3642;0,937"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_45" o:spid="_x0000_s1079"
  style='position:absolute;left:10212;top:937;width:293;height:2705'
  coordorigin="10212,937" coordsize="293,2705" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_46" o:spid="_x0000_s1080" style='position:absolute;
   left:10212;top:937;width:293;height:2705;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="293,2705" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l293,r,2705l,2705,,xe" filled="f" strokeweight=".30761mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,937;293,937;293,3642;0,3642;0,937"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_43" o:spid="_x0000_s1081"
  style='position:absolute;left:10505;top:558;width:288;height:3084'
  coordorigin="10505,558" coordsize="288,3084" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_44" o:spid="_x0000_s1082" style='position:absolute;
   left:10505;top:558;width:288;height:3084;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="288,3084" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l288,r,3084l,3084,,e" fillcolor="#dc9bb2" stroked="f">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,558;288,558;288,3642;0,3642;0,558"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_41" o:spid="_x0000_s1083"
  style='position:absolute;left:10505;top:558;width:288;height:3084'
  coordorigin="10505,558" coordsize="288,3084" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_42" o:spid="_x0000_s1084" style='position:absolute;
   left:10505;top:558;width:288;height:3084;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="288,3084" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l288,r,3084l,3084,,xe" filled="f" strokeweight=".30761mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,558;288,558;288,3642;0,3642;0,558"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_39" o:spid="_x0000_s1085"
  style='position:absolute;left:4930;top:111;width:2;height:3576'
  coordorigin="4930,111" coordsize="2,3576" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_40" o:spid="_x0000_s1086" style='position:absolute;
   left:4930;top:111;width:2;height:3576;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="2,3576" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,3576l,e" filled="f" strokeweight=".30761mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3687;0,111"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_37" o:spid="_x0000_s1087"
  style='position:absolute;left:4884;top:3642;width:6125;height:2'
  coordorigin="4884,3642" coordsize="6125,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_38" o:spid="_x0000_s1088" style='position:absolute;
   left:4884;top:3642;width:6125;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="6125,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l6125,e" filled="f" strokeweight=".28717mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;6125,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_35" o:spid="_x0000_s1089"
  style='position:absolute;left:4884;top:3054;width:46;height:2' coordorigin="4884,3054"
  coordsize="46,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_36" o:spid="_x0000_s1090" style='position:absolute;
   left:4884;top:3054;width:46;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="46,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l46,e" filled="f" strokeweight=".28717mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;46,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_33" o:spid="_x0000_s1091"
  style='position:absolute;left:4884;top:2463;width:46;height:2' coordorigin="4884,2463"
  coordsize="46,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_34" o:spid="_x0000_s1092" style='position:absolute;
   left:4884;top:2463;width:46;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="46,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l46,e" filled="f" strokeweight=".28717mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;46,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_31" o:spid="_x0000_s1093"
  style='position:absolute;left:4884;top:1875;width:46;height:2' coordorigin="4884,1875"
  coordsize="46,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_32" o:spid="_x0000_s1094" style='position:absolute;
   left:4884;top:1875;width:46;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="46,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l46,e" filled="f" strokeweight=".28717mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;46,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_29" o:spid="_x0000_s1095"
  style='position:absolute;left:4884;top:1290;width:46;height:2' coordorigin="4884,1290"
  coordsize="46,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:shape id="Freeform_x0020_30" o:spid="_x0000_s1096" style='position:absolute;
   left:4884;top:1290;width:46;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="46,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l46,e" filled="f" strokeweight=".28717mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;46,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_27" o:spid="_x0000_s1097"
  style='position:absolute;left:4884;top:699;width:46;height:2' coordorigin="4884,699"
  coordsize="46,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_28" o:spid="_x0000_s1098" style='position:absolute;
   left:4884;top:699;width:46;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="46,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l46,e" filled="f" strokeweight=".28717mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;46,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_25" o:spid="_x0000_s1099"
  style='position:absolute;left:4884;top:111;width:46;height:2' coordorigin="4884,111"
  coordsize="46,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:shape id="Freeform_x0020_26" o:spid="_x0000_s1100" style='position:absolute;
   left:4884;top:111;width:46;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="46,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l46,e" filled="f" strokeweight=".28717mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;46,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_23" o:spid="_x0000_s1101"
  style='position:absolute;left:5942;top:3642;width:2;height:46' coordorigin="5942,3642"
  coordsize="2,46" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_24" o:spid="_x0000_s1102" style='position:absolute;
   left:5942;top:3642;width:2;height:46;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="2,46" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,45l,e" filled="f" strokeweight=".30761mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3687;0,3642"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_21" o:spid="_x0000_s1103"
  style='position:absolute;left:6955;top:3642;width:2;height:46' coordorigin="6955,3642"
  coordsize="2,46" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:shape id="Freeform_x0020_22" o:spid="_x0000_s1104" style='position:absolute;
   left:6955;top:3642;width:2;height:46;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="2,46" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,45l,e" filled="f" strokeweight=".30761mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3687;0,3642"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_19" o:spid="_x0000_s1105"
  style='position:absolute;left:7970;top:3642;width:2;height:46' coordorigin="7970,3642"
  coordsize="2,46" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_20" o:spid="_x0000_s1106" style='position:absolute;
   left:7970;top:3642;width:2;height:46;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="2,46" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,45l,e" filled="f" strokeweight=".30761mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3687;0,3642"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_17" o:spid="_x0000_s1107"
  style='position:absolute;left:8983;top:3642;width:2;height:46' coordorigin="8983,3642"
  coordsize="2,46" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_18" o:spid="_x0000_s1108" style='position:absolute;
   left:8983;top:3642;width:2;height:46;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="2,46" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,45l,e" filled="f" strokeweight=".30761mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3687;0,3642"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_15" o:spid="_x0000_s1109"
  style='position:absolute;left:9996;top:3642;width:2;height:46' coordorigin="9996,3642"
  coordsize="2,46" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_16" o:spid="_x0000_s1110" style='position:absolute;
   left:9996;top:3642;width:2;height:46;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="2,46" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,45l,e" filled="f" strokeweight=".30761mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3687;0,3642"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_13" o:spid="_x0000_s1111"
  style='position:absolute;left:11009;top:3642;width:2;height:46'
  coordorigin="11009,3642" coordsize="2,46" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_14" o:spid="_x0000_s1112" style='position:absolute;
   left:11009;top:3642;width:2;height:46;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="2,46" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,45l,e" filled="f" strokeweight=".30761mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,3687;0,3642"
    o:connectangles="0,0"/>
  </v:shape></v:group><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="410" height="240" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[endif]-->300</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:-1.0pt; text-align:right">250</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-3.15pt">230</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:-1.0pt">262</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p style="margin-left:88.75pt; margin-right:-2.3pt; text-indent:-17.15pt">Number of breast cancers</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-3.15pt">200</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:-3.15pt">150</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:-3.15pt">100</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:-1.0pt"><!--[if gte vml 1]><v:group
 id="Group_x0020_7" o:spid="_x0000_s1031" style='position:absolute;
 margin-left:282.25pt;margin-top:1.8pt;width:9.45pt;height:5.4pt;z-index:-251657216;
 mso-position-horizontal-relative:page' coordorigin="5645,36" coordsize="189,108"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:group id="Group_x0020_10" o:spid="_x0000_s1032" style='position:absolute;
  left:5690;top:91;width:98;height:2' coordorigin="5690,91" coordsize="98,2"
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_11" o:spid="_x0000_s1033" style='position:absolute;
   left:5690;top:91;width:98;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="98,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l99,e" filled="f" strokecolor="#7e0000" strokeweight="4.54pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;99,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_8" o:spid="_x0000_s1034"
  style='position:absolute;left:5690;top:44;width:98;height:91' coordorigin="5690,44"
  coordsize="98,91" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_9" o:spid="_x0000_s1035" style='position:absolute;
   left:5690;top:44;width:98;height:91;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="98,91" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m99,l,,,91r99,l99,xe" filled="f" strokeweight=".29669mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="99,44;0,44;0,135;99,135;99,44"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="13" height="8" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /><!--[endif]-->Never took COCs</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:-3.15pt"><!--[if gte vml 1]><v:group
 id="Group_x0020_2" o:spid="_x0000_s1026" style='position:absolute;
 margin-left:282.25pt;margin-top:.05pt;width:9.45pt;height:9.1pt;z-index:-251656192;
 mso-position-horizontal-relative:page' coordorigin="5645,1" coordsize="189,182"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEA6zAxtXwFAABqFgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsmFFzozYQx9870++g4bEdx8gGDJ5z
bi52nLmZtM1cfB9ABmyYYokK7Djt9Lt3JSEQNlycu1yfzg9GWMuy+9dq9Ru/e3/cZegQ8yJldGbh
K9tCMQ1ZlNLtzPq8Wg58CxUloRHJGI1n1nNcWO+vf/7pHZluOcmTNETggRZTMrOSssynw2ERJvGO
FFcsjynMbRjfkRJu+XYYcfIEnnfZcGTb3nBHUmpdN64WpCRoz9OvcJWx8M84mhN6IAW4zMKp+UsV
YxZ+u2cypYc7nj/mD1xEHv5+eOAojWYWKEfJDiSyhtVEZQa3w5Onto2D44bvhD3bbNBxZo1d33En
roWeYYx9zxnbyl98LFEIBhiUwzAfggHGrjup5sPkjxc8hMntF31AkCoYGBgByqGIsCdvrPO+42yf
o9Fp+uJR6eMelqhQYoBqd1qCHm3Q+uk3FoGcZF8yWSRvrpTrOUpoXMXcCOQHlcK+zOcrpRm1pXH/
L2lcL4BqhAJxJu3iCWA3i8IJ6oyrojl7oimW9jM9ShS5qpDzbTHWGix5HItegLxaBm1d5O3aUL/L
wmhMYJu9VBJnWehN05MDbN99Ud7FTO5AcrgvSrl3txGMZN1G1Z5egZ6bXQZN7tcBspF4kfxSqWxr
M9gMyuyXIVrZ6AnBmyuX2hMUheEJjydIr1LjBkSr3QiLBOkVa2wcbaMimvhBZ0RQ4bWrldMZkadN
pKfuiCbaBhLriwiKy8jM7YsItlYTkd8ZEW7L7XRphE2twaJLI9wWu3/ZTMFXeNQdVFvx7qBMufuC
auvdH5Sp+Qp73UG1Re9ePGxKbq4ebLG61kmiyz880qr+YYSIIAFbduCcFeKMWoHy0ERWY1Ha4AKs
xGbpMVYtdiU70YvGEKjwDGt7iWsMyybNZWd90TkGQaV5YHpXj1UJ8zgsUSYP81J+85nFLbSeWWu1
j3NSCp1EvmKInqCZwhIksqeKX3fsEK+YnC+FWKoRQz9WCTXTGTXNApV5badn9TWXzior7UxP6qsy
Um+8xObsbWHGilgFKrKTq1tnLIQy2mXBsjRaplkmci34dj3PODoQEG8xD25u9LnZMstkoVAmHlOv
Ub9An65EFR1bEuA/AR459s0oGCw9fzJwlo47CCa2P7BxcBN4thM4i+W/oiyxM03SKIrpfUpjTaPY
OUO9XRpyVrBNeRWy3RB4Kw1jTaTAo9hWPCqX1B25suJb0beStOWnWtWWGWAQjSA7Mk1iEt1W45Kk
mRoP2xFLkSFtfZVCgNZFRZjl8VEeruXxhkXPwu0arnAacqZKFOgdBgnjf1voCZh8ZhV/7QmPLZR9
pIUoTMeBmijlDcDlCG64ObM2ZwgNwdXMKi3Y+WI4L+EOHtnnPN0m8CYslaHsA4DZJhUnJkSrYhLR
ZUX5WD5nooxgj4ivmEYPhJNPEHMmu0lMB58fK+nAAh5vktsX8WP+Cbah8quyl3JIw5pG60EPlkKz
VjiusFT2KihgAzy/D5Y2DFJxTjeDQCga2M+eeDP2gtarNKjZy1FdDGRowOqt2euLecNKao43m8lr
2KuPK0weuIi9HA85VbANVpkkAAZdVNHmgN7z20SBi8irMx4TAnriaSNAbzwmBKwu4i489jsUaoGX
MOnS6JS8ehfN1PtC8uoJy9S7N6wT9uoNy5T9QvbqXL4WehnrB/vgB3lJZqwO/rcnrxNY6iOvV+CS
ZhrNW/ragrPgIqtTPHsNedX8BIctFbiCbc/zvyOvwGvkOd5FaXZw69/6zsAZebcDx14sBh+Wc2fg
LfHEXYwX8/kCtylNsN+3U5qIp0VdLThbys85nBnopcgVtuEP9NJceRl6ic4l/rsDHDv5l7UCNPmv
sPgr17y//g8AAP//AwBQSwMEFAAGAAgAAAAhAJxOXiHiBgAAOhwAABoAAABjbGlwYm9hcmQvdGhl
bWUvdGhlbWUxLnhtbOxZT28bRRS/I/EdRntv4/+NozpV7NgNtGmj2C3qcbwe704zu7OaGSf1DbVH
JCREQRyoxI0DAiq1EpfyaQJFUKR+Bd7M7K534jVJ2wgqaA7x7tvfvP/vzZvdy1fuRQwdEiEpjzte
9WLFQyT2+YTGQce7NRpcWPeQVDieYMZj0vHmRHpXNt9/7zLe8BlNxhyLySgkEUHAKJYbuOOFSiUb
a2vSBzKWF3lCYng25SLCCm5FsDYR+AgERGytVqm01iJMY28TOCrNqM/gX6ykJvhMDDUbgmIcgfSb
0yn1icFODqoaIeeyxwQ6xKzjAc8JPxqRe8pDDEsFDzpexfx5a5uX1/BGuoipFWsL6wbmL12XLpgc
1IxMEYxzodVBo31pO+dvAEwt4/r9fq9fzfkZAPZ9sNTqUuTZGKxXuxnPAsheLvPuVZqVhosv8K8v
6dzudrvNdqqLZWpA9rKxhF+vtBpbNQdvQBbfXMI3ulu9XsvBG5DFt5bwg0vtVsPFG1DIaHywhNYB
HQxS7jlkytlOKXwd4OuVFL5AQTbk2aVFTHmsVuVahO9yMQCABjKsaIzUPCFT7ENO9nA0FhRrAXiD
4MITS/LlEknLQtIXNFEd78MEx14B8vLZ9y+fPUHH958e3//p+MGD4/s/WkbOqh0cB8VVL7797M9H
H6M/nnzz4uEX5XhZxP/6wye//Px5ORDKZ2He8y8f//b08fOvPv39u4cl8C2Bx0X4iEZEohvkCO3z
CAwzXnE1J2PxaitGIabFFVtxIHGMtZQS/n0VOugbc8zS6Dh6dInrwdsC2kcZ8OrsrqPwMBQzRUsk
XwsjB7jLOetyUeqFa1pWwc2jWRyUCxezIm4f48My2T0cO/HtzxLom1laOob3QuKoucdwrHBAYqKQ
fsYPCCmx7g6ljl93qS+45FOF7lDUxbTUJSM6drJpsWiHRhCXeZnNEG/HN7u3UZezMqu3yaGLhKrA
rET5EWGOG6/imcJRGcsRjljR4dexCsuUHM6FX8T1pYJIB4Rx1J8QKcvW3BRgbyHo1zB0rNKw77J5
5CKFogdlPK9jzovIbX7QC3GUlGGHNA6L2A/kAaQoRntclcF3uVsh+h7igOOV4b5NiRPu07vBLRo4
Ki0SRD+ZiZJYXiXcyd/hnE0xMa0GmrrTqyMa/13jZhQ6t5Vwfo0bWuXzrx+V6P22tuwt2L3Kambn
RKNehTvZnntcTOjb35238SzeI1AQy1vUu+b8rjl7//nmvKqez78lL7owNGg9i9hB24zd0cqpe0oZ
G6o5I9elGbwl7D2TARD1OnO6JPkpLAnhUlcyCHBwgcBmDRJcfURVOAxxAkN71dNMApmyDiRKuITD
oiGX8tZ4GPyVPWo29SHEdg6J1S6fWHJdk7OzRs7GaBWYA20mqK4ZnFVY/VLKFGx7HWFVrdSZpVWN
aqYpOtJyk7WLzaEcXJ6bBsTcmzDUIBiFwMstON9r0XDYwYxMtN9tjLKwmCicZ4hkiCckjZG2ezlG
VROkLFeWDNF22GTQB8dTvFaQ1tZs30DaWYJUFNdYIS6L3ptEKcvgRZSA28lyZHGxOFmMjjpeu1lr
esjHScebwjkZLqMEoi71HIlZAG+YfCVs2p9azKbKF9FsZ4a5RVCFVx/W70sGO30gEVJtYxna1DCP
0hRgsZZk9a81wa3nZUBJNzqbFvV1SIZ/TQvwoxtaMp0SXxWDXaBo39nbtJXymSJiGE6O0JjNxD6G
8OtUBXsmVMLrDtMR9A28m9PeNo/c5pwWXfGNmMFZOmZJiNN2q0s0q2QLNw0p18HcFdQD20p1N8a9
uimm5M/JlGIa/89M0fsJvH2oT3QEfHjRKzDSldLxuFAhhy6UhNQfCBgcTO+AbIH3u/AYkgreSptf
QQ71r605y8OUNRwi1T4NkKCwH6lQELIHbclk3ynMquneZVmylJHJqIK6MrFqj8khYSPdA1t6b/dQ
CKluuknaBgzuZP6592kFjQM95BTrzelk+d5ra+CfnnxsMYNRbh82A03m/1zFfDxY7Kp2vVme7b1F
Q/SDxZjVyKoChBW2gnZa9q+pwitutbZjLVlca2bKQRSXLQZiPhAl8A4J6X+w/1HhM/sFQ2+oI74P
vRXBxwvNDNIGsvqCHTyQbpCWOIbByRJtMmlW1rXp6KS9lm3W5zzp5nJPOFtrdpZ4v6Kz8+HMFefU
4nk6O/Ww42tLW+lqiOzJEgXSNDvImMCUfcnaxQkaB9WOB1+TIND34Aq+R3lAq2laTdPgCj4ywbBk
vwx1vPQio8BzS8kx9YxSzzCNjNLIKM2MAsNZ+g0mo7SgU+nPJvDZTv94KPtCAhNc+kUla6rO577N
vwAAAP//AwBQSwMEFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAABjbGlwYm9hcmQvZHJhd2luZ3Mv
X3JlbHMvZHJhd2luZzEueG1sLnJlbHOEj80KwjAQhO+C7xD2btJ6EJEmvYjQq9QHCMk2LTY/JFHs
2xvoRUHwsjCz7DezTfuyM3liTJN3HGpaAUGnvJ6c4XDrL7sjkJSl03L2DjksmKAV201zxVnmcpTG
KSRSKC5xGHMOJ8aSGtHKRH1AVzaDj1bmIqNhQaq7NMj2VXVg8ZMB4otJOs0hdroG0i+hJP9n+2GY
FJ69elh0+UcEy6UXFqCMBjMHSldnnTUtXYGJhn39Jt4AAAD//wMAUEsBAi0AFAAGAAgAAAAhALvl
SJQFAQAAHgIAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYA
CAAAACEArTA/8cEAAAAyAQAACwAAAAAAAAAAAAAAAAA2AQAAX3JlbHMvLnJlbHNQSwECLQAUAAYA
CAAAACEA6zAxtXwFAABqFgAAHwAAAAAAAAAAAAAAAAAgAgAAY2xpcGJvYXJkL2RyYXdpbmdzL2Ry
YXdpbmcxLnhtbFBLAQItABQABgAIAAAAIQCcTl4h4gYAADocAAAaAAAAAAAAAAAAAAAAANkHAABj
bGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbFBLAQItABQABgAIAAAAIQCcZkZBuwAAACQBAAAqAAAA
AAAAAAAAAAAAAPMOAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHNQ
SwUGAAAAAAUABQBnAQAA9g8AAAAA
">
 <v:group id="Group_x0020_5" o:spid="_x0000_s1027" style='position:absolute;
  left:5690;top:47;width:98;height:91' coordorigin="5690,47" coordsize="98,91"
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_6" o:spid="_x0000_s1028" style='position:absolute;
   left:5690;top:47;width:98;height:91;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="98,91" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,90r99,l99,,,,,90xe" fillcolor="#dc9bb2" stroked="f">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,137;99,137;99,47;0,47;0,137"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_3" o:spid="_x0000_s1029"
  style='position:absolute;left:5690;top:46;width:98;height:91' coordorigin="5690,46"
  coordsize="98,91" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_4" o:spid="_x0000_s1030" style='position:absolute;
   left:5690;top:46;width:98;height:91;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="98,91" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m99,l,,,92r99,l99,xe" filled="f" strokeweight=".84pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="99,46;0,46;0,138;99,138;99,46"
    o:connectangles="0,0,0,0,0"/>
  </v:shape></v:group><w:wrap anchorx="page"/>
</v:group><![endif]--><!--[if !vml]--><img width="8" height="8" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /><!--[endif]-->Used COCs for 5 years</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-3.15pt">100</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-3.15pt">111</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:-3.15pt">160</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:-1.0pt">181</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:41.35pt; text-align:right">50</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-1.0pt; text-align:right">0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 &nbsp;4.5</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:-3.3pt">16 &nbsp;17.5</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:-1.0pt">44 &nbsp;48.7</p><p>&nbsp;</p><p style="margin-left:53.1pt; margin-right:-1.0pt">Took the Pill at these ages:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Under 20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20-24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25-29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30-34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 35-39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40-44</p><p style="margin-left:46.9pt; margin-right:-1.0pt">Cancers found up to the age of:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 55</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p style="margin-left:75.9pt; margin-right:11.3pt; text-indent:-35.5pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In rare cases, benign liver tumours, and even more rarely, malignant liver tumours have been reported in users of CHCs. &nbsp;In isolated cases, these tumours have led to life-threatening intra-abdominal haemorrhages.&nbsp; A hepatic tumour should be considered in the differential diagnosis when upper abdominal pain, enlarged liver or signs of intra-abdominal haemorrhage occur in women taking CHCs.</p><p style="margin-left:75.9pt; margin-right:11.3pt; text-indent:-35.5pt">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>ALT elevations</u></strong></p><p style="margin-left:75.9pt; margin-right:24.95pt; text-indent:-35.5pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;During clinical trials with patients treated for hepatitis C virus infections</p><p style="margin-left:75.9pt; margin-right:24.95pt; text-indent:.6pt">(HCV) with medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin, transaminase (ALT) elevations higher than 5 times the upper limit of normal (ULN) occurred significantly more frequently in women using ethinylestradiol-containing medications such as combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other conditions</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:75.9pt; margin-right:24.95pt; text-indent:-35.5pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using CHCs.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:75.9pt; margin-right:3.95pt; text-indent:-35.5pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Although small increases in blood pressure have been reported in many women taking CHCs, clinically relevant increases are rare. A relationship between CHC use and clinical hypertension has not been established. However, if a sustained clinically significant hypertension develops during the use of a CHC then it is prudent for the physician to withdraw the CHC and treat the hypertension. Where considered appropriate, CHC use may be resumed if normotensive values can be achieved with antihypertensive therapy.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:75.9pt; margin-right:2.9pt; text-indent:-35.5pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following conditions have been reported to occur or deteriorate with both pregnancy and CHC use, but the evidence of an association with CHC use is inconclusive: jaundice and/or pruritus related to cholestasis; gallstone formation; porphyria; systemic lupus erythematosus; haemolytic uraemic syndrome: Sydenham&rsquo;s chorea; herpes gestationis; otosclerosis-related hearing loss; hereditary angioedema.</p><p style="margin-left:75.8pt; margin-right:20.4pt; text-indent:-34.8pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute or chronic disturbances of liver function may necessitate the discontinuation of CHC use until markers of liver function return to normal. Recurrence of cholestatic jaundice which occurred previously during pregnancy or use of sex steroids necessitates the discontinuation of CHCs.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:75.9pt; margin-right:10.55pt; text-indent:-35.5pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Although CHCs may have an effect on peripheral insulin resistance and glucose tolerance, there is no evidence for a need to alter the therapeutic regimen in diabetics using CHCs. However, diabetic women should be carefully observed while taking CHCs.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:41.0pt; margin-right:-1.0pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Crohn&rsquo;s disease and ulcerative colitis have been associated with CHC use.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:75.9pt; margin-right:2.2pt; text-align:justify; text-indent:-35.5pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chloasma &nbsp;may &nbsp;occasionally &nbsp;occur, &nbsp;especially &nbsp;in &nbsp;women &nbsp;with &nbsp;a &nbsp;history &nbsp;of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation whilst taking this preparation.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:75.9pt; margin-right:35.9pt; text-indent:-35.5pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Marvelon contains &lt; 80 mg lactose per tablet. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take medicine.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><em>Re</em><em>lative Contraindications</em></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt">Severe depression or a history of this condition. Depressed mood and depression are well- known undesirable effects of hormonal contraceptive use (see section 4.8). Depression can be serious and is a well-known risk factor for suicidal behaviour and suicide. Women should be advised to contact their physician in case of mood changes and depressive symptoms, including shortly after initiating the treatment.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>4.4.2&nbsp;&nbsp;&nbsp;&nbsp; Medical Examination/consultation</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:7.85pt">Prior to the initiation or reinstitution of Marvelon a complete medical history (including family history) should be taken and pregnancy must be ruled out. Blood pressure should be measured and a physical examination should be performed, guided by the contraindications (see section</p><p style="margin-left:5.0pt; margin-right:14.8pt">4.3) and warnings (see section 4.4). It is important to draw a woman&rsquo;s attention to the information on venous and arterial thrombosis, including the risk of Marvelon compared with other CHCs, the symptoms of VTE and ATE, the known risk factors and what to do in the event of a suspected thrombosis.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:6.25pt; text-align:justify">The woman should also be instructed to carefully read the user leaflet and to adhere to the advice &nbsp;given. &nbsp;The &nbsp;frequency and &nbsp;nature &nbsp;of &nbsp;examinations &nbsp;should &nbsp;be &nbsp;based &nbsp;on &nbsp;established practice guidelines and be adapted to the individual woman.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:6.15pt; text-align:justify">Women should be advised that hormonal contraceptives do not protect against HIV infections (AIDS) and other sexually transmitted diseases. If there is risk of STI/HIV (including during pregnancy or postpartum), the correct and consistent use of condoms is recommended, either alone or with another contraceptive method.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>4.4.3&nbsp;&nbsp;&nbsp;&nbsp; Reduced Efficacy</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:36.25pt">The efficacy of Marvelon may be reduced in the event of missed tablets (Section 4.2.3), gastrointestinal disturbances (Section 4.2.4) or concomitant medications that decrease the plasma concentration of etonogestrel, the active metabolite of desogestrel (Section 4.5.1).</p><p style="margin-left:5.0pt; margin-right:36.25pt">&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>4.4.4&nbsp;&nbsp;&nbsp; Reduced Cycle Control/ irregular bleeding</strong></p><p style="margin-left:5.0pt; margin-right:29.3pt">With all CHCs, irregular bleeding (spotting or breakthrough bleeding) may occur, especially during the first months of use. Therefore, the evaluation of any irregular bleeding is only meaningful after an adaptation interval of about three cycles.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:31.45pt">If bleeding irregularities persist or occur after previously regular cycles, then non- hormonal causes should be considered and adequate diagnostic measures are indicated to exclude malignancy or pregnancy. These may include curettage.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:2.9pt">In some women withdrawal bleeding may not occur during the tablet-free interval. If the CHC has been taken according to the directions described in Section 4.2, it is unlikely that the woman is pregnant. However, if the CHC has not been taken according to these directions prior to the first missed withdrawal bleed or if two withdrawal bleeds are missed, pregnancy must be ruled out before CHC use is continued.</p><p style="margin-left:5.0pt; margin-right:-1.0pt">&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interaction with other medicinal products and other forms of interaction</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>4.5.1&nbsp;&nbsp;&nbsp; Interactions</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:9.7pt">Interactions between oral contraceptives and other medicinal products may lead to breakthrough bleeding and/or contraceptive failure. The following interactions have been reported in the literature:</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt">- Hepatic metabolism:</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:8.65pt">Interactions can occur with medicinal or herbal products that induce microsomal enzymes, specifically cytochrome P450 enzymes (CYP), which can result in increased clearance reducing plasma concentrations of sex hormones and may decrease the effectiveness of combined oral contraceptives, including Marvelon. These products include phenytoin, phenobarbital, primidone, bosentan, carbamazepine, rifampicin, rifabutin and possibly also oxcarbazepine,</p><p style="margin-left:5.0pt; margin-right:4.7pt">modafinil, topiramate, felbamate, griseofulvin, some HIV protease inhibitors (e.g., ritonavir) and non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz) and products containing the herbal remedy St. John&rsquo;s wort.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:3.8pt">Enzyme induction can occur after a few days of treatment. Maximal enzyme induction is generally observed within a few weeks. After drug therapy is discontinued, enzyme induction can last for about 28 days.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:16.8pt">Women receiving any of the above mentioned hepatic enzyme-inducing medicinal or herbal products should be advised that the efficacy of Marvelon may be reduced. A barrier contraceptive method should be used in addition to Marvelon during administration of the hepatic enzyme-inducing medicinal product, and for 28 days after discontinuation of the hepatic enzyme-inducing medicinal product. If concomitant drug administration runs beyond the end of the tablets in the current COC pack, the next COC pack should be started right away without the usual tablet-free interval.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:36.2pt">For women on long-term therapy with enzyme-inducing medicinal products, an alternative method of contraception unaffected by enzyme-inducing medicinal products should be considered.</p><p style="margin-left:5.0pt; margin-right:2.35pt">-When co-administered with hormonal contraceptives, many combinations of HIV protease inhibitors (e.g., nelfinavir) and non-nucleoside reverse transcriptase inhibitors (e.g., nevirapine), and/or combinations with Hepatitis C virus (HCV) medicinal products (e.g., boceprevir, telaprevir), can increase or decrease plasma concentrations of progestins, including</p><p style="margin-left:5.0pt; margin-right:10.4pt">etonogestrel, the active metabolite of desogestrel, or estrogens. The net effect of these changes may be clinically relevant in some cases.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:5.55pt">- Concomitant administration of strong (e.g., ketoconazole, itraconazole, clarithromycin) or moderate (e.g., fluconazole, diltiazem, erythromycin) CYP3A4 inhibitors may increase the serum concentrations of estrogens or progestins, including etonogestrel, the active metabolite of desogestrel.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:15.5pt">- Oral contraceptives may interfere with the metabolism of other drugs. Accordingly, plasma and tissue concentrations may be increased (e.g., ciclosporin) or decreased (e.g., lamotrigine).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:22.35pt">Note: The prescribing information of concomitant medications should be consulted to identify potential interactions.</p><p style="margin-left:5.0pt; margin-right:22.35pt">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><em>Pharmacodynamic interactions</em></p><p style="margin-left:5.0pt; margin-right:-1.0pt"><em>&nbsp;</em></p><p style="margin-left:5.0pt; margin-right:22.35pt">Concomitant use with medicinal products containing ombitasvir/paritaprevir/ritonavir and</p><p style="margin-left:5.0pt; margin-right:22.35pt">dasabuvir, with or without ribavirin may increase the risk of ALT elevations (see sections 4.3 and 4.4). Therefore, Marvelon -users must switch to an alternative method of contraception (e.g., progestagen-only contraception or non-hormonal methods) prior to starting therapy with this combination drug regimen. Marvelon can be restarted 2 weeks following completion of treatment with this combination drug regimen.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>4.5.2&nbsp;&nbsp;&nbsp; Laboratory Tests</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:16.5pt">The use of contraceptive steroids may influence the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal and renal function, plasma levels of (carrier) proteins, e.g. corticosteroid binding globulin and lipid/lipoprotein fractions, parameters of carbohydrate metabolism and parameters of coagulation and fibrinolysis. Changes generally remain within the normal laboratory range<strong>.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnancy and lactation</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt">Marvelon is not indicated for use during pregnancy. If pregnancy occurs during treatment with</p><p style="margin-left:5.0pt; margin-right:-1.0pt">Marvelon, further intake should be stopped.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:7.95pt; text-align:justify">However, most epidemiological studies have revealed neither an increased risk of birth defects in children born to women who used &nbsp;CHCs prior to pregnancy, nor a teratogenic effect when CHCs were taken inadvertently during early pregnancy.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt">The increased risk of VTE during the postpartum period should be considered when re-starting</p><p style="margin-left:5.0pt; margin-right:-1.0pt">Marvelon (see sections 4.2 and 4.4).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:14.35pt">Lactation may be influenced by CHCs as they may reduce the quantity and change the composition of breast milk. Therefore, the use of CHCs should generally not be recommended until the nursing mother has completely weaned her child. Small amounts of the contraceptive steroids and/or their metabolites may be excreted with the milk but there is no evidence that this adversely affects infant health.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.0pt; margin-right:-1.0pt">No effects on ability to drive and use machines have been observed.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:11.0pt; margin-right:-1.0pt"><em>Description of selected adverse reactions</em></p><p style="margin-left:11.0pt; margin-right:2.15pt; text-align:justify">As with all COCs, changes in vaginal bleeding patterns may occur, especially during the first months of use. These may include changes in bleeding frequency (absent, less, more frequent or continuous), intensity (reduced or increased) or duration.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:11.0pt; margin-right:17.75pt">An increased risk of arterial and venous thrombotic and thromboembolic events, including myocardial infarction, stroke, transient ischaemic attacks, venous thrombosis and pulmonary embolism has been observed in women using CHCs, which are discussed in more detail in section 4.4.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:11.0pt; margin-right:.1in">Possibly related undesirable effects that have been reported in users of Marvelon or CHC users in general are listed in the table below1. All ADRs are listed by system organ class and frequency; common (&ge;1/100), uncommon (&ge;1/1,000 to &lt; 1/100) and rare (&lt;1/1,000).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:28.1pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:-1.0pt"><strong>System Organ Class</strong></p></td><td style="border-color:black; height:28.1pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:-1.0pt"><strong>Common</strong></p></td><td style="border-color:black; height:28.1pt; vertical-align:top; width:114.95pt"><p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>Uncommon</strong></p></td><td style="border-color:black; height:28.1pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:-1.0pt"><strong>Rare</strong></p></td></tr><tr><td style="border-color:black; height:28.2pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:30.1pt">Immune system disorders</p></td><td style="height:28.2pt; vertical-align:top; width:115.1pt"><p>&nbsp;</p></td><td style="height:28.2pt; vertical-align:top; width:114.95pt"><p>&nbsp;</p></td><td style="height:28.2pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Hypersensitivity</p></td></tr><tr><td style="border-color:black; height:28.1pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:.25in">Metabolism and nutrition disorders</p></td><td style="height:28.1pt; vertical-align:top; width:115.1pt"><p>&nbsp;</p></td><td style="height:28.1pt; vertical-align:top; width:114.95pt"><p style="margin-left:5.0pt; margin-right:-1.0pt">Fluid retention</p></td><td style="height:28.1pt; vertical-align:top; width:115.1pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:28.1pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Psychiatric disorders</p></td><td style="height:28.1pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:23.05pt">Depressed mood, mood altered</p></td><td style="height:28.1pt; vertical-align:top; width:114.95pt"><p style="margin-left:5.0pt; margin-right:-1.0pt">Libido decreased</p></td><td style="height:28.1pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Libido increased</p></td></tr><tr><td style="border-color:black; height:28.1pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:29.4pt">Nervous system disorders</p></td><td style="height:28.1pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Headache</p></td><td style="height:28.1pt; vertical-align:top; width:114.95pt"><p style="margin-left:5.0pt; margin-right:-1.0pt">Migraine</p></td><td style="height:28.1pt; vertical-align:top; width:115.1pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:28.1pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Eye disorders</p></td><td style="height:28.1pt; vertical-align:top; width:115.1pt"><p>&nbsp;</p></td><td style="height:28.1pt; vertical-align:top; width:114.95pt"><p>&nbsp;</p></td><td style="height:28.1pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:46.65pt">Contact lens intolerance</p></td></tr><tr><td style="border-color:black; height:55.7pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Vascular disorders</p></td><td style="height:55.7pt; vertical-align:top; width:115.1pt"><p>&nbsp;</p></td><td style="height:55.7pt; vertical-align:top; width:114.95pt"><p>&nbsp;</p></td><td style="height:55.7pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:13.95pt">Venous thromboembolism2</p><p style="margin-left:5.1pt; margin-right:13.95pt">Arterial thromboembolism2</p></td></tr><tr><td style="border-color:black; height:28.1pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:30.35pt">Gastrointestinal disorders</p></td><td style="height:28.1pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:.2in">Nausea, abdominal pain</p></td><td style="height:28.1pt; vertical-align:top; width:114.95pt"><p style="margin-left:5.0pt; margin-right:-1.0pt">Vomiting, diarrhoea</p></td><td style="height:28.1pt; vertical-align:top; width:115.1pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:42.0pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:11.4pt">Skin and subcutaneous tissue disorders</p></td><td style="height:42.0pt; vertical-align:top; width:115.1pt"><p>&nbsp;</p></td><td style="height:42.0pt; vertical-align:top; width:114.95pt"><p style="margin-left:5.0pt; margin-right:-1.0pt">Rash, urticaria</p></td><td style="height:42.0pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:4.75pt">Erythema nodosum, erythema multiforme</p></td></tr><tr><td style="border-color:black; height:28.1pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:5.4pt">Reproductive system and breast disorders</p></td><td style="height:28.1pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:17.4pt">Breast pain, breast tenderness</p></td><td style="height:28.1pt; vertical-align:top; width:114.95pt"><p style="margin-left:5.0pt; margin-right:-1.0pt">Breast enlargement</p></td><td style="height:28.1pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:16.4pt">Vaginal discharge, breast discharge</p></td></tr><tr><td style="border-color:black; height:14.3pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Investigations</p></td><td style="height:14.3pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Weight increased</p></td><td style="height:14.3pt; vertical-align:top; width:114.95pt"><p>&nbsp;</p></td><td style="height:14.3pt; vertical-align:top; width:115.1pt"><p style="margin-left:5.1pt; margin-right:-1.0pt">Weight decreased</p></td></tr></tbody></table><p style="margin-left:11.0pt; margin-right:14.85pt">1 The most appropriate MedDRA term (version 11) to describe a certain adverse reaction is listed. Synonyms or related conditions are not listed, but should be taken into account as well.</p><p style="margin-left:11.0pt; margin-right:-1.0pt">2 Incidence in observational cohort studies of &ge;1/10000 to 1/1000 women-years.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:11.0pt; margin-right:-1.0pt"><u>Reporting of suspected adverse reactions</u></p><p style="margin-left:11.0pt; margin-right:4.6pt">Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via :</p><p style="margin-left:45.0pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Saudi Arabia: </u></p><p style="text-align:justify">The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA</p><p style="text-align:justify">o Fax: +966-11-205-7662</p><p style="text-align:justify">o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p style="text-align:justify">o Toll free phone: 8002490000</p><p style="text-align:justify">o E-mail: npc.drug@sfda.gov.sa</p><p style="text-align:justify">o Website: www.sfda.gov.sa/npc</p><p style="margin-left:45.0pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Other GCC States: </u></p><p style="text-align:justify">Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:2.75pt; text-align:justify">There have been no reports of serious deleterious effects from overdose. &nbsp;Symptoms that may occur in this case are: nausea, vomiting and slight vaginal bleeding.&nbsp; There are no antidotes and further treatment should be symptomatic.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic properties</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:93.8pt">Pharmacotherapeutic group: progestogens and estrogens, fixed combinations, ATC code: G03AA09</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt">Marvelon is an oral contraceptive combination containing 150 micrograms desogestrel and</p><p style="margin-left:5.0pt; margin-right:-1.0pt">30 micrograms ethinylestradiol.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt">Ethinylestradiol is a well-known synthetic estrogen.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:19.05pt">Desogestrel is a synthetic progestogen.&nbsp; After oral administration it has a strong ovulation- inhibiting activity, a strong progestational and anti-estrogenic activity, no estrogenic activity, very weak androgenic/anabolic activity.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><u>Paediatric population</u></p><p style="margin-left:5.0pt; margin-right:-1.0pt">No clinical data on efficacy and safety are available in adolescents below 18 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>Desogestrel</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><u>Absorption</u></p><p style="margin-left:5.0pt; margin-right:14.7pt">Orally administered desogestrel is rapidly and completely absorbed and converted to etonogestrel. Peak serum concentrations are reached at about 1.5 hours. Bioavailability is 62 -</p><p style="margin-left:5.0pt; margin-right:-1.0pt">81 %.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><u>Distribution</u></p><p style="margin-left:5.0pt; margin-right:-1.0pt">Etonogestrel is bound to serum albumin and to sex hormone binding globulin (SHBG). Only 2 -</p><p style="margin-left:5.0pt; margin-right:6.3pt">4 % of the total serum drug concentrations are present as free steroid, 40 - 70 % are specifically bound to SHBG. The ethinylestradiol-induced increase in SHBG influences the distribution over the serum proteins, causing an increase of the SHBG-bound fraction and a decrease of the albumin-bound fraction. The apparent volume of distribution of desogestrel is 1.5 l/kg.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><u>Biotransformation</u></p><p style="margin-left:5.0pt; margin-right:48.3pt">Etonogestrel is completely metabolized by the known pathways of steroid metabolism, including cytochrome P450 3A4. The metabolic clearance rate from serum is about</p><p style="margin-left:5.0pt; margin-right:-1.0pt">2 ml/min/kg. No interaction was found with the co-administered ethinylestradiol.</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><u>&nbsp;</u></p><p style="margin-left:5.0pt; margin-right:-1.0pt"><u>Elimination</u></p><p style="margin-left:5.0pt; margin-right:31.1pt">Etonogestrel serum levels decrease in two phases. The terminal disposition phase is characterized by a half-life of approximately 30 hours. Desogestrel and its metabolites are excreted at a urinary to biliary ratio of about 6:4.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><u>Steady-state conditions</u></p><p style="margin-left:5.0pt; margin-right:15.1pt">Etonogestrel pharmacokinetics are influenced by SHBG levels, which are increased threefold by ethinylestradiol. Following daily ingestion, drug serum levels increase about two- to threefold, reaching steady state conditions during the second half of a treatment cycle.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>Ethinylestradiol</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><u>Absorption</u></p><p style="margin-left:5.0pt; margin-right:7.05pt">Orally administered ethinylestradiol is rapidly and completely absorbed. Peak serum concentrations are reached within 1-2 hours. Absolute bioavailability as a result of presystemic conjugation and first-pass metabolism is approximately 60%.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><u>Distribution</u></p><p style="margin-left:5.0pt; margin-right:9.0pt">Ethinylestradiol is highly but non-specifically bound to serum albumin (approximately 98.5%) and induces an increase in the serum concentrations of SHBG. An apparent volume of distribution of about 5 l/kg was determined.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><u>Biotransformation</u></p><p style="margin-left:5.0pt; margin-right:2.7pt">Ethinylestradiol is subject to presystemic conjugation in both small bowel mucosa and the liver. Ethinylestradiol is primarily metabolized by aromatic hydroxylation but a wide variety of hydroxylated and methylated metabolites are formed, and these are present as free metabolites and as conjugates with glucuronides and sulfate. The metabolic clearance rate is about</p><p style="margin-left:5.0pt; margin-right:-1.0pt">5 ml/min/kg.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><u>Elimination</u></p><p style="margin-left:5.0pt; margin-right:29.05pt">Ethinylestradiol serum levels decrease in two phases, the terminal disposition phase is characterized by a half-life of approximately 24 hours. Unchanged drug is not excreted, ethinylestradiol metabolites are excreted at a urinary to biliary ratio of 4:6. The half-life of metabolite excretion is about 1 day.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><u>Steady-state conditions</u></p><p style="margin-left:5.0pt; margin-right:-1.0pt">Steady state concentrations are reached after 3-4 days when serum drug levels are higher by 30</p><p style="margin-left:5.0pt; margin-right:-1.0pt">- 40% as compared to single dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.0pt; margin-right:18.35pt; text-align:justify">Preclinical studies on ethinylestradiol and desogestrel revealed no special hazard for humans based on conventional studies of repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:49.45pt">However, it must be borne in mind that sex steroids can promote the growth of certain hormone-dependent tissues and tumours.</p><p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.0pt; margin-right:-1.0pt"><strong>6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</strong></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:280.0pt">potato starch</p><p style="margin-left:5.0pt; margin-right:280.0pt">povidone</p><p style="margin-left:5.0pt; margin-right:280.0pt">stearic acid</p><p style="margin-left:5.0pt; margin-right:280.0pt">silica colloidal anhydrous</p><p style="margin-left:5.0pt; margin-right:280.0pt">alpha-tocopherol</p><p style="margin-left:5.0pt; margin-right:280.0pt">lactose monohydrate</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.0pt; margin-right:-1.0pt">Not applicable.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.0pt; margin-right:-1.0pt">Store below 30 &deg;C. Do not freeze.</p><p style="margin-left:5.0pt; margin-right:-1.0pt">Store in the original package, in order to protect from light and moisture.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:5.0pt; margin-right:2.5pt">Push-through packs of 21 white tablets each. The pack is PVC/Al blister consisting of aluminium foil with a heat-seal coating and a PVC film. &nbsp;Each blister is packed in a printed aluminium pouch.&nbsp; The pouch is packed in a printed cardboard box together with the package leaflet (1, 3 or 50 pouches per box). Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:5.0pt; margin-right:-1.0pt">See Section 4.2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                7	MARKETING AUTHORIZATION HOLDER & MANUFACTURER:

N.V. Organon
Kloosterstraat 6
5349 AB Oss 
The Netherlands







            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                14 Dec 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>